VOLUME 10 1979

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Editor-in-Chief

MATTHEW J. WAYNER

Published by

ANKHO International Inc

Fayetteville, New York

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Editor-in-Chief

MATTHEW J. WAYNER

Brain Research Laboratory, Syracuse University, 601 University Avenue, Syracuse, N. Y. 13210 U.S.A.

Regional Editors

A. BARBEAU, Department of Neurobiology, Clinical Research Institute of Montreal, 110 West Pine Avenue, Montreal (130), Quebec, Canada

J. R. BOISSIER, Faculté de Médecine de Paris, Unité de Neuropsychopharmacologie, 2 rue d'Alésia, 75014 Paris, France

G. R. BREESE, Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514

E. A. CARLINI, Department of Psychobiology, Escola Paulista de Medicina, Rua Botucatu, 862, 04023 – São Paulo, Brasil

J. COCHIN, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, 80 East Concord Street, Boston, Massachusetts 02118

D. V. COSCINA, Section of Neurochemistry, Clarke Institute of Psychiatry, 250 College Street, Toronto, Ontario M5T 1R8, Canada

G. ELLMAN, Langley Porter Institute, San Francisco, California 94122

K. ERIKSSON, Research Laboratories of State Alcohol Monopoly, Box 350, 00101 Helsinki 10, Finland

J. L. FALK, Department of Psychology, Rutgers University, New Brunswick, New Jersey 08903

E. GELLER, Neurobiochemistry Laboratory, T-85 Veterans Administration, Brentwood Hospital, Los Angeles, California 90073

S. P. GROSSMAN, Department of Psychology, University of Chicago, Chicago, Illinois 60637

Y. GUTMAN, Department of Pharmacology, The Hebrew University, Hadassah Medical School, P.O. Box 1172, Jerusalem, Israel

G. H. HALL, Department of Pharmacology, School of Pharmacy, Sunderland Polytechnic, Sunderland, SR1 3SD, Co. Durham, England

J. HANO, Polish Academy of Sciences, Institute of Pharmacology, 52, Ojcowska Street, 31 344 Krakow, Poland

J. A. HARVEY, Department of Psychology, University of Iowa, Iowa City, Iowa 52242

P. JANSSEN, Research Laboratoria, Janssen Pharmaceutica, 2340-Beerse, Belgium

D. A. KHARKEVICH, Department of Pharmacology, First Medical Institute, 2/6, Bolshaja Pirogovhkaja Street, Moscow, G-435, USSR

J. KNOLL, Director, Department of Pharmacology, Semmelweis University of Medicine,1445 Budapest, VIII, Nagyvárad tér 4

I. P. LAPIN, Laboratory of Psychopharmacology, Bekhterev Institute, Bekhtereva ul., 3, 193019 Leningrad, USSR

A. E. LEBLANC, Biological Studies Research Division, Alcoholism and Drug Addiction Research Foundation, 33 Russell Street, Toronto, Ontario M5S 2S1, Canada

V. G. LONGO, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Roma, Italy

H. MATTHIES, Institut für Pharmakologie und Toxikologie, Medizinische Akademie Magdeburg, 301 Magdeburg, Leipziger Strasse 44, German Democratic Republic

N. K. MELLO, Alcohol and Drug Abuse Research Center, Harvard Medical School, McLean Hospital, Belmont, Massachusetts 02178

R. D. MYERS, Departments of Psychiatry and Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC 27514

R. H. RECH, Department of Pharmacology, Michigan State University, B440 Life Sciences, East Lansing, Michigan 48824

J. A. ROSECRANS, Department of Pharmacology, Virginia Commonwealth University, Medical College of Virginia, Health Sciences Center, Richmond, Virginia 23219

C. R. SCHUSTER, Department of Psychiatry, University of Chicago, 950 East 59th Street, Chicago, Illinois 60637

D. S. SEGAL, Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, California 92037

L. S. SEIDEN, Department of Pharmacology, University of Chicago, Chicago, Illinois 60637

E. B. SIGG, Department of Neuropharmacology, Research Division, Hoffman-La Roche Inc., Nutley, New Jersey 07110

G. SINGER, Department of Psychology, La Trobe University, Bundoora, Victoria 3083, Australia

T. L. SOURKES, Allan Memorial Institute of Psychiatry, 1025 Pine Avenue West, Montreal 112, P.Q., Canada

P. STERN, Department of Pharmacology, Medical Faculty, Moše Pijade 6, Sarajeva 71001, Yugoslavia

W. C. STERN, Medical Division, Burroughs Wellcome Co., 3030 Cornwallis Road, Research Triangle Park, NC 27709

S. TADOKORO, Behavior Research Institute, School of Medicine, Gunma University, 3-39-22, Showamachi Maebashi 371, Japan

T. THOMPSON, Department of Psychiatry, University of Minnesota, Research Unit, Medical School, Box 392, Mayo Memorial Building, Minneapolis, Minnesota 55455

U. UNGERSTEDT, Department of Pharmacology, Karolinska Institutet, S-104 01 Stockholm 60, Sweden

W. L. VEALE, Division of Medical Physiology, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada

J. E. VILLARREAL, Department of Behavioral Pharmacology, Instituto Miles de Terepeutica Experimental, Division de Laboratorios Miles de Mexico, S.A. de C.V., Apartado Postal 22026, Mexico 22, D.F.

Z. VOTAVA, Department of Pharmacology, Research Institute of Pharmacy and Biochemistry, Praha 3, Kouřimská 17, Czechoslovakia

W. WUTTKE, Institut für Pharmakologie, Farbenfabriken Bayer AG, 56 Wuppertal-Elberfeld, Friederich-Ebert-Strasse 217, Germany

T. YANAGITA, Central Institute for Experimental Animals, 1433 Nogawa, Kawasaki 211, Japan

Editorial Advisory Board

B. AGRANOFF (*Ann Arbor*)
B. BEER (*Pearl River*)
M. H. APRISON (*Indianapolis*)
E. F. DOMINO (*Ann Arbor*)
D. X. FREEDMAN (*Chicago*)
E. GLASSMAN (*Chapel Hill*)
H. KALANT (*Toronto*)
A. J. MANDELL (*San Diego*)
J. MENDELSON (*Boston*)
P. A. SHORE (*Dallas*)
S. H. SNYDER (*Baltimore*)
E. USDIN (*Rockville*)
R. J. WURTMAN (*Cambridge*)

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR
ISSN 0091-3057

Subscription, postpaid: $200 per year for Libraries, Research Establishments and all other multiple-reader Institutions. Private individuals whose departmental libraries subscribe may obtain this Journal for their personal use at a reduced rate of $30 per year.

Publishing and Advertising Offices:
ANKHO Iinternational Inc.
7374 Highbridge Terrace, P.O. Box 426, Fayetteville, New York 13066 U.S.A.

Back issues are available. Write for Back Issues Price List.

Published monthly. Copyright © 1979 ANKHO International Inc.

Second class postage paid at Fayetteville, N.Y. 13066.

Printed at SALINA PRESS, Syracuse, New York U.S.A.

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 10 NUMBER 1 JANUARY 1979

CONTENTS

Non-effect of Massachusetts cement kiln dust upon the food intake, body weight, or activity of female rats. GOLD, R. M., M. G. KLEIN, B. A. RINGUETTE, B. B. LOWELL and R. KATZ . 1

Effects of clozapine on the activity of central dopaminergic and noradrenergic neurons. SOUTO, M., J. M. MONTI and H. ALTIER 5

Interaction of brain noradrenaline and the pituitary-adrenal axis in learning and extinction. MASON, S. T., D. C. S. ROBERTS and H. C. FIBIGER 11

Disruption of taste aversion learning by pretreatment with diazepam and morphine. BROWN, Z. W., Z. AMIT, B. SMITH and G. ROCKMAN 17

Effects of methomyl and ethanol on behavior in the Sprague-Dawley rat. BRACY, O. L., R. S. DOYLE, M. KENNEDY, S. M. McNALLY, J. D. WEED and B. M. THORNE .. 21

Serotonin-norepinephrine interactions in the tremorolytic actions of phenoxybenzamine and trazodone. HWANG, E. C. and M. H. VAN WOERT 27

Reversal of ethanol induced body dehydration with prolonged consumption in rats. WRIGHT, J. W. and K. DONLON 31

Possible involvement of serotonin in extinction. BENINGER, R. J. and A. G. PHILLIPS 37

Central cholinergic involvement in behavioral hyper-reactivity. RUSSELL, R. W. and J. MACRI 43

Cross-tolerance between Δ^9-tetrahydrocannabinol and ethanol: The role of drug disposition. SIEMENS, A. J. and O. L. DOYLE 49

Possible involvement of brainstem norepinephrine in pentylenetetrazol convulsions in rats. OISHI, R., N. SUENAGA and T. FUKUDA 57

Abomasal function following injections of elfazepam and 9-aza-cannabinol. KEIM, D. A., C. A. BAILE, J. R. BOLTON, P. J. WANGSNESS and M. A. DELLA FERA 63

Opiate modification of intracranial self-stimulation in the rat. WEIBEL, S. L. and H. H. WOLF 71

Evaluation of the non-specific effects of catecholamine and serotonin neurotoxins by injection into the medial forebrain bundle of the rat. LORDEN, J. F., G. A. OLTMANS, R. DAWSON, JR. and M. CALLAHAN 79

Cholecystokinin, amphetamine and diazepam and feeding in lean and obese Zucker rats. McLAUGHLIN, C. L. and C. A. BAILE 87

Drug induced activity in lead-exposed mice. RAFALES, L. S., R. L. BORNSCHEIN, I. A. MICHAELSON, R. K. LOCH and G. F. BARKER 95

Rapid substitution procedure for intravenous drug self-administration studies in rhesus monkeys. AIGNER, T. G. and R. L. BALSTER 105

Physical dependence following prolonged ethanol or *t*-butanol administration to rats. WOOD, J. M. and R. LAVERTY 113

Effects of chronic intraventricular administration of angiotensin II on drinking behavior and blood pressure. GRONAN, R. J. and D. H. YORK 121

Free-operant and auto-titration brain self-stimulation procedures in the rat: A comparison of drug effects. SCHAEFER, G. J. and S. G. HOLTZMAN 127

Avoidance, operant and locomotor behavior in rats with neostriatal injections of kainic acid. SANBERG, P. R., M. PISA and H. C. FIBIGER 137

$ACTH_{4-9}$ analog (ORG 2766) facilitates acquisition of an inhibitory avoidance response in rats. MARTINEZ, J. L., JR., B. J. VASQUEZ, R. A. JENSEN, B. SOUMIREU-MOURAT and J. L. McGAUGH 145

Effects of gonadectomy and hormone replacement on brain monoamine synthesis in male rats. ENGEL, J., S. AHLENIUS, O. ALMGREN, A. CARLSSON, K. LARSSON and P. SÖDERSTEN 149

Effects of food deprivation on etonitazene consumption in rats. CARROLL, M. E. and R. A. MEISCH 155

Videotaping: The evaluation of stereotypic effects of antiparkinsonian agents. WILCOX, R. E., W. H. RIFFEE and R. V. SMITH 161

BRIEF COMMUNICATION

Effects of goldthioglucose lesions on central catecholamine levels in the mouse. LORDEN, J. F., R. DAWSON, JR. and M. CALLAHAN 165

ANNOUNCEMENTS

May 7–9, 1979. Bethesda, Maryland. International Peptide Symposium 171

May 9–11, 1979. Saskatoon, Canada. Silver Jubilee Psychiatric Research Meeting 172

June 26–30, 1979. Trois-Rivières, Quebec. International Congress in Physical Education 173

July 11–13, 1979. Baltimore, Maryland. Twelfth Miles International Symposium; Polypeptide Hormones 174

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 10 NUMBER 2 FEBRUARY 1979

CONTENTS

Tonic immobility: Effects of dopamine receptor blockade and stimulation. WALLNAU, L. B., C. L. CARNRIKE, JR. and G. I. DEWEY 177

Scotophobin A causes several responses in goldfish if the pineal gland is present. SATAKE, N. and B. E. MORTON 183

Altered response to apomorphine and haloperidol after nine days of cocaine injections. EPSTEIN, P. N. and H. L. ALTSHULER 189

An electrophysiological correlate of amphetamine revealed motor imbalance in albino rats. SHAVIT, Y. and M. MYSLOBODSKY 195

The effect of metal complex of thyrotropin-releasing hormone on locomotor activity of neonatal chicken. TONOUE, T., S. MINAGAWA, N. KATO, M. KAN, T. TERAO, K. NONOYAMA and K. OHKI 201

The effects and interactions of scopolamine, physostigmine and methamphetamine on human memory. MEWALDT, S. P. and M. M. GHONEIM 205

Increasing the rate of ethanol consumption in food- water-satiated rats. MACDONALL, J. S. and H. MARCUCELLA 211

Effects of diazepam and ethanol alone and in combination on conditioned suppression of key-pecking in the pigeon. EDWARDS, J. D. and D. A. ECKERMAN 217

Effect of α-methyltryptamine on spontaneous activity in mice. RUSTERHOLZ, D. B., J. P. LONG and D. E. NICHOLS 223

Effects of desglycinamide^{9}-lysine^{8}-vasopressin and prolyl-leucyl-glycinamide on oral ethanol intake in the rat. MUCHA, R. F. and H. KALANT 229

Interaction of food deprivation with different measures of amphetamine effects. COLE, S. O. 235

Prenatal effects of alcohol on adult learning in rats. ABEL, E. L. 239

Biochemical effects of cycloheximide in developing chick brain. WOOLSTON, M. E., I. G. MORGAN and J. W. HAMBLEY 245

Aversive properties of cycloheximide versus memory inhibition in chickens' formation of visually cued food aversions. BOLAS, K. C., W. P. BELLINGHAM and G. M. MARTIN 251

Response perseveration in rats exposed to alcohol prenatally. RILEY, E. P., E. A. LOCHRY, N. R. SHAPIRO and J. BALDWIN 255

The effects of acetylmethadol on motor activity and schedule-controlled responding. MCGIVNEY, W. T. and D. E. MCMILLAN 261

Metabolism correlates of cocaine-induced stereotypy in rats. ESTEVEZ, V. S., B. T. HO and L. F. ENGLERT 267

Generalization of norcocaine to the discriminative stimulus properties of cocaine. MCKENNA, M. L., B. T. HO and L. F. ENGLERT 273

Effect of addition of ethanol and NaCl on saccharin + glucose polydipsia. KULKOSKY, P. J. ... 277

The effect of sulfinpyrazone on morphological changes in the coronary vasculature induced by prolonged unpredictable stress in the rat. CAIRNCROSS, K. D., J. R. BASSETT and C. MARTIN 285

Mescaline increases startle responding equally in normal and raphe-lesioned rats. GEYER, M. A., G. J. ROSE and L. R. PETERSEN 293

Effects of methylphenidate on schedule dependent and schedule induced behavior. WAYNER, M. J., R. B. MINTZ, F. B. JOLICOEUR and D. B. RONDEAU 299

Relationship between facial flushing and blood acetaldehyde levels after alcohol intake. MIZOI, Y., I. IJIRI, Y. TATSUNO, T. KIJIMA, S. FUJIWARA, J. ADACHI AND S. HISHIDA 303

BRIEF COMMUNICATION

Effect on core temperature of restraint after peripherally and centrally injected morphine in the Sprague-Dawley rat. MARTIN, G. E. and N. L. PAPP 313

ANNOUNCEMENTS

July 11–13, 1979. Baltimore, Maryland. Twelfth Miles International Symposium; Polypeptide Hormones 317

Curt P. Richter Prize in Psychoneuroendocrinology 318

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 10 NUMBER 3 MARCH 1979

CONTENTS

6-Hydroxydopamine reduces preference for conspecific but not other familiar odors in rat pups. MARASCO, E. M., C. A. CORNWELL-JONES and S. K. SOBRIAN 319

ACTH self-administration in rats. JOUHANEAU-BOWERS, M. and J. LE MAGNEN 325

Relations between metabolic and nervous tolerance towards ethanol in naive and chronically intoxicated rats. MICELI, D. and J. LE MAGNEN 329

The influence of mouse genotype on the changes in brain cyclic nucleotide levels induced by acute alcohol administration. CHURCH, A. C. and D. FELLER 335

Effects of alcohol and caffeine on wheel running activity in the Mongolian gerbil. PETTIJOHN, T. F. 339

Behavioral and biochemical effects of chronic consumption of ethanol by hamsters. HARRIS, R. A., W. KRAUSE, E. GOH and J. CASE 343

Relations between nicotine-induced convulsive behavior and blood and brain levels of nicotine as a function of sex and age in two inbred strains of mice. TEPPER, J. M., J. R. WILSON and K. SCHLESINGER 349

The effect of psychoactive drugs on plasma corticosterone levels and behaviour in the bulbectomised rat. CAIRNCROSS, K. D., A. WREN, C. FORSTER, B. COX and H. SCHNIEDEN .. 355

Diurnal rhythms in noradrenaline turnover and motility after reserpine and 6-hydroxydopamine. LEMMER, B. and K. WENDA 361

PA-learning in young rats with dorsal hippocampal- and hippocampo-entorhinal atropine. BLOZOVSKI, D. 369

Neurochemical basis of the dorsal bundle extinction effect. MASON, S. T. and H. C. FIBIGER 373

Mediation of footshock sensitivity by serotonergic projection to hippocampus. SMITH, R. F. 381

A modification of the dialytrode for simultaneous CNS recording and chemical stimulation. CORNISH, K. G. and R. E. HALL 389

Impairment of acquisition of a DRL schedule following prolonged ethanol consumption. DENOBLE, V. J. and H. BEGLEITER 393

Quantitative relationships among various measures of morphine tolerance and physical dependence in the rat. MUCHA, R. F., H. KALANT and M. A. LINSEMAN 397

Interactions of acetylmethadol or methadone with other drugs in rhesus monkeys. DOWNS, D. A... 407

Effects of the neuropeptide DG-AVP on morphine and food self-administration by dependent rhesus monkey. MELLO, N. K. and J. H. MENDELSON 415

Significance of central noradrenergic system on harmaline induced tremor. YAMAZAKI, M., C. TANAKA and S. TAKAORI 421

BRIEF COMMUNICATIONS

An electrode-cannula unit for intracerebral electrical stimulation, EEG recording and drug administration in small animals. LAIRD, H. E., II,, J. E. HERMANSEN and R. J. HUXTABLE ... 429

Rat rotation monitoring for pharmacology research. WALSH, M J. and E. K. SILBERGELD 433

A comparison of methylphenidate induced active avoidance and water maze performance facilitation. KINNEY, L. and C. V. VORHEES 437

A reward-reduction model of depression using self stimulating rats: An appraisal. BINKS, S. M., J. K. MURCHIE and D. T. GREENWOOD 441

ANNOUNCEMENTS

Call for Papers

7 June 1979. Philadelphia, Pennsylvania. Protracted Effects of Perinatal Drug Dependence. Sattelite Meeting of the Committee on Problems of Drug Dependence 445

July 11–13, 1979. Baltimore, Maryland. Twelfth Miles International Symposium; Polypeptide Hormones. 446

Announcing a New Journal. *Neurobehavioral Toxicology*. 447

Harold L. Stuart Postdoctoral Fellowship in Neurobiology-Nutrition 448

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 10 NUMBER 4 APRIL 1979

CONTENTS

Scotophobin A causes dark avoidance in goldfish by elevating pineal N-acetylserotonin. SATAKE, N. and B. E. MORTON. 449

Pineal hydroxyindole-O-methyltransferase: Mechanism, and inhibition by scotophobin A. SATAKE, N. and B. E. MORTON. 457

Enhanced suppressive effects of aversive events induced in rats by picrotoxin: Possibility of a GABA control on behavioral inhibition. SOUBRIE, P., M. H. THIEBOT and P. SIMON. 463

Schedule-induced drinking and thirst: A pharmacological analysis. SANGER, D. J. and P. K. CORFIELD-SUMNER. 471

Potentiation of haloperidol-induced catalepsy by dopamine agonists: Possible involvement of central 5-hydroxytryptamine. CARTER, C. J. and C. J. PYCOCK. 475

Exposure to a nonfunctional hot plate as a factor in the assessment of morphine-induced analgesia and analgesic tolerance in rats. BARDO, M. T. and R. A. HUGHES. 481

Effects of cerebral intraventricular magnesium injections and a low magnesium diet on nonspecific excitability level, audiogenic seizure susceptibility and serotonin. BUCK, D. R. , A. W. MAHONEY and D. G. HENDRICKS. 487

Evidence supporting lack of discriminative stimulus properties of a combination of naltrexone and morphine. JÄRBE, T. U. C., P. LOMAN and M. D. B. SWEDBERG. 493

Morphine potentiation of tonic immobility: Effects of naloxone, PCPA, and 5,6-DHT. WALLNAU, L. B. and G. G. GALLUP, JR. 499

Behavioral effects of aluminum ingestion on animal and human subjects. BOWDLER, N. C., D. S. BEASLEY, E. C. FRITZE, A. M. GOULETTE, J. D. HATTON, J. HESSION, D. L. OSTMAN, D. J. RUGG and C. J. SCHMITTDIEL. 505

Sensorimotor deficits produced by phenytoin and chlorpromazine in unanesthetized cats. CARP, J. S. and R. J. ANDERSON. 513

Puromycin: Two distinct behavioral effects with different temporal parameters in the pigeon. STETTNER, L. J., R. A. BARRACO, B. J. KLAUENBERG and H. NORMILE. 521

Alteration of alcohol effects by calcium and other inorganic cations. HARRIS, R. A. 527

Discriminative stimulus properties of cocaine: Neuropharmacological characteristics as derived from stimulus generalization experiments. COLPAERT, F. C., C. J. E. NEIMEGEERS and P. A. J. JANSSEN. 535

Brain serotonin metobolism with relation to the head twitches elicited by lithium in combination with reserpine in mice. FURUKAWA, T., K. YAMADA, Y. KOHNO and N. NAGASAKI. . 547

Impaired thermal regulation in juvenile rats following perinatal methadone exposure. THOMPSON, C. I., I. S. ZAGON and P. J. MCLAUGHLIN. 551

Endocrine factors contributing to the ethanol preferences of rodents. GOAS, J. A., R. W. PELHAM and A. S. LIPPA. 557

Effects of prolintane on 3,4-dihydroxyphenylacetic acid concentration in rat brain after spiperone treatment. FULLER, R. W. and H. D. SNODDY. 561

Discriminative stimulus properties of *levo-alpha*-acetylmethadol and its metabolites. HOLTZMAN, S. G. 565

Facilitation of avoidance acquistion in rats produced by p-chlorophenylalanine or p-chloroamphetamine. VOORHEES, C. V. 569

Methylphenidate and *d*-amphetamine: Effects and interactions with alphamethyltyrosine and tetrabenazine on DRL performance in rats. SEIDEN, L. S., J. ANDRESEN and R. C. MACPHAIL. 577

Spontaneous vs. naloxone-induced abstinence in dependent rats self-administering l-alpha-acetylmethadol (LAAM) or morphine. YOUNG, G. A., G. F. STEINFELS and N. KHAZAN. 585

Effects of methylphenidate of food and water consumption at different body weights. BARONE, F. C., M. J. WAYNER, H. K. LEE, W. H. TSAI, D. L. DEHAVEN and W. WOODSON, JR. 591

Alcohol-deprivation effect in rats genetically selected for their ethanol preference. SINCLAIR, J. D. 597

On the role of ascending dopamine systems in the control of voluntary ethanol intake and ethanol intoxication. KIIANMAA, K., K. ANDERSSON and K. FUXE. 603

THEORETICAL REVIEW

Influence of opioids on central thermoregulatory mechanisms. CLARK, W. G. 609

BRIEF COMMUNICATIONS

Facilitation by opiate antagonists of sexual performance in the male rat. MYERS, B. M. and M. J. BAUM. 615

An easily assembled and inexpensive apparatus for continuous monitoring of expired carbon dioxide concentrations in artificially ventilated animals. STRAHLENDORF, H. K., J. C. STRAHLENDORF and G. JOHNSON. 619

Detection of antagonist activity for narcotic analgesics in mouse hot-plate test. JANICKI, P. and J. LIBICH. 623

ANNOUNCEMENTS

Announcing a New Journal. *Neurobehavioral Toxicology* 627

Call for Papers

7 June 1979. Philadelphia, Pennsylvania. Protracted Effects of Perinatal Drug Dependence. Satellite Meeting of the Committee on Problems of Drug Dependence 628

July 11—13, 1979. Baltimore, Maryland. Twelfth Miles International Symposium; Polypeptide Hormones. 629

Harold L. Stuart Postdoctoral Fellowship in Neurobiology-Nutrition 630

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 10 NUMBER 5 MAY 1979

CONTENTS

The use of Doppler shift radar to monitor physiological and drug induced activity patterns in the rat. MARSDEN, C. A. and B. KING 631

Ethanol intake during scheduled and non-scheduled food presentations. BARTNESS, T. J. and L. A. ALFERINK 637

Retrograde amnesia in chicks and mice induced by 3,4-dehydro-DL-proline, a proline analog. DAVIS, J. L. and A. CHERKIN 643

Brain biochemical and behavioral changes in 4 weeks old rat after neonatal oxygen deprivation. HEDNER, T., P. LUNDBORG and J. ENGEL 647

LiCl-induced selective depression of saccharin drinking in the mouse. HAMBURGER, J. N. and C. L. KUTSCHER 651

Effects of serotonin content on pain sensitivity in the rat. TELNER, J. I., F. LEPORE and J. -P. GUILLEMOT 657

Effects of lithium chloride injections on rank-related fighting, maternal aggression and locust-killing responses in naive and experienced 'TO' strain mice. BRAIN, P. F. and S. AL-MALIKI .. 663

On the action of nicotine and cotinine on central 5-hydroxytryptamine neurons. FUXE, K., B. J. EVERITT and T. HÖKFELT 671

Lateralisation of function in the chicken fore-brain. ROGERS L. J. and J. M. ANSON 679

Ascending 5-HT pathways and behavioural habituation. DEAKIN, J. F. W., S. E. FILE, J. R. G. HYDE and N. K. MACLEOD 687

Role of pars compacta of the substantia nigra in circling behavior. HODGE, G. K. and L. L. BUTCHER 695

Comparison of behavioral effects of systemic L-DOPA and intracranial dopamine in mesolimbic forebrain of nonhuman primates. DILL, R. E., D. L. JONES, J. C. GILLIN and G. MURPHY 711

Juvenile-onset obesity and deficits in caloric regulation in MSG-treated rats. KANAREK, R. B., J. MEYERS, R. G. MEADE and J. MAYER 717

Catecholaminergic and cholinergic agents and duration regulation of ICSS in the rat. EDWARDS, M., J. WISHIK and H. M. SINNAMON 723

Reversal learning deficits in young monkeys exposed to lead. BUSHNELL, P. J. and R. E. BOWMAN 733

Development of motor activity in young rats following perinatal methadone exposure. ZAGON, I. S., P. J. MCLAUGHLIN and C. I. THOMPSON 743

Decreased resistance to extinction after haloperidol: Implications for the role of dopamine in reinforcement. PHILLIPS, A. G. and H. C. FIBIGER 751

Opiate and non-opiate mechanisms of stress-induced analgesia: Cross-tolerance between stressors. SPIAGGIA, A., R. J. BODNAR, D. D. KELLY and M. GLUSMAN 761

Effects of a fixed time schedule and body weight on ethanol self-administration. OEI, T. P. S. and G. SINGER 767

Facilitation of conditioned motor suppression by microinjections of dopamine in the caudate nucleus of cats. ZARCO-CORONADO, I., C. REYES-VAZQUEZ and H. BRUST-CARMONA 771

Ethanol drinking by rhesus monkeys with concurrent access to water. HENNINGFIELD, J. E. and R. A. MEISCH 777

Differential effects on learning by ventromedial vs. lateral hypothalamic posttrial injection of substance P. STAUBLI, U. and J. P. HUSTON 783

Distribution, survival and biological effects in mice of a behaviorally active, enzymatically stable peptide: Pharmacokinetics of cyclo(Leu-Gly) and puromycin-induced amnesia. RAINBOW, T. C., J. B. FLEXNER, L. B. FLEXNER, P. L. HOFFMAN and R. WALTER 787

BRIEF COMMUNICATIONS

Lack of tolerance development to benzodiazepines in antagonism of the pentylenetetrazol discriminative stimulus. SHEARMAN, G. T., S. MIKSIC and H. LAL 795

Simple cannula for repeated intracerebral drug administration in rats. CRANE, L. A. and S. D. GLICK 799

MEETING REPORT

Symposium on recent developments in the study of the mechanisms of benzodiazepine actions. Maui, Hawaii, December 1978 801

Molecular mechanisms regulating the interactions between the 1,4-benzodiazepines and GABA receptors in the central nervous system. GUIDOTTI, A., M. BARALDI, J. P. SCHWARTZ and E. COSTA 803

Moldulation of benzodiazepine binding site sensitivity. TALLMAN, J. F. and D. W. GALLAGER 809

CNS benzodiazepine receptors: Physiological studies and putative endogenous ligands. SKOLNICK, P., P. J. MARANGOS, P. SYAPIN, F. K. GOODWIN and S. M. PAUL 815

Some properties of brain specific benzodiazepine receptors: New evidence for multiple receptors. SQUIRES, R. F., D. I. BENSON, C. BRAESTRUP, J. COUPET, C. A. KLEPNER, V. MYERS and B. BEER 825

Benzodiazepine receptors: Cellular and behavioral characteristics. LIPPA, A. S., D. CRITCHETT, M. C. SANO, C. A. KLEPNER, E. N. GREENBLATT, J. COUPET and B. BEER . 831

BOOKS RECEIVED 845

ANNOUNCEMENTS

Announcing a New Journal. ***Neurobehavioral Toxicology*** 846

University of Miami School of Medicine Award for Diagnostic Research 847

Proceedings of Workshop on Test Methods for Definition of Effects of Toxic Substances on Behavior and Neuromotor Function 848

November 6-10, 1979. Myrtle Beach, South Carolina. International Symposium on GABA and other Inhibitory Neurotransmitters 849

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 10 NUMBER 6 JUNE 1979

CONTENTS

Delta 9-tetrahydrocannabinol: Elevation of absolute visual thresholds of rabbits. ROSE, S. E., W. O. DWYER and A. L. YEHLE. 851

Functional development of dopamine receptors in the rat forebrain. ORMOND, D. L. and C. VAN HARTESVELDT. 855

Effects of d-amphetamine and methylphenidate upon auditory threshold in the squirrel monkey. DELAY, E. R., N. O. STEINER and W. ISAAC. 861

Prostaglandin synthetase inhibitors antagonize the depressant effects of ethanol. GEORGE, F. R. and A. C. COLLINS. 865

Metabolic and pharmacodynamic tolerance to ethanol in rats. WOOD, J. M. and R. LAVERTY. 871

Adrenal demedullation and peripheral 6-OHDA administration in the rabbit: Effects on body weight, general activity and cardiovascular responsivity. JOSEPH, J., W. BOGGAN and D. A. POWELL. 875

Cerebral blood flow after treatment with ORG-2766, a potent analog of ACTH 4-9. GOLDMAN, H., S. MURPHY, D. R. SCHNEIDER and B. T. FELT. 883

Learning ability in adult female rats perinatally exposed to methadone. ZAGON, I. S., P. J. MCLAUGHLIN and C. I. THOMPSON. 889

Prostaglandin E_1 inhibits acute cell dehydration thirst. GOLDSTEIN, D. J., D. J. MARANTE PEREZ, J-P. GUNST and J. A. HALPERIN. 895

Effects of [des-Tyr^1]-γ-endorphin and α-endorphin on substantia nigra self-stimulation. DORSA, D. M., J. M. VAN REE and D. DE WIED. 899

Effects of psychotropic drugs on pressor and behavioral responses to brain stimulation in unrestrained, unanesthetized rats. KAWASAKI, H., S. WATANABE and S. UEKI. 907

Inhibition of the action of anticonvulsants by lithium treatment. KADZIELAWA, K. 917

Is the noradrenergic "feeding circuit" in hypothalamus really an olfactory system? MYERS, R. D., M. L. MCCALEB and K. A. HUGHES. 923

BRIEF COMMUNICATIONS

Biochemical aspects of protein synthesis inhibition by cycloheximide in one or both hemispheres of the chick brain. GIBBS, M. E., A. L. RICHDALE and K. T. NG. 929

Dissimilar effects of lithium isotopes on motility in rats. LIEBERMAN, K. W., G. J. ALEXANDER and P. STOKES 933

Specific modulation of brain stimulation reward by haloperidol. ESPOSITO, R. U., W. FAULKNER and C. KORNETSKY. 937

Meperidine does not block the cholinergic effects of oxotremorine. LEANDER, J. D. 941

Effect of brain peptides on hypokinesia produced by anterolateral hypothalamic 6-OHDA lesions in rats. RONDEAU, D. B., F. B. JOLICOEUR, F. BELANGER and A. BARBEAU. 943

Cyclobenzaprine and ethanol interaction. MESSIHA, F. S. and C. D. BARNES. 947

Hyperphagia following intraventricular p-chlorophenylalanine-, leucine- or tryptophan-methyl esters: Lack of correlation with whole brain serotonin levels. MACKENZIE, R. G., B. G. HOEBEL, R. P. DUCRET and M. E. TRULSON. 951

Changes in brain levels of NE and 5-HT are not responsible for attenuation of audiogenic seizures by spinal cordotomy. WILLOTT, J. F., C. E. LINTS and L. H. NENJA. 957

ERRATUM 959

ANNOUNCEMENTS

September 2–6,1979. Jerusalem, Israel. Seventh International Meeting of the International Society for Neurochemistry 960

November 6–10, 1979. Myrtle Beach, South Carolina. International Symposium on GABA and Other Inhibitory Neurotransmitters 961

Supplement to *Brain Research Bulletin* Volume 4, 1979. *The Anatomy of the Brain of the Bottlenose Dolphin* (Tursiops truncatus). *Rhinic Lobe (Rhinencephalon): The Archicortex* 962

Supplement to *Neuroscience and Biobehavioral Reviews* Volume 3, 1979. *Blood Supply to the Brain of the Dolphin*, Tursiops truncatus, *With Comparative Observations on Special Aspects of the Cerebrovascular Supply of Other Vertebrates* 963

Supplement to *Pharmacology Biochemistry and Behavior*, Volume 5, 1976. *The Neuropeptides, Pharmacology, Physiological Substrates and Behavioral Effects* 964

AIMS AND SCOPE

Pharmacology Biochemistry & Behavior will publish original reports of systematic studies in the areas of pharmacology, biochemistry, toxicology and behavior in which the primary emphasis and theoretical context are behavioral; and brief communications which describe a new method, technique or apparatus and results of experiments which can be reported briefly with limited figures and tables. Behavioral studies as such will not be published unless they are obviously pertinent and make a significant contribution to pharmacology, biochemistry or toxicology. A limited number of relevant reviews and theoretical articles, results of symposia, and more comprehensive studies as monograph supplements will also be published. Articles will be published in English.

The accepted abbreviation for *Pharmacology Biochemistry & Behavior* for bibliographic citation is *Pharmac. Biochem. Behav.*

INSTRUCTIONS TO AUTHORS

Manuscripts should be sent directly to the Editor-in-Chief or to the most proximal Regional Editor for review and will be published within three months or less after formal acceptance.

STYLE OF MANUSCRIPT

General Form. (1) Manuscripts should be submitted in duplicate and should be typewritten, double spaced with wide margins on good quality paper. (2) The title page should contain: title of paper; author(s); laboratory or institution of origin with city, state, zip code, and country; complete address for mailing proofs; a running head not to exceed 50 characters including spaces between words. (3) References, footnotes, and legends for illustrations should be typed on separate sheets, double spaced. (4) Illustrations (unmounted photographs) should be identified on the reverse with figure number and author(s) name; when necessary the top should be clearly marked. (5) Each table should be typed on a separate sheet and double spaced. (6) All dimensions and measurements must be specified in the metric system. Standard nomenclature, abbreviations and symbols, as specified by Royal Society Conference of Editors. Metrication in Scientific Journals, *Am. Scient.* **56**: 159–164, 1968, should be used throughout. (7) Italics should not be used for the purpose of emphasis.

Title. The title should not be longer than 85 characters, including spaces between words.

Papers in a series such as: "Studies on . . . I." will not be accepted.

Length of Paper. The Editors insist upon clear, concise statement of facts and conclusions. Fragmentation of material into numerous short reports is discouraged.

Abstract. Each paper submitted must be accompanied by an abstract, which does not exceed 170 words and must be suitable for use by abstracting journals. Abstracts should be prepared as follows:

> EVANS, B. K., S. ARMSTRONG, G. SINGER, R. D. COOK AND G. BURNSTOCK. *Intracranial injection of drugs: comparison of diffusion of* . . . PHARMAC. BIOCHEM. BEHAV. Marked differences in extent of diffusion have been . . .

A list of from 3–12 (or more) words or short phrases suitable for indexing terms should be typed at the bottom of the abstract page accompanying the manuscript. These terms will be printed with the paper at the end of the abstract.

Drugs. Proprietary (trademarked) names should be capitalized. The chemical name should precede the trade, popular name, or abbreviation of a drug the first time it occurs.

Footnotes. Title page footnotes should be numbered consecutively. Text footnotes should not be used, the material should be incorporated into the text. Table footnotes: see *Tables* (b).

References. Literature cited should be numbered in brackets in text (only one reference to a number) and listed in alphabetical order on a separate sheet at the end of the manuscript. *Do not recite names of authors within the text.* Journal citations in the reference list should contain the following: (a) surnames and initials of all authors (surname of first author precedes initials; initials precede surnames of all co-authors); (b) title of article; (c) journal title abbreviated as listed in the 4th edition of the *World List of Scientific Periodicals;* (d) volume, inclusive pages, and year. Example:

1. Abrams, R. and H. T. Hammel. Hypothalamic temperature in unanesthetized albino rats during feeding and sleeping. *Am. J. Physiol.* **206**: 641–646, 1964.

Book references should be in the following order: author, title, city of publication, publisher, year, and pages. Example:

1. Thompson, T. and C. R. Schuster. *Behavioral Pharmacology.* Englewood, New Jersey: Prentice-Hall, Inc., 1968, p. 297.

Citations such as "Unpublished observations," "Personal communication," "Manuscript in preparation," "To be published," should not be entered in the list of References, but may be noted in the text without serial numbers, in parentheses.

Illustrations. (a) Prepare for use in a single column width whenever possible. (b) All drawings for reduction to a given size should be drawn and lettered to the same scale. (c) All illustrations should be referred to as figures and numbered in Arabic numerals. (d) Lettering should be done in India ink or other suitable material and must be proportionate to the size of the illustrations if it is to be legible after reduction. Lettering should be sized so that its smallest elements (subscripts or superscripts) will be readable when reduced. (e) When possible all lettering should be within the framework of the illustration; likewise the key to symbols should be on the face of the chart. The following standard symbols should be used as they are easily available to the printer. ○ ● △ ▲ □ ■ + (f) Actual magnification of all photomicrographs should be given. Dimension scale should be indicated. (g) Sharply contrasting unmounted photographs of figures on glossy paper are required.

Tables. (a) Each table should have a brief heading; explanatory matter should be in footnotes, not as part of the title. (b) Table footnotes should be indicated in the body of the table in order of their appearance with the following symbols: * † ‡ § ¶ # **, etc. (c) Tables must not duplicate material in text or illustrations. (d) Vertical rules should be omitted. (e) Short or abbreviated column heads should be used. (f) Statistical measures of variation, SD, SE, etc., should be identified. (g) Analysis of Variance Tables should not be submitted but significant F's should be incorporated where appropriate within the text. The appropriate form for reporting F values is: $F(11,20) = 3.05$, $p<0.01$.

Formulas and Equations. Structural chemical formulas, process flow-diagrams, and complicated mathematical expressions should be kept to a minimum. Usually chemical formulas and flow-diagrams should be drawn in India ink for reproduction as line cuts.

All subscripts, superscripts, Greek letters, and unusual characters must be clearly identified.

Anesthesia. In describing surgical procedures on animals, the type and dosage of the anesthetic agent should be specified. Curarizing agents are not anesthetics; if these were used, evidence must be provided that anesthesia of suitable grade and duration was employed.

Proofs. Corrections to the proofs must be restricted to printer's errors only. Other than these, any other alterations will be charged to the author.

Reprints. Each author will receive with his galley proofs a reprint order form which must be completed and returned with the proofs. Late orders cannot be filled since reprints are run at the time the Journal is printed. Senior author receives 25 reprints free.

Pharmacology Biochemistry & Behavior, Vol. 10, © Ankho International Inc., 1979. Printed in the U.S.A.

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 10 1979

SUBJECT INDEX

Abomasal function
  9-aza-cannabinol, 63
  action potential, 63
  contraction, 63
  elfazepam, 63
  pH, 63
  slow wave, 63
Absolute visual threshold
  aversive classical conditioning, 851
  Δ^9-THC, 851
Abstinence
  l-α-acetylmethadol, 585
  lever pressing, 585
  morphine, 585
  naloxone, 585
  REM sleep, 585
Acetylcholine
  central cholinergic involvement in behavioral hyper-reactivity, 43
  hemicholinium-3, 43
Acetylcholinesterase levels
  activity, 21
  emotional behavior, 21
  ethanol, 21
  methomyl, 21
  open-field behavior, 21
Acetylmethadol
  duration of action, 261
  motor activity, 261
  schedule-controlled responding, 261
  time course, 261
L-α-Acetylmethadol
  abstinence, 585
  d-amphetamine, 407
  cocaine, 407
  diazepam, 407
  discriminative stimulus, 565
  ethanol, 407
  lever pressing, 585
  methadone, 565
  morphine, 585
  naloxone, 585
  operant behavior, 407
  REM sleep, 585
N-acetylserotonin
  dark avoidance, 449
  pineal gland, 449
  scotophobin, 449
$ACTH_{4-9}$ analog
  facilitates acquisition of an inhibitory avoidance response, 145
  ORG-2766, 883
  regional blood brain flow, 883
ACTH
  brain rewarding system, 325
  neuropeptides, 325
  self administration, 325
Action potential
  abomasal function following injections of elfazepam and 9-aza-cannabinol, 63
Active avoidance
  adult learning, 889
  avoidance facilitation, 437
  methylphenidate, 437
  perinatal exposure to methadone, 889
  water maze, 437
Activity
  acetylcholinesterase levels, 21
  adrenal demedullation, 875
  blood pressure, 875
  body weight, 875
  cardiovascular responsivity, 875
  cement kiln dust, 1
  ethanol, 21
  6-hydroxydopamine, 875
  interaction of food deprivation with different measures of amphetamine effects, 235
  methomyl, 21
Activity cage
  behavioral development, 743
  motor activity, 743
  perinatal methadone exposure, 743
Activity wheel
  behavioral development, 743
  motor activity, 743
  perinatal methadone exposure, 743
Acute cell dehydration thirst
  compound 48/80, 895
  drinking, 895
  mast cells, 895
  prostaglandin E_1, 895
Adiposity
  body weight, 717
  caloric regulation, 717
  juvenile-onset obesity, 717
  monosodium glutamate, 717

Adjunctive drinking
methylphenidate, 299
schedule dependent behavior, 299
schedule induced behavior, 299
Adrenal demedullation
activity, 875
blood pressure, 875
body weight, 875
cardiovascular responsivity, 875
6-hydroxydopamine, 875
Adrenalectomy
interaction of brain noradrenaline and the pituitary-adrenal axis in learning and extinction, 11
Adult learning
active avoidance, 889
light-dark discrimination, 889
passive avoidance, 889
perinatal methadone exposure, 889
Age
blood and brain levels of nicotine, 349
nicotine-induced convulsive behavior, 349
sex, 349
Alcohol dehydrogenase
cyclobenzaprine and ethanol interaction, 947
Alcohol deprivation effect
ethanol, 597
genetic selection for preference, 597
spontaneous alternation, 597
strain differences, 597
Alcohol intake
blood acetaldehyde level, 303
carotid arterial blood flow, 303
facial flushing, 303
pulse rate, 303
skin temperature, 303
urinary epinephrine and norepinephrine, 303
Alcohol withdrawl
blood ethanol, 277
ethanol intake, 277
glucose, 277
polydipsia, 277
saccharin, 277
Alphamethyltyrosine
d-amphetamine, 577
catecholamines, 577
DRL performance, 577
drug behavior interaction, 577
methylphenidate, 577
tetra benazine, 577
Aluminum
behavior, 505
learning ability, 505
motor coordination and activity, 505
toxicity, 505
visual temporal activity, 505
Amino acids
3,4-dehydro-DL-proline, 643
memory, 643
l-proline, 643
retrograde amnesia, 643
Amnesia
cyclo(leu-gly), 787
learning deficits, 521
memory, 521, 787
pituitary peptides, 787
protein synthesis inhibition, 521
puromycin, 521
puromycin amnesia, 787
temporal gradient, 521
time course, 787
visual discrimination, 521
Amphetamine
auto-titration brain stimulation, 127
circling behavior, 695
depression, 441
discriminative stimulus properties of cocaine, 535
dopamine, 695
dopamine asymmetry, 195
drug effects, 127
eating, 87
effects of clozapine on the activity of central dopaminergic and noradrenergic neurons, 5
free-operant brain stimulation, 127
haloperidol, 127
hemispheric asymmetry, 195
lean and obese Zucker rats, 87
median raphe, 695
α-methyltyrosine, 127
motor imbalance, 195
obesity, 87
pars compacta of the substantia nigra, 695
reward-reduction model, 441
rotation behavior, 195
self-stimulation, 441
stimulus generalization, 535
visual evoked potential, 195
d-Amphetamine
activity, 235
alphamethyltyrosine, 577
anorexia, 235
avoidance behavior, 137
catalepsy, 475
catecholamines, 577
chlordiazepoxide, 471
circadian rhythm, 631
dopamine agonists, 475
doppler shift radar to monitor physiological and drug induced activity patterns, 631
DRL performance, 577
drug behavior interaction, 577
food deprivation, 235
food-dish contact time, 235
5-hydroxytryptamine, 475
interactions of acetylmethadol or methadone, 407
interrelationship of drug effects, 235
kainic acid, 137
locomotor behavior, 137
methylphenidate, 577
neostriatal lesions, 137
operant behavior, 137
schedule-induced drinking, 471
tetrabenazine, 577
thirst, 471
d-Amphetamine sulfate
auditory threshold, 861
behavioral depressant in diurnal animals, 861
Analgesia
behavioral tolerance, 481
hot plate, 481
morphine, 481
naloxone, 481
pharmacological tolerance, 481
Angiotensin II
blood pressure, 121
drinking, 121
eating, 121
urine, 121
Anorexia
interaction of food deprivation with different measures of amphetamine effects, 235
Anosmic opponents
maternal aggression, 663
LiCl, 663
locust-killing responses, 663
rank-related responses, 663
Antagonist activity
hot plate behavior, 623
morphine, 623
nalorphine, 623
naloxone, 623

narcotic analgesics, 623
opiate agonists, 623
opiate antagonists, 623
pentazocine, 623
Antagonistic effect
conditioned suppression of key-pecking, 217
diazepam and ethanol drug interaction, 217
Anticholinergic
atropine, 941
meperidine does not block the cholinergic effects of oxtremorine, 941
Anticonvulsants
carbonic anhydrase inhibitors, 917
inhibition of the action, 917
lithium, 917
maximal electroshock, 917
phenobarbital, 917
phenytoin, 917
Antidepressants
bulbectomy, 355
effect of psychoactive drugs on plasma corticosterone levels and behavior, 355
Antiparkinsonian agents
apomorphine, 161
N-n-propylnorapomorphine, 161
stereotypy, 161
videotaping, 161
Apomorphine
catalepsy, 177, 189, 475
circling behavior, 695
cocaine, 189
dopamine, 177, 695
dopamine agonists, 475
evaluation of stereotypic effects of antiparkinsonian agents, 161
haloperidol, 177
6-hydroxydopamine, 943
5-hydroxytryptamine, 475
hypokinesia, 943
locomotor activity, 177
median raphe, 695
motor activity, 943
pars compacta of the substantia nigra, 695
serotonin, 177
stereotypy, 189
tolerance, 189
tonic immobility, 177
videotaping, 161
Apparatus modification of the dialytrode for simultaneous CNS recording and chemical stimulation, 389
an easily assembled and inexpensive apparatus for continuous monitoring of expired carbon dioxide concentrations in artifically ventilated animals, 619
an electrode-cannula unit for intracerebral electrical stimulation, EEG recording and drug administration in small animals, 429
simple cannula for repeated intracerebral drug administration, 799
videotaping: the evaluation of stereotypic effects of antiparkinsonian agents, 161
Artifically ventilated animals
apparatus for continuous monitoring of expired carbon dioxide concentration, 619
Ascending dopamine systems
role in the control of voluntary ethanol intake and intoxication, 603
Atropine
anticholinergic, 941
hippocampal complex, 369
meperidine, 941
oxtremorine, 941
passive avoidance learning, 369
Audiogenic seizures
5-hydroxytryptamine, 957
norepinephrine, 957
spinal cordotomy, 957
Audiogenic seizure susceptibility
intraventricular magnesium injection, 487
magnesium deficiency, 487
Auditory habituation
cycloheximide, 679
forebrain, 679
hemispheric lateralisation, 679
response to novelty, 679
visual learning, 679
Auditory threshold
d-amphetamine sulfate, 861
methylphenidate hydrochloride, 861
Auto-titration brain stimulation
amphetamine, 127
drug effects, 127
free-operant brain stimulation, 127
haloperidol, 127
α-methyltyrosine, 127
Aversive classical conditioning
absolute visual threshold, 851
Δ^9-THC, 851
Aversive properties
cycloheximide, 251
conditioned aversions, 251
memory inhibition, 251
Avoidance acquisition
p-chloroamphetamine, 569
p-chlorophenylalanine, 569
open field activity, 569
shuttle-box learning, 569
y-maze, 569
Avoidance behavior
d-amphetamine, 137
neostriatal injections of kainic acid, 137
Avoidance facilitation
active avoidance, 437
methylphenidate, 437
water maze, 437
9-Aza-cannabinol
abomasal function, 63
action potential, 63
contractions, 63
pH, 63
slow wave, 63

Basal ganglia
ORG-2766 a potent analog of $ACTH_{4-9}$, 883
regional blood brain flow, 883
Behavior
aluminum, 505
antidepressants, 355
bulbectomy, 355
central stimulants, 355
corticosterone levels, 355
effect of psychoactive drugs, 355
learning ability, 505
motor coordination and activity, 505
tranquilizers, 355
visual temporal activity, 505
Behavioral characteristics
benzodiazepine receptors, 831
functional localization, 831
Behavioral depressant
d-amphetamine sulfate in diurnal animals, 861
Behavioral development
activity cage, 743
activity wheel, 743
motor activity, 743
open field behavior, 743
perinatal methadone exposure, 743
Behavioral effect
chronic ethanol consumption, 343
metabolic response, 343

Behavioral experiments
cycloheximide, 245
Behavioral inhibition
GABA, 463
non-reward induced inhibition, 463
novelty-induced inhibition, 463
picrotoxin, 463
punishment-induced inhibition, 463
Behavioral inhibitory actions
catecholamines, 771
caudate nucleus, 771
cholinergic and aminergic balance, 771
dopamine, 771
motor conditioned responses, 771
Behavioral responses
brain stimulation, 907
chlorpromazine, 907
diazepam, 907
imipramine, 907
pentobarbital, 907
psychotropic drugs, 907
Behavioral tolerance
analgesia, 481
hot plate, 481
morphine, 481
naloxone, 481
pharmacological tolerance, 481
Benzodiazepine receptors
behavioral characteristics, 831
cellular characteristics, 831
cellular localization, 831
functional localization, 831
interaction with neurotransmitter systems, 831
multiple receptors, 825
receptor specificity, 831
thermostabilities, 825
Benzodiazepines
binding site sensitivity, 809
central nervous system, 803
chlordiazepoxide, 795
diazepam, 795, 809
diphenylhydantoin, 809
drug discrimination, 795
GABA, 809
GABA receptors, 803
molecular mechanisms relating the interaction, 803
muscimol, 809
pentylenetetrazol, 795
tolerance, 795
Benzolylnorecgonine
cocaine, 273
discriminative stimulus, 273
Binding site sensitivity
benzodiazepines, 809
diazepam, 809
diphenylhydantoin, 809
GABA, 809
muscimol, 809
Biochemical aspects
inhibition of ^{14}C-leucine, 929
protein synthesis inhibition by cycloheximide, 929
Biochemical effect
chronic ethanol consumption, 343
metabolic response, 343
Blood acetaldehyde level
alcohol intake, 303
carotid arterial blood flow, 303
facial flushing, 303
pulse rate, 303
skin temperature, 303
urinary epinephrine and norepinephrine, 303
Blood ethanol
alcohol withdrawl, 277
ethanol intake, 277
glucose, 277
polydipsia, 277
saccharin, 277
Blood levels
levels of nicotine as a function of sex and age, 349
nicotine-induced convulsive behavior, 349
Blood pressure
activity, 875
adrenal demedullation, 875
angiotensin II, 121
body weight, 875
cardiovascular responsivity, 875
drinking, 121
eating, 121
6-hydroxydopamine, 875
urine, 121
Body dehydration
ethanol, 31
hypovolemia, 31
prolonged consumption, 31
Body temperature
core temperature, 313
impaired thermal regulation following perinatal methadone exposure, 551
morphine, 313
restraint, 313
Body weight
activity, 875
adiposity, 717
adrenal demedullation, 875
blood pressure, 875
caloric regulation, 717
cardiovascular responsivity, 875
cement kiln dust, 1
corticosterone, 767
drinking, 591
eating, 591
ethanol self administration, 767
food deprivation, 591
6-hydroxydopamine, 875
juvenile-onset obesity, 717
methylphenidate, 591
monosodium glutamate, 717
schedule induced, 767
Brain
adrenal medulla, 875
basal ganglia, 883
caudate nucleus, 771
caudate-putamen, 855
diencephalon, 723
dorsal bundle, 11, 373
forebrain, 319, 603, 679, 855
frontal cortex, 855, 883
hippocampo-entorhinal area, 369, 381
hippocampus, 369, 883
hypothalamus, 923, 943
lateral hypothalamus, 783
locus coeruleus, 5, 11, 373, 421
medial forebrain bundle, 79
median raphe, 695
mesencephalic reticular formation, 907
mesolimbic area, 711
midbrain, 723
neostriatum, 137
occipital cortex, 883
olfactory bulbs, 319, 355
olfactory tubercle, 855
pars compacta, 695
pineal gland, 183, 449, 457
piriform cortex, 855
posterior hypothalamus, 907
raphe nuclei, 293, 499, 657, 687
septal area, 883
substantia nigra, 695, 899

ventral tegmental area, 5
ventromedial hypothalamus, 783
zona compacta, 5
Brain DOPAC
CNS stimulants, 561
prolintane, 561
spiperone, 561
Brain levels
levels of nicotine as a function of sex and age, 349
nicotine-induced convulsive behavior, 349
Brain rewarding system
ACTH, 325
neuropeptides, 325
self administration, 325
Brain stimulation
behavioral responses, 907
chlorpromazine, 907
diazepam, 907
imipramine, 903
pentobarbital, 903
pressor responses, 903
psychotropic drugs, 903
Brain-stimulation reward
decreased resistance to extinction after haloperidol, 751
role of dopamine in reinforcement, 751
Bulbectomy
antidepressants, 355
central stimulants, 355
effect of psychoactive drugs on plasma corticosterone levels and behavior, 355
tranquilizers, 355
t-Butanol
catecholamine, 113
6-hydroxydopamine, 113
physical dependence, 113

Caffeine
ethanol, 339
wheel running activity, 339
Calcium
chloral hydrate, 527
convulsions, 527
ethanol dependence, 527
hypothermia, 527
magnesium, 527
pentobarbital, 527
Caloric regulation
adiposity, 717
body weight, 717
juvenile-onset obesity, 717
monosodium glutamate, 717
Cannula
chronic implantation, 799
repeated intracerebral drug administration, 799
Carbon dioxide
apparatus for continuous monitoring, 619
artificially ventilated animals, 619
Carbonic anhydrase inhibitors
inhibition of the action of anticonvulsants by lithium treatment, 917
maximal electroshock, 917
Cardiac
diurnal turnover, 361
6-hydroxydopamine, 361
motility, 361
noradrenaline turnover, 361
Cardiovascular responsivity
activity, 875
adrenal demedullation, 875
blood pressure, 875
body weight, 875
6-hydroxydopamine, 875

Carotid arterial blood flow
alcohol intake, 303
blood acetaldehyde level, 303
facial flushing, 303
pulse rate, 303
skin temperature, 303
urinary epinephrine and norepinephrine, 303
Castration
catecholamine synthesis, 149
hormone replacement, 149
serotonin synthesis, 149
testosterone, 149
Catalepsy
d-amphetamine, 475
apomorphine, 177, 189, 475
cocaine, 189
dopamine, 177
dopamine agonists, 475
haloperidol, 177
haloperidol induced, 475
5-hydroxytryptamine, 475
locomotor activity, 177
serotonin, 177
stereotypy, 189
tolerance, 189
tonic immobility, 177
Catatonia
5,6-DHT, 499
p-chlorophenylalanine, 499
morphine, 499
naloxone, 499
serotonergic-raphe system, 499
tonic immobility, 499
Catechol
drug-induced tremor, 27
Catecholamine-serotonin interaction
p-chlorophenylalanine, 223
hyperactivity, 223
α-methyltryptamine, 223
spontaneous activity, 223
Catecholamine synthesis
castration, 149
hormone replacement, 149
serotonin synthesis, 149
testosterone, 149
Catecholaminergic agents
haloperidol, 723
intracranial self-stimulation, 723
phentolamine, 723
propranolol, 723
scopolamine, 723
Catecholamines
alphamethyltyrosine, 577
d-amphetamine, 577
behavioral inhibitory actions, 771
t-butanol, 113
caudate nucleus, 771
cholinergic and aminergic balance, 771
5,6 dihydroxytryptamine, 79
5,7 dihydroxytryptamine, 79
dopamine, 771
DRL performance, 577
drug behavior interactions, 577
goldthioglucose, 165
6 hydroxydopamine, 79, 113
medical forebrain bundle, 79
methylphenidate, 577
motor conditioned responses, 771
non specific effects of catecholamine and serotonin neurotoxins, 79
obesity, 165
physical dependence, 113
tetrabenazine, 577
Caudate nucleus
behavioral inhibitory actions of catecholamines, 771

cholinergic and aminergic balance, 771
dopamine, 771
motor conditioned responses, 771
Cell dehydration
drinking, 651
LiCl, 651
saccharin, 651
selective depression, 651
taste aversion, 651
Cellular characteristics
benzodiazepine receptors, 831
Cellular localization
benzodiazepine receptors, 831
functional localization, 831
Cement kiln dust
activity, 1
body weight, 1
eating, 1
Massachusetts, 1
Central catecholamine mechanisms
conditioned avoidance response, 647
developing brain, 647
hypoxia, 647
monoamine synthesis, 647
neonatal oxygen deprivation, 647
Central nervous system
molecular mechanisms regulating the interactions between the benzodiazepines and GABA receptors, 803
Central opiate receptors
intracranial self-stimulation, 71
levorphanol, 71
morphine, 71
narcotic antagonists, 71
opiate reinforcement theory, 71
Central stimulants
bulbectomy, 355
effect of psychoactive drugs on plasma corticosterone levels and behavior, 355
Chemical stimulation
CNS recording, 389
dialytrode, 389
Chloral hydrate
calcium, 527
ethanol dependence, 527
Chlordiazepines
benzodiazepines, 795
diazepam, 795
drug discrimination, 795
pentylenetetrazol, 795
tolerance, 795
Chlordiazepoxide
d-amphetamine, 471
schedule-induced drinking, 471
thirst, 471
p-Chloroamphetamine
avoidance acquisition, 569
p-chlorophenylalanine, 569
circadian rhythm, 631
doppler shift radar to monitor physiological and drug induced activity, 631
open field activity, 569
shuttle box learning, 569
p-Chlorophenylalanine
avoidance acquisition, 569
catatonia, 499
catecholamine-serotonin interaction, 223
p-chloroamphetamine, 569
5,6-DHT, 499
hyperactivity, 223
α-methyltryptamine, 223
morphine, 499
naloxone, 499
open field activity, 569
pain sensitivity, 657
raphe nucleus, 657
serotonin, 657
serotonergic-raphe system, 499
shuttle-box learning, 569
spontaneous activity, 223
tonic immobility, 499
tryptophan, 657
p-Chlorophenylalanine methyl ester
hyperphagia, 951
serotonin, 951
Chlorpromazine
effects on pressor and behavioral responses to brain stimulation, 907
motor skills, 513
phenytoin, 513
psychotropic drugs, 907
sensorimotor deficits, 513
suprasegmental reflex activity, 513
Cholecystokinin
eating, 87
lean and obese Zucker rats, 87
obesity, 87
Cholinergic agents
haloperidol, 723
intracranial self-stimulation, 723
phentolamine, 723
propranolol, 723
scopolamine, 723
Cholinergic and aminergic balance
behavioral inhibitory actions of catecholamines, 771
caudate nucleus, 771
dopamine, 771
motor conditioned responses, 771
Cholinergic system
acetylcholine, 43
behavioral hyper-reactivity, 43
hemicholinium-3, 43
Chromatophores
dark avoidance, 183
pineal gland, 183
scotophobin, 183
shock threshold, 183
Chronic ethanol treatment
intravenous infusion, 329
metabolism, 329
nervous tolerance, 329
Chronic implantation
cannula, 799
repeated intracerebral drug administration, 799
Circadian rhythm
d-amphetamine, 631
p-chloroamphetamine, 631
doppler shift radar to monitor physiological and drug induced activity, 631
Circling behavior
amphetamine, 695
apomorphine, 695
dopamine, 695
median raphe, 695
pars compacta of the substantia nigra, 695
rotation monitoring for pharmacology research, 433
rotometer, 433
Clonidine
drug-induced tremor, 27
Clozapine
amphetamine, 5
effect on the activity of central dopaminergic and noradrenergic neurons, 5
locus coeruleus, 5
ventral tegmental area, 5
zona compacta, 5
Cocaine
amphetamines, 535
apomorphine, 189
benzoylecgonine, 273
benzoylnorecgonine, 273

catalepsy, 189
discriminative stimulus, 273
discriminative stimulus properties, 535
dopamine, 535
ecgonine methyl ester, 273
hallucinogens, 535
haloperidol, 189
interactions of acetyl methadol or methadone, 407
metabolism, 267
norcocaine, 273
operant behavior, 407
pimozide, 273
propranolol, 535
reserpine, 273
stereotyped behavior, 267
stereotypy, 189
stimulus generalization, 535
tolerance, 189
Cognitive development
lead acetate, 733
reversal learning deficits, 733
visual discrimination, 733
Cold-water swims
cross tolerance between stressors, 761
2-deoxy-D-glucose, 761
morphine, 761
pain inhibitory mechanisms, 761
stress-induced analgesia, 761
Compound 48/80
acute cell dehydration thirst, 895
drinking, 895
mast cells, 895
prostaglandin E_1, 895
Concurrent schedule
ethanol-water, 777
ethanol as a reinforcer, 777
self administration, 777
Conditioned aversions
aversive properties of cycloheximide versus memory inhibition, 251
Conditioned avoidance response
central catecholamine mechanisms, 647
developing brain, 647
hypoxia, 647
monoamine synthesis, 647
neonatal oxygen deprivation, 647
Conditioned taste aversion
diazepam, 17
disruption, 17
morphine, 17
Condition suppression
antagonistic effect, 217
diazepam, 217
drug interaction, 217
ethanol, 217
synergistic effect, 217
Continuous monitoring
expired carbon dioxide concentration in artifically ventillated animals, 619
Contractions
abomasal function following injections of elfazepam and 9-aza-cannabinol, 63
Convulsions
brainstem norepinephrine, 57
pentylenetetrazol, 57
Convulsions
calcium, 527
ethanol dependence, 527
Core temperature
body temperature, 313
morphine, 313
restraint, 313
Coronary vasculature
morphological changes, 285
sulfinpyrazone, 285
unpredictable stress, 285
Corticosterone
body weight, 767
ethanol selfadministration, 767
schedule induced, 767
Cotinine
extensor reflex activity, 671
5-hydroxytryptamine, 671
nicotine, 671
CNS benzodiazepine receptors
endogenous ligands, 815
physiological studies, 815
purines, 815
CNS depression
ethanol, 865
prostaglandin synthetase inhibitors antagonize the depressant effects of ethanol, 865
sedative hypnotics, 865
CNS recording
chemical stimulation, 389
dialytrode, 389
CNS stimulants
brain DOPAC, 561
prolintane, 561
spiperone, 561
Cross tolerance
drug disposition, 49
ethanol, 49
rotarod performance, 49
Δ^9-THC, 49
Cross tolerance between stressors
cold-water swims, 761
2-deoxy-D-glucose, 761
morphine, 761
pain inhibitory mechanisms, 761
stress-induced analgesia, 761
Cyclic AMP
cyclic nucleotides, 335
ethanol, 335
ethanol hypothermia, 335
ethanol narcosis, 335
genotype, 335
psychopharmacogenetics, 335
Cyclic GMP
cyclic nucleotides, 335
ethanol, 335
ethanol hypothermia, 335
ethanol narcosis, 225
genotype, 335
psychopharmacogenetics, 335
Cyclic nucleotides
cyclic AMP, 335
cyclic GMP, 335
ethanol, 335
ethanol hypothermia, 335
ethanol narcosis, 335
genotype, 335
psychopharmacogenetics, 335
Cyclo(Leu-Gly)
amnesia, 787
memory, 787
pituitary peptides, 787
puromycin amnesia, 787
time course, 787
Cyclobenzaprine
alcohol dehydrogenase, 947
ethanol interaction, 947
Cycloheximide
auditory habituation, 679
aversive properties, 251
behavioral experiments, 245
biochemical aspects of protein synthesis inhibition, 929
biochemical effects, 245
conditioned aversions, 251
forebrain, 679

hemispheric lateralisation, 679
inhibition of ^{14}C-leucine, 929
lysine, 245
memory inhibitions, 251
protein synthesis, 245
response to novelty, 679
visual learning, 679
Dark avoidance
N-acetylserotonin, 449
chromatophores, 183
pineal gland, 183, 449
scotophobin, 183, 449
shock threshold, 183
3,4-Dehydro-DL-proline
amino acids, 643
memory, 643
L-proline, 643
retrograde amnesia, 643
2-Deoxy-D-glucose
cold-water swims, 761
cross tolerance between stressors, 761
morphine, 761
pain inhibitory mechanisms, 761
stress-induced analgesia, 761
Dependence
convulsions, 527
effects of calcium on ethanol dependence, 527
hypothermia, 527
Depression
amphetamine, 441
imipramine, 441
intracranial dopamine, 711
locomotor activity, 711
mesolimbic forebrain, 711
protriptyline, 441
reward-reduction model, 441
self-stimulation, 441
systemic L-DOPA, 711
Desglycinamide^{9}-lysine^{8}-vasopressin
ethanol consumption, 229
pituitary peptide, 229
Developing brain
central catecholamine mechanisms, 647
conditioned avoidance response, 647
hypoxia, 647
monoamine synthesis, 647
neonatal oxygen deprivation, 647
DG-AVP
food self-administration, 415
morphine self-administration, 415
Diabetes
endocrine factors contributing to ethanol preference, 557
glucose, 557
insulin, 557
Dialytrode
chemical stimulation, 389
CNS recording, 389
Diazepam
antagonistic effect, 217
benzodiazepams, 795
benzodiazepine bind site sensitivity, 809
chlordiazepoxide, 795
conditioned suppression of key-pecking, 217
diphenyhydantoin, 809
disruption of taste aversion, 17
drug discrimination, 795
drug interaction, 217
eating, 87
effects on pressor and behavioral responses to brain stimulation, 907
ethanol, 217
GABA, 809
interactions of acetylmethadol or methadone, 407
lean and obese Zucker rats, 87
learning, 17
muscimol, 809
obesity, 87
operant behavior, 407
pentylenetetrazol, 795
psychotropic drugs, 907
synergistic effect, 217
tolerance, 795
5,6-Dihydroxytryptamine
catatonia, 499
p-chlorophenylalanine, 499
medial forebrain bundle, 79
morphine, 499
naloxone, 499
non-specific effects of catecholamine and serotonin neurotoxins, 79
serotonergic-raphe system, 499
tonic immobility, 499
5,7-Dihydroxytryptamine
dorsal bundle, 373
extinction, 373
medial forebrain bundle, 79
non-specific effects of catecholamine and serotonin neurotoxins, 79
noradrenaline, 373
Diphenylhydentoin
benzodiazepine binding site sensitivity, 809
diazepam, 809
GABA, 809
muscinol, 809
Discriminated escape
response perseveration in rats exposed to ethanol prenatally, 255
Discriminative stimulus
l-α-acetylmethadol, 565
benzoylecgonine, 273
benzoylnorecgonine, 273
cocaine, 273
combination of naltrexone and morphine, 493
ecgonine methyl ester, 273
methadone, 565
norcocaine, 273
pimozide, 273
reserpine, 273
Discriminative stimulus properties
amphetamines, 535
cocaine, 535
dopamine, 535
hallucinogens, 535
propranolol, 535
stimulus generalization, 535
Diurnal animals
d-amphetamine sulfate as a behavioral depressant, 861
Diurnal rhythms
cardiac noradrenaline turnover and motility, 361
6-hydroxydopamine, 361
reserpine, 361
Dopamine
amphetamine, 695
apomorphine, 177, 695
behavioral inhibitory actions of catecholamines, 771
brain stimulation reward, 751
catalepsy, 177
caudate nucleus, 771
cholinergic and aminergic balance, 771
circling behavior, 695
decreased resistance to extinction after haloperidol, 751
discriminative stimulus properties of cocaine, 535
α-endorphin, 899
[des-tyr^{1}]-γ-endorphin, 899
forebrain, 855
functional development, 855
haloperidol, 177, 899, 937
intracranial self-stimulation, 899
locomotor activity, 177
median raphe, 695
motor conditioned responses, 771

pars compacta of the substantia nigra, 695
receptors, 855
reinforcement, 751
reinforcement thresholds, 937
rotational behavior, 855
self-stimulation, 937
serotonin, 177
stimulus generalization, 535
substantia nigra, 899
tonic immobility, 177
Dopamine agonists
d-amphetamine, 475
apomorphine, 475
haloperidol induced catalepsy, 475
5-hydroxytryptamine, 475
Dopamine asymmetry
an electrophysiological correlate of amphetamine revealed motor imbalance, 195
Dopaminergic neurons
amphetamine, 5
effect of clozapine, 5
ventral tegmental area, 5
zona compacta, 5
Doppler shift radar
d-amphtamine, 631
p-chloroamphetamine, 631
circadian rhythm, 631
monitor physiological and drug induced activity, 631
Dorsal bundle
5,7-dihydroxytryptamine, 373
extinction, 373
6-hydroxydopamine, 373
kainic acid, 373
noradrenaline, 373
Dose response
quantitative relationships among measures of morphine tolerance and physical dependence, 397
Drinking
acute cell dehydration thirst, 895
angiotensin II, 121
blood pressure, 121, 591
body weight, 591
cell dehydration, 651
compound 48/80, 895
eating, 121
food deprivation, 591
LiCl, 651
mast cells, 895
methyl phenidate, 591
prostaglandins, 895
saccharin, 651
selective depression, 651
taste aversion, 651
urine, 121
DRL performance
alphamethyltyrosine, 577
d-amphetamine, 577
catecholamines, 577
drug behavior interaction, 577
methylphenidate, 577
tetrabenazine, 577
DRL schedule
impairment of acquisition after prolonged ethanol consumption, 393
Drug
Acetylcholine, 43
levo-alpha-acetylmethadol, 565, 585
acetylmethadol, 261, 407
N-acetylserotonin, 449
actinomycine D, 361
alphamethyltyrosine, 577
aluminum, 505
amphetamine, 5, 87, 127, 137, 195, 235, 355, 441, 471, 475, 553, 577, 695
d-amphetamine, 631
d-amphetamine sulfate, 105, 407, 861
angiotensin II, 121
apomorphine, 161, 177, 189, 475, 695, 943
atropine, 369, 941
9-aza-cannabinol, 63
benzodiazepines, 795, 803, 809, 815, 825, 831
benzoylecgonine, 273
t-butanol, 105
caffeine, 339
calcium, 527
carbon dioxide, 619
catechol, 27
chloral hydrate, 527
chlorisondamine, 361
chlordiazepoxide, 355, 471, 795
p-chloroamphetamine, 569, 631
para-chlorophenylalanine, 37, 223, 499, 569, 657, 951
chlorpromazine, 355, 513, 907
chlorpromazine hydrochloride, 105
cholecystokinin, 87
clonidine, 27
clozapine, 5
cocaine, 189, 267, 273, 407, 535
codeine phosphate, 105
compound 48/80, 895
corticosterone, 767
cotinine, 671
cyclazocine lactate, 105
cyclobenzaprine, 947
cycloheximide, 245, 251, 679
cyclo(leu-gly), 787
3,4-dehydro-DL-proline, 643
2-deoxy-D-glucose, 761
desglycinamide^{9}-lysine^{8}-vasopressin, 229
dextrophan, 71
DG-AVP (desglycinamide^{9}-arginine^{8}-vasopressin), 415
diazepam, 17, 87, 217, 407, 795, 809, 907
3,4-dihydroxyphenylacetic acid (DOPAC), 561
5,6-dihydroxytryptamine, 79, 499
5,7-dihydroxytryptamine, 79, 373
diphenylhydantoin, 809
dopamine, 177, 535, 603, 711, 751, 771, 855
ecgonine methyl ester, 273
elfazepam, 63
[des-tyr^{1}]-γ-endorphin, 899
epinephrine, 303
ethanol, 21, 31, 49, 113, 211, 217, 239, 255, 277, 303, 329, 335, 339, 343, 393, 407, 527, 557, 597, 603, 637, 767, 777, 865, 871, 947
etonitazene, 155
fenfluramine hydrochloride, 105
goldthioglucose, 165
glucose, 277
α-HHC (±)9-nor-9-α-hydroxy-hexa+hydrocannabinol, 105
haloperidol, 127, 177, 189, 475, 723, 751, 899, 937
harmaline, 27, 421
hemicholium-3, 43
6-hydroxydopamine, 57, 79, 319, 361, 373, 421, 695, 943
5-hydroxyindoleacetic acid, 547
hydroxyindole-0-methyl transferase, 457
5-hydroxytryptamine, 475, 547, 687, 957
d, l-5 hydroxytryptophan, 381
imipramine, 441, 907
kainic acid, 137, 373
kepone, 27
lead acetate, 733
leucine, 951
levallorphan tartrate, 105
levorphanol, 71
LiCl, 651, 663
lithium, 547, 917, 933
Lysine^{8}-vasopressin, 229
magnesium, 487, 527
mecamylamine, 671
melatonin, 457

meperidine, 941
mescaline, 293
methamphetamine, 205
methadone, 407, 551, 565, 743, 889
methomyl (carbamate pesticide), 21
methyl phenidate, 299, 437, 577, 591
methyl phenidate hydrochloride, 105, 861
α-methyltryptamine, 223
alpha-methyltyrosine, 127
monosodium, glutamate, 717
morphine, 17, 71, 313, 397, 415, 481, 493, 499, 585, 609, 623
morphine sulfate, 105
muscimol, 809
NaCl, 277
nalorphine, 623
nalorphine hydrochloride, 105
naloxone, 481, 499, 585, 615, 623
naltrexone, 71, 493, 615
nicotine, 349, 671
noradrenaline, 11, 361, 373
norcocaine, 273
norepinephrine, 27, 57, 303, 319, 421, 711, 957
ORG-2766, 883
oxotremorine, 27, 941
pentazocine, 609, 623
pentazocine lactate, 105
pentobarbital, 527, 907
pentylene tetrazol, 57, 795
phenobarbital, 917
phenoxybenzamine, 27
phentolamine, 723
phenytoin, 513, 917
physostigmine, 205
picrotoxin, 463
pimozide, 273
procaine hydrochloride, 105
prolintane, 561
prolyl-leucyl-glycinamide, 229
propranolol, 535, 723
prostaglandin E_1, 895
protriptyline, 441
N-n-propylnorapomorphine, 161
puromycin, 521, 787
reserpine, 273, 361, 547
saccharin, 277, 651
scopalamine, 723
scopolamine hydrobromide, 105, 2o5
scotophobin, 183, 449, 457
serotonin, 27, 37, 79, 177, 293, 373, 381, 487, 499, 547, 657, 951
somatostatin, 943
spiperone, 561
substance P, 783, 943
sulfinpyrazone, 285
tetrabenazine, 577
Δ^9-THC, 49, 851
l-threo-3,4-dihydroxyphenylserine, 421
trazodone, 27
tryptophan, 657, 951
tryptophan hydroxylase, 293
Drug administration
EEG recording, 429
electrode-cannula, 429
intracerebral electrical stimulation, 429
Drug behavioral interations
alphamethyltyrosine, 577
d-amphetamine, 577
catecholamines, 577
DRL performance, 577
methyl phenidate, 577
tetrabenazine, 577
Drug challenge
drug induced activity, 95
lead exposure, 95
locomotor activity, 95
Drug discrimination
benzodiazepines, 795
chlordiazepoxide, 795
diazepam, 795
pentylenetetrazol, 795
tolerance, 795
Drug disposition
THC-ethanol cross tolerance, 49
rotarod performance, 49
Drug effects
amphetamine, 127
auto-titration brain stimulation, 127
free-operant brain stimulation, 127
haloperidol, 127
α-methyltyrosine, 127
Drug induced activity
d-amphetamine, 631
p-chloroamphetamine, 631
circadian rhythm, 631
doppler shift radar for monitoring, 631
drug challenge, 95
lead exposure, 95
locomotor activity, 95
Drug-induced tremor
catechol, 27
clonidine, 27
harmaline, 27
kepone, 27
oxotremorine, 27
Drug interaction
antagonistic effect, 217
conditioned suppression, 217
diazepam, 217
ethanol, 217
synergistic effect, 217
Drug self-adminstration
fixed-ratio, 105
potential reinforcement efficacy, 105
schedule of reinforcement, 105
substitution proceedure, 105
Duration of action
effects of acetylmethadol on motor activity and schedule-controlled responding, 261

Eating
amphetamine, 87
angiotensin II, 121
blood pressure, 121
body weight, 591
cement kiln dust, 1
cholecystokinin, 87
diazepam, 87
drinking, 121, 591
food deprivation, 591
hypothalamus, 923
impaired thermal regulation following perinatal methadone exposure, 551
lean and obese Zucker rats, 87
methyl phenidate, 299, 591
noradrenergic activity, 923
obesity, 87
olfactory stimulation, 923
push-pull perfusion, 923
schedule dependent behavior, 299
schedule induced behavior, 299
urine, 121
Ecgonine methyl ester
cocaine, 273
discriminative stimulus, 273
EEG recording
drug administration, 429
electrode-cannula, 429
intracerebral electrical stimulation, 429

Electrode-cannula
drug administration, 429
EEG recording, 429
intracerebral electrical stimulation, 429
Elfazepam
abomasal function, 63
action potential, 63
contraction, 63
pH, 63
slow wave, 63
Emotional behavior
acetylcholinesterase levels, 21
ethanol, 21
methomyl, 21
Endocrine factors
diabetes, 557
ethanol preference, 557
glucose, 557
insulin, 557
Endogenous ligands
CNS benzodiazepine receptors, 815
physiological studies, 815
purines, 815
Endogenous opioid peptides
hyperthermia, 609
influence on thermoregulatory mechanisms, 609
morphine, 609
pentazocine, 609
pharmacological responses, 609
α-Endorphin
dopamine, 899
[des-tyr^1]-γ-endorphin, 899
haloperidol, 899
intracranial self-stimulation, 899
substantia nigra, 899
[Des-Tyr^1]-γ-endorphin
dopamine, 899
α-endorphin, 899
haloperidol, 899
intracranial self-stimulation, 899
substantia nigra, 899
Ethanol
acetylcholinesterase levels, 21
activity, 21
alcohol dehydrogenase, 947
alcohol deprivation effect, 597
antagonistic effect, 217
behavioral effect, 343
biochemical effect, 343
body dehydration, 31
body weight, 767
caffeine, 339
calcium, 527
catecholamine, 113
chloral hydrate, 527
chronic consumption, 343
chronic treatment, 329
CNS depression, 865
concentration, 211
concurrent water-ethanol schedule, 777
conditioned suppression, 217
consumption, 211, 229
convulsions, 527
corticosterone, 767
cyclic AMP, 335
cyclic GMP, 335
cyclic nucleotides, 335
dependence, 527
desglycinamide^9-lysine^8-vasopressin, 229
diabetes, 557
diazepam, 217
discriminated escape, 255
drug disposition, 49
drug interaction, 217
emotional behavior, 21
endocrine factors, 557
fetal alcohol syndrome, 255
food satiation, 211
genetic selection for preference, 597
genotype, 335
glucose, 557
growth, 239
hypothermia, 335, 527
hypovolemia, 31
6-hydroxydopamine, 113
impairment of acquisition of a DRL schedule, 393
insulin, 557
interaction with cyclobenzaprine, 947
interactions of acetylmethadol or methadone, 407
intravenous infusion, 329
lysine^8-vasopressin, 229
magnesium, 527
memory, 239
metabolic response, 343
metabolic tolerance, 871
metabolism, 329
nervous tolerance, 329
open-field behavior, 21
operant behavior, 407
pentobarbital, 527
pharmacodynamic tolerance, 871
physical dependence, 113
preference, 557
prenatal effects on adult learning, 239
prenatal exposure, 255
prolonged consumption, 31
prolyl-leucyl-glycinamide, 229
prostaglandin symthetase inhibitors antagonize the depressant effects, 865
psychopharmacogenetics, 335
reinforcer, 777
response perseveration, 255
role of ascending dopamine systems in the control of voluntary intake and intoxication, 603
rotarod performance, 49
schedule induced, 767
sedative hypnotics, 865
self-administration, 767, 777
spontaneous alternation, 255, 597
strain differences, 597
synergistic effect, 217
Δ^9-THC cross tolerance, 49
tolerance, 871
water-ethanol choice, 211
water satiation, 211
wheel running activity, 339
Ethanol hypothermia
cyclic AMP, 335
cyclic GMP, 335
cyclic nucleotides, 335
genotype, 335
psychopharmacogenetics, 335
Ethanol intake
alcohol withdrawl, 277
blood ethanol, 277
glucose, 277
non-scheduled food presentation, 637
polydipsia, 277
saccharin, 277
schedule-induced polydipsia, 637
scheduled food presentations, 637
Ethanol narcosis
cyclic AMP, 335
cyclic GMP, 335
cyclic nucleotides, 335
genotype, 335
psychopharmacogenetics, 335
Etonitazene intake
food deprivation, 155
self-mutilation, 155

stereotypy, 155
Exploration
habituation, 687
5-hydroxytryptamine, 687
orienting, 687
raphe nucleus, 687
Extensor reflex activity
cotinine, 671
5-hydroxytryptamine, 671
nicotine, 671
Extinction
adrenalectomy, 11
brain stimulation reward, 751
p-chlorophenylalanine, 37
decreased resistence after haloperidol, 751
5,7-dihydroxytryptamine, 373
dorsal bundle, 373
6-hydroxydopamine, 373
interaction of brain noradrenaline and the pituitary-adrenal axis, 11
kainic acid, 373
noradrenaline, 373
role of dopamine in reinforcement, 751
serotonin, 37

Facial flushing
alcohol intake, 303
blood acetaldehyde level, 303
carotid arterial blood flow, 303
pulse rate, 303
skin temperature, 303
urinary epinephrine and norepinephrine, 303
Fetal alcohol syndrome
response perseveration in rats exposed to ethanol prenatally, 255
Fixed-ratio
rapid substitution procedure for IV drug self-administration studies, 105
Food deprivation
activity, 235
anorexia, 235
d-amphetamine, 235
body weight, 591
drinking, 591
eating, 591
etonitazene intake, 155
food-dish contact time, 235
interrelationship of drug effects, 235
methylphenidate, 591
self-mutilation, 155
stereotypy, 155
Food-dish contact time
interaction of food deprivation with different measures of amphetamine effects, 235
Food satiation
ethanol consumption, 211
water-ethanol choice, 211
Food self-administration
DG-AVP (desglycinamide^{9}-arginine^{8}-vasopressin), 415
morphine self-administration, 415
Footshock sensitivity
hippocampus, 381
d, l-5-hydroxytryptophan, 381
septal area, 381
serotonin, 381
Forebrain
auditory habituation, 679
cycloheximide, 679
dopamine receptors, 855
functional development, 855
hemispheric lateralisation, 679
6-hydroxydopamine, 319
imprinting, 319
norepinephrine, 319
odors, 319
olfactory bulbs, 319
pheromones, 319
response to novelty, 679
rotational behavior, 855
visual learning, 679
Free operant brain stimulation
amphetamine, 127
auto-titration brain stimulation, 127
drug effects, 127
haloperidol, 127
α-methyltyrosine, 127
Frontal cortex
ORG-2766 a potent analog of $ACTH_{4-9}$, 883
regional brain blood flow, 883
Functional development
dopamine receptors, 855
forebrain, 855
rotational behavior, 855
Functional localization
behavioral characteristics, 831
benzodiazepine receptors, 831
cellular localization, 831

GABA
behavioral inhibition, 463
benzodiazepines binding site sensitivity, 809
diazepam, 809
diphenylhydantoin, 809
muscimol, 809
non-reward induced inhibition, 463
novelty-induced inhibition, 463
picrotoxin, 463
punishment-induced inhibition, 463
GABA receptors
1,4 benzodiazepines, 803
central nervous system, 803
molecular mechanisms relating the interaction, 803
Glucose
alcohol withdrawl, 277
blood ethanol, 277
diabetes, 557
ethanol, 277
endocrine factors contibuting to ethanol preference, 557
insulin, 557
polydipsia, 277
saccharin, 277
Gold thioglucose
catecholamines, 165
obesity, 165
Growth
ethanol, 239
Genetic selection
alcohol deprivation effect, 597
ethanol preference, 597
spontaneous alternation, 597
strain differences, 597
Genotype
cyclic AMP, 335
cyclic GMP, 335
cyclic nucleotides, 335
ethanol, 335
ethanol hypothermia, 335
ethanol narcosis, 335
psychopharmacogenetics, 335

Habituation
5-hydroxytryptamine, 687
exploration, 687
orienting, 687
raphe nucleus, 687
Halluncinogens
discriminative stimulus properties of cocaine, 535
stimulus generalizations, 535

Haloperidol
amphetamine, 127
apomorphine, 177
auto-titration brain stimulation, 127
brain-stimulation reward, 751
catalepsy, 177, 189, 475
catecholaminergic agents, 273
cholinergic agents, 273
cocaine, 189
decreased resistance to extinction, 751
dopamine, 177, 899, 937
dopamine agonists, 475
drug effects, 127
α-endorphin, 899
[des-tyr¹]-γ-endorpnin, 899
free-operant brain stimulation, 127
5-hydroxytryptamine, 475
intracranial self-stimulation, 273, 899
locomotor activity, 177
α-methyltyrosine, 127
reinforcement thresholds, 937
role of dopamine in reinforcement, 751
self-stimulation, 937
serotonin, 177
stereotypy, 189
substantia nigra, 899
tolerance, 189
tonic immobility, 177
Harmaline
drug-induced tremor, 27
locus coeruleus, 421
norepinephrine, 421
significance of central noradrenergic system on harmaline induced tremor, 421
Head twitches
brain serotonin metabolism, 547
lithium, 547
reserpine, 547
Hemicholinium-3
acetylcholine, 43
central cholinergic involvement in behavioral hyper-reactivity, 43
Hemispheric asymmetry
an electrophysiological correlate of amphetamine revealed motor imbalance, 195
Hemispheric lateralisation
auditory habituation, 679
cycloheximide, 679
forebrain, 679
response to novelty, 679
visual learning, 679
Hippocampus
atropine, 369
footshock sensitivity, 381
d, l-5-hydroxytryptophan, 381
ORG-2766 a potent analog of $ACTH_{4-9}$, 883
passive avoidance learning, 369
regional brain blood flow, 883
septal area, 381
serotonin, 381
Hormone
$ACTH_{4-9}$, 145, 325
corticosterone, 11, 355
testosterone, 149
thyrotropin-releasing hormone, 201, 943
Hormone replacement
castration, 149
catecholamine synthesis, 149
serotonin synthesis, 149
testosterone, 149
Hot plate
analgesia, 481
behavioral tolerance, 481
morphine, 481
naloxone, 481
pharmacological tolerance, 481
6-Hydroxydopamine
activity, 875
adrenal demedullation, 875
apomorphine, 943
blood pressure, 875
body weight, 875
t-butanol, 113
cardiac noradrenaline turnover, 361
cardiovascular responsivity, 875
catecholamine, 113
diurnal rhythms, 361
dorsal bundle, 373
ethanol, 113
extinction, 373
forebrain, 319
hypokinesia, 943
imprinting, 319
medial forebrain bundle, 79
motility, 361
motor activity, 943
noradrenaline, 373
norepinephrine, 319
non-specific effects of catecholamine and serotonin neurotoxins, 79
odors, 319
olfactory bulbs, 319
pheromone, 319
physical dependence, 113
reserpine, 361
somatostatin, 943
substance P, 943
thyrotropin-releasing hormone, 943
5-Hydroxyindoleacetic acid
brain serotonin metabolism, 547
head twitches, 547
lithium, 547
reserpine, 547
Hydroxyindole-O-methyltransferase
pineal gland, 457
inhibition by scotophobin A, 457
melatonin, 457
scotophobin, 457
5-Hydroxytryptamine
d-amphetamine, 475
apomorphine, 475
audiogenic seizures, 957
brain serotonin metabolism, 547
catalepsy, 475
cotinine, 671
dopamine agonists, 475
exploration, 687
extensor reflex activity, 671
habituation, 687
haloperidol induced catalepsy, 547
head twitches, 547
lithium, 547
nicotine, 671
norepinephrine, 957
orienting, 687
raphe nucleus, 687
reserpine, 547
spinal cordotomy, 957
d, l-5-Hydroxytryptophan
footshock sensitivity, 381
hippocampus, 381
septal area, 381
serotonin, 381
Hyperactivity
catecholamine-serotonin interaction, 223
p-chlorophenylalanine, 223
α-methyltryptamine, 223
spontaneous activity, 223

Hyperphagia
p-chlorophenylalanine-methyl ester, 951
leucine-methyl ester, 951
serotonin, 951
tryptophan-methyl ester, 951
Hyper-reactivity
acetylcholine, 43
central cholinergic involvement, 43
hemicholinium-3, 43
Hyperthermia
endogenous opioid peptides, 609
influence of opioids on central thermoregulatory mechanisms, 609
pentazocine, 609
Hypokinesia
apomorphine, 943
6-hydroxydopamine, 943
motor activity, 943
somatostatin, 943
substance P, 943
thyrotropin-releasing hormone, 943
Hypothalamus
eating, 923
noradrenergic activity, 923
olfactory stimulation, 923
push-pull perfusion, 923
Hypothermia
calcium, 527
ethanol dependence, 527
Hypovolemia
reversal of ethanol induced body dehydration with prolonged consumption, 31
Hypoxia
central catecholamine mechanisms, 647
conditioned avoidance response, 647
developing brain, 647
monoamine synthesis, 647
neonatal oxygen deprivation, 647

Imipramine
depression, 441
effects on pressor and behavioral responses to brain stimulation, 907
psychotropic drugs, 907
reward-reduction model, 441
self-stimulation, 441
Imprinting
forebrain, 319
6-hydroxydopamine, 319
norepinephrine, 319
odors, 319
olfactory bulbs, 319
pheromones, 319
Inhibitory avoidance task
$ACTH_{4-9}$ facilitates acquisition, 145
Interrelationship of drug effects
interaction of food deprivation with different measures of amphetamine effects, 235
Intoxication
ethanol, 603
role of ascending dopamine systems in the control of voluntary ethanol intake and intoxication, 603
Intracerebral drug administration
cannula, 799
chronic implantation, 799
Intracerebral electrical stimulation
drug administration, 429
EEG recording, 429
electrode-cannula, 429
Intracranial dopamine
depression, 711
locomotor activity, 711
mesolimbic forebrain, 711
systemic L-DOPA, 711

Intracranial self-stimulation
catecholaminergic agents, 723
central opiate receptors, 71
cholinergic agents, 723
dopamine, 899
α-endorphin, 899
[des-tyr^1]-γ-endorphin, 899
haloperidol, 723, 899
levorphanol, 71
morphine, 71
narcotic antagonists, 71
opiate reinforcement theory, 71
phentolamine, 723
propranolol, 723
scopolamine, 723
substantia nigra, 899
Intravenous ethanol infusion
chronic treatment, 329
metabolism, 329
nervous tolerance, 329
Insulin
diabetes, 557
endocrine factors contributing to ethanol preference, 557
glucose, 557

Juvenile-onset obesity
adiposity, 717
body weight, 717
caloric regulation, 717
monosodium glutamate, 717

Kainic acid
d-amphetamine, 137
avoidance behavior, 137
dorsal bundle, 373
extinction, 373
locomotor behavior, 137
neostriatal lesions, 137
noradrenaline, 373
operant behavior, 137
Kepone
drug-induced tremor, 27

Lateral hypothalamus
differential effects on learning by posttrial injections of substance p, 783
memory, 783
Lead acetate
cognitive development, 733
reversal learning deficits, 733
visual discrimination, 733
Lead exposure
drug challenge, 95
drug induced activity, 95
locomotor activity, 95
Learning
adrenalectomy, 11
aluminum, 505
behavior, 505
differential effects on learning by VMH vs LH posttrial injections of substance P, 783
interaction of brain noradrenaline and the pituitary-adrenal axis, 11
memory, 783
prenatal effects of ethanol on adult learning, 239
Learning deficits
amnesia, 521
memory, 521
protein synthesis inhibition, 521
puromycin, 521
temporal gradient, 521
visual discrimination, 521

^{14}C-Leucine
biochemical aspects of protein synthesis inhibition by cycloheximide, 929
Leucine-methyl ester
hyperphagia, 951
serotonin, 951
Lever pressing
abstinence, 585
l-α-acetylmethadol, 585
morphine, 585
naloxone, 585
REM sleep, 585
Levorphanol
central opiate receptor, 71
intracranial self-stimulation, 71
morphine, 71
narcotic antagonists, 71
opiate reinforcement, 71
LiCl
anosmic opponents, 663
cell dehydration, 651
drinking, 651
locust-killing responses, 663
maternal aggression, 663
rank-related responses, 663
saccharin, 651
selective depression, 651
taste aversion, 651
Light-dark discrimination
adult learning, 889
perinatal exposure to methadone, 889
Lithium
brain serotonin metabolism, 547
carbonic anhydrase inhibitors, 917
dissimilar effects of lithium isotopes on motility, 933
head twitches, 547
5-hydroxyindoleacetic acid, 547
5-hydroxytryptamine, 547
inhibition of the action of anticonvulsants, 917
maximal electroshock, 917
phenobarbital, 917
phenytoin, 917
reserpine, 547
Locomotor activity
d-amphetamine, 137
apomorphine, 177
catalepsy, 177
depression, 711
dopamine, 177
drug challenge, 95
drug induced activity, 95
effect of metal complex of thyrotropin-releasing hormone, 201
haloperidol, 177
intracranial dopamine, 711
lead exposure, 95
mesolimbic forebrain, 711
neostriatal injections of kainic acid, 137
serotonin, 177
systemic L-DOPA, 711
tonic immobility, 177
Locus coeruleus
effects of clozapine on the activity of central dopaminergic and noradrenergic neurons, 5
norepinephrine, 421
significance of central noradrenergic system on harmaline induced tremor, 421
Locust-killing responses
anosmic opponents, 663
maternal aggression, 663
LiCl, 663
rank-related responses, 663
Lysine
cycloheximide, 245
protein synthesis, 245
Lysine^{8}-vasopressin
ethanol consumption, 229
pituitary peptide, 229

Magnesium
audiogenic seizure susceptibility, 487
calcium, 527
deficiency, 487
ethanol dependence, 527
intraventricular injections, 487
nonspecific excitability level, 487
serotonin, 487
Mast cells
acute cell dehydration thirst, 895
compound 48/80, 895
drinking, 895
prostaglandin E_1, 895
Maternal aggression
anosmic opponents, 663
LiCl, 663
locust-killing responses, 663
rank-related responses, 663
Maternal narcotics
impaired thermal regulation following perinatal methadone exposure, 551
Maximal electroshock
carbonic anhydrase inhibitors, 917
inhibition of the action of anticonvulsants by lithium treatment, 917
phenobarbital, 917
phenytoin, 917
Medial forebrain bundle
5,6-dihydroxytryptamine, 79
5,7-dihydroxytryptamine, 79
6-hydroxydopamine, 79
non-specific effects of catecholamine and serotonin neurotoxins, 79
Median raphe
amphetamine, 695
apomorphine, 695
circling behavior, 695
dopamine, 695
pars compacta of the substantia nigra, 695
Melatonin
hydroxyindole-O-methyltransferase, 457
pineal gland, 457
scotophobin, 457
Memory
amino acids, 643
amnesia, 521, 787
cyclo(leu-gly) 787
3,4-dehydro-DL-proline, 643
differential effects on learning by VMH vs LH posttrial injections of substance P, 783
ethanol, 239
learning deficits, 521
methamphetamine, 205
physostigmine, 205
pituitary peptides, 787
prenatal effects on adult learning, 235
L-proline, 643
protein synthesis, 521
puromycin, 521
puromycin amnesia, 787
retrograde amnesia, 643
scopolamine, 205
subjective arousal , 205
temporal gradient, 521
time course, 787
visual discrimination, 521
Memory inhibitions
aversive properties of cycloheximide, 251
conditioned aversions, 251

Meperidine
atropine, 941
does not block the cholinergic effects of oxtremorine, 941
Mescaline
raphe nuclei lesion, 293
serotonin, 293
startle responding, 293
tryptophan hydroxylase, 293
Mesolimbic forebrain
depression, 711
intracranial dopamine, 711
locomotor activity, 711
systemic L-DOPA, 711
Metabolic response
behavioral and biochemical effect of chronic ethanol consumption, 343
Metabolic tolerance
ethanol, 871
pharmacodynamic tolerance, 871
Metabolism
chronic ethanol treatment, 329
cocaine, 267
ethanol, 329
intravenous ethanol infusion, 329
nervous tolerance, 329
stereotyped behavior, 267
Metal complex
locomotor activity, 201
thyrotropin-releasing hormone, 201
Methadone
l-α-acetylmethadol, 565
active avoidance, 889
activity cage, 743
activity wheel, 743
adult learning, 889
d-amphetamine, 407
behavioral development, 743
body temperature, 551
cocaine, 407
diazepam, 407
discriminative stimulus, 565
eating, 551
ethanol, 407
light-dark discrimination, 889
maternal narcotics, 551
motor activity, 743
open field behavior, 743
operant behavior, 407
passive avoidance, 889
perinatal exposure, 743, 889
progeny, 551
thermal regulation, 551
Methamphetamine
memory, 205
physostigmine, 205
scopolamine, 205
subjective arousal , 205
Method
rat rotation monitoring for pharmacology research, 433
videotaping; the evaluation of stereotypic effects of antiparkinsonian agents, 161
Methomyl (carbamate pesticide)
acetylcholinesterase levels, 21
activity, 21
emotional behavior, 21
open-field behavior, 21
Methylphenidate
active avoidance, 437
adjunctive drinking, 299
alphamethyltyrosine, 577
d-amphetamine, 577
auditory threshold, 861
avoidance facilitation, 437
body weight, 591
catecholamines, 577
DRL performance, 577
drinking, 591
drug behavior interactions, 577
eating, 299, 591
food deprivation, 591
schedule dependent behavior, 299
schedule induced behavior, 299
tetrabenazine, 577
water maze, 437
α-Methyltryptamine
catecholamine-serotonin interaction, 223
para-chlorophenylalanine, 223
hyperactivity, 223
spontaneous activity, 223
α-Methyltyrosine
amphetamine, 127
auto-titration brain stimulation, 127
drug effects, 127
free-operant brain stimulation, 127
haloperidol, 127
Molecular mechanisms
relating the interaction between the benzodiazepines and GABA-receptors in the central nervous system, 803
Monoamine synthesis
central catecholamine mechanisms, 647
conditioned avoidance response, 647
developing brain, 647
hypoxia, 647
neonatal oxygen deprivation, 647
Monosodium glutamate
adiposity, 717
body weight, 717
caloric regulation, 717
juvenile-onset obesity, 717
Morphine
abstinence, 585
l-α-acetylmethadol, 585
analgesia, 481
antagonist activity, 623
behavioral tolerance, 481
body temperature, 313
catatonia, 499
central opiate receptors, 71
p-chlorophenylalanine, 499
cold-water swims, 761
core temperature, 313
cross tolerance between stressors, 761
5,6-DHT, 499
2-deoxy-D-glucose, 761
DG-AVP (desglycinamide^{9}-arginine^{8}-vasopressin), 415
discriminative stimulus, 493
disruption of taste aversion learning, 17
dose response, 397
endogenous opioid peptides, 609
food self-administration, 415
hot plate, 481, 623
hyperthermia, 609
intracranial self stimulation, 71
lever pressing, 585
levorphanol, 71
naloxone, 481, 499, 585
naltrexone, 493
narcotic analgesics, 623
narcotic antagonists, 71
opiate agonists, 623
opiate antagonists, 623
opiate reinforcement theory, 71
pain inhibitory mechanisms, 761
pentazocine, 609
pharmacological responses, 609
pharmacological tolerance, 481
physical dependence, 397
REM sleep, 585
restraint, 313
self-administration, 415

serotonergic-raphe system, 499
stress-induced analgesia, 761
swimming, 397
temperature, 397
thermoregulatory mechanisms, 609
tolerance, 397
tonic immobility , 499
weight change, 397
Morphological changes
coronary vasculature, 285
sulfinpyrazone, 285
unpredictable stress, 285
Motility
cardiac noradrenaline turnover, 361
dissimilar effects of lithium isotopes on motility, 933
diurnal rhythms, 361
6-hydroxydopamine, 361
reserpine, 361
Motor activity
acetylmethadol, 261
activity cage, 743
activity wheel, 743
apomorphine, 943
behavioral development, 743
duration of activity, 261
6-hydroxydopamine, 943
hypokinesia, 943
open field behavior, 743
perinatal methadone exposure, 743
schedule-controlled responding, 261
somatostatin, 943
substance P, 943
thyrotropin-releasing hormone, 943
time course, 261
Motor conditioned responses
behavioral inhibitory actions of catecholamines, 771
caudate nucleus, 771
cholinergic and aminergic balance, 771
dopamine, 771
Motor coordination and activity
aluminum, 505
behavior, 505
Motor imbalance
amphetamine, 195
dopamine asymmetry, 195
hemispheric asymmetry, 195
rotation behavior, 195
visual evoked potential, 195
Motor skills
chlorpromazine, 513
phenytoin, 513
sensorimotor deficits, 513
suprasegmental reflex activity, 513
Multiple receptors
benzodiazepine receptors, 825
thermostabilities, 825
Muscimol
benzodiazepines binding site sensitivity, 809
diazepam, 809
diphenylhydantoin, 809
GABA, 809

Nalorphine
antagonist activity, 623
hot plate behavior, 623
narcotic analgesics, 623
opiate agonists, 623
opiate antagonists, 623
Naloxone
abstinence, 585
l-α-acetylmethadol, 585
analgesia, 481
antagonist activity, 623
behavioral tolerance, 481
catatonia, 499
p-chlorophenylalanine, 499
5,6-DHT, 499
facilitation by opiate antagonists of sexual performance in the male rat, 615
hot plate, 481, 623
lever pressing, 585
morphine, 481, 499, 585
narcotic analgesics, 623
opiate agonists, 623
opiate antagonists, 623
pharmacological tolerance, 481
REM sleep, 585
serotonergic-raphe system, 499
tonic immobility, 499
Naltrexone
discriminative stimulus, 493
facilitation by opiate antagonists of sexual performance in the male rat, 615
morphine, 493
Narcotic analgesics
antagonist activity, 623
hot plate behavior, 623
morphine, 623
nalorphine, 623
naloxone, 623
opiate agonists, 623
opiate antagonists, 623
pentazocine, 623
Narcotic antagonists
central opiate receptors, 71
intracranial self-stimulation, 71
levorphanol, 71
morphine, 71
opiate reinforcement, 71
Neonatal oxygen deprivation
central catecholamine mechanisms, 647
conditioned avoidance response, 647
developing brain, 647
hypoxia, 647
monoamine synthesis, 647
Neostriatal lesions
d-amphetamine, 137
avoidance behavior, 137
kainic acid, 137
locomotor activity, 137
operant behavior, 137
Nervous tolerance
chronic ethanol treatment, 329
ethanol, 329
intravenous ethanol infusion, 329
metabolism, 329
Neuropeptides
ACTH, 325
brain rewarding system, 325
self administration, 325
Neurotransmitter systems
interaction with benzodiazepine receptors, 831
Neutral amino acid methyl esters
p-chlorophenylalanine, 951
hyperphagia, 951
leucine, 951
tryptophan, 951
Nicotine
age, 349
blood and brain levels, 349
convulsions, 349
cotinine, 671
extensor reflex activity, 671
5-hydroxytryptamine, 671
sex, 349
Non-scheduled food presentations
ethanol intake, 637
Nonspecific excitability level
intraventricular magnesium injections, 487

magnesium deficiency, 487
Non-reward induced inhibition
behavioral inhibition, 463
GABA, 463
picrotoxin, 463
Noradrenaline
cardiac NA turnover, 361
5,7-dihydroxytryptamine, 373
diurnal rhythms, 361
dorsal bundle, 373
extinction, 373
6-hydroxydopamine, 361, 373
interaction with the pituitary-adrenal axis in learning and extinction, 11
kainic acid, 373
reserpine, 361
Noradrenergic activity
eating, 923
hypothalamus, 923
locus coeruleus, 5
push-pull perfusion, 923
Noradrenergic neurons
amphetamine, 5
effect of clozapine, 5
locus coeruleus, 5
Norcocaine
cocaine, 273
discriminative stimulus, 273
Norepinephrine
audiogenic seizures, 957
forebrain, 319
6-hydroxydopamine, 319
5-hydroxytryptamine, 957
imprinting, 319
involvement in pentylenetetrazol convulsions, 57
locus coeruleus, 421
odors, 319
olfactory bulbs, 319
pheromones, 319
significance of central noradrenergic system on harmaline induced tremor, 421
spinal cordotomy, 957
Novelty-induced inhibition
behavioral inhibition, 463
GABA, 463
picrotoxin, 463

Obesity
amphetamine, 87
catecholamines, 165
cholecystokinin, 87
diazepam, 87
eating, 87
goldthioglucose, 165
lean and obese Zucker rats, 87
Occipital cortex
ORG-2766 a potent analog of $ACTH_{4-9}$, 883
regional brain blood flow, 883
Odors
forebrain, 319
6-hydroxydopamine, 319
imprinting, 319
norepinephrine, 319
olfactory bulbs, 319
pheromones, 319
Olfactory bulbs
forebrain, 319
6-hydroxydopamine, 319
imprinting, 319
norepinephrine, 319
odors, 319
pheromones, 319
Olfactory stimulation
eating, 923
hypothalamus, 923
noradrenergic stimulation, 923
push-pull perfusion, 923
Open-field behavior
acetylcholinesterase levels, 21
avoidance acquisition, 569
behavioral development, 743
p-chloroamphetamine, 569
p-chlorophenylalanine, 569
ethanol, 21
methomyl, 21
motor activity, 743
perinatal methadone exposure, 743
shuttle-box learning, 569
Operant behavior
α-1-acetylmethadol, 407
d-amphetamine, 127, 407
cocaine, 407
diazepam, 407
ethanol, 407
methadone, 407
neostriatal injections of kainic acid, 137
operant behavior, 407
ORG-2766
analog of $ACTH^{4-9}$, 883
basal ganglia, 883
frontal cortex, 883
hippocampus, 883
occipital cortex, 883
regional brain blood flow, 883
septal area, 883
Orienting
habituation, 687
5-hydroxytryptamine, 687
exploration, 687
raphe nucleus, 687
Oxotremorine
anticholinergic, 941
atropine, 941
drug-induced tremor, 27
meperidine, 941
Opiate agonists
antagonist activity, 623
hot plate behavior, 623
morphine, 623
nalorphine, 623
naloxone, 623
narcotic analgesics, 623
Opiate antagonists
antagonist activity, 623
facilitation of sexual performance, 615
hot plate behavior, 623
morphine, 623
nalorphine, 623
naloxone, 615, 623
naltrexone, 615
narcotic analgesics, 623
Opiate reinforcement theory
central opiate receptor, 71
intracranial self-stimulation, 71
levorphanol, 71
morphine, 71
narcotic antagonists, 71

Pain inhibitory mechanisms
cold-water swims, 761
cross tolerance between stressors, 761
2-deoxy-D-glucose, 761
morphine, 761
stress-induced analgesia, 761
Pain sensitivity
p-chlorophenylalanine, 657
raphe nucleus, 657
serotonin, 657

tryptophan, 657
Parachlorphenylalanine
extinction, 37
serotonin, 37
Pars compacta of the substantia nigra
amphetamine, 695
apomorphine, 695
circling behavior, 695
dopamine, 695
median raphe, 695
Passive avoidance
adult learning, 889
atropine, 369
hippocampal complex, 369
perinatal exposure to methadone, 889
Pentazocine
antagonist activity, 623
endogenous opioid peptides, 609
hot plate behavior, 623
hyperthermia, 609
morphine, 609
narcotic analgesics, 623
opiate agonists, 623
opiate antagonists, 623
pharmacological responses, 609
thermoregulatory mechanisms, 609
Pentobarbital
calcium, 527
effects on pressor and behavioral responses to brain stimulation, 907
ethanol dependence, 527
psychotropic drugs, 907
Pentylenetetrazol
benzodiazepines, 795
chlordiazepoxide, 795
convulsions, 57
diazepam, 795
drug discrimination, 795
norepinephrine, 57
tolerance, 795
Perinatal exposure
active avoidance, 889
adult learning, 889
development of motor activity following methadone exposure, 743
light-dark discrimination, 889
methadone, 889
passive avoidance, 889
pH
abomasal function following injections of elfazepam and 9-aza-cannabinol, 63
Pharmacodynamic tolerance
ethanal, 871
metabolic tolerance, 871
Pharmacology research
circling behavior, 433
rotation monitoring, 433
rotometer, 433
Pharmacological responses
endogenous opioid peptides, 609
morphine, 609
pentazocine, 609
Pharmacological tolerance
analgesia, 481
behavioral tolerance, 481
hot plate, 481
morphine, 481
naloxone, 481
Phenobarbital
inhibition of the action of anticonvulsants by lithium treatment, 917
maximal electroshock, 917
Phenoxybenzamine
serotonin-norepinephrine interactions, 27
trazodone, 27
tremorolytic actions, 27
Phentolamine
catecholaminergic agents, 273
cholinergic agents, 273
intracranial self-stimulation, 273
Phenytoin
chlorpromazine, 513
inhibition of the action of anticonvulsants by lithium treatment, 917
maximal electroshock, 917
motor skills, 513
sensorimotor deficits, 513
suprasegmental reflex activity, 513
Pheromones
forebrain, 319
6-hydroxydopamine, 319
imprinting, 319
norepinephrine, 319
odors, 319
olfactory bulbs, 319
Physical dependence
t-butanol, 113
catecholamine, 113
dose response, 397
ethanol, 113
6-hydroxydopamine, 113
morphine, 397
swimming, 397
temperature, 397
tolerance, 397
weight change, 397
Physiological activity
d-amphetamine, 631
p-chloroamphetamine, 631
circadian rhythm, 631
doppler shift radar for monitoring, 631
Physiological studies
CNS benzodiazepine receptors, 815
endogenous ligands, 815
purines, 815
Physostigmine
memory, 205
methamphetamine, 205
scopolamine, 205
Picrotoxin
behavioral inhibition, 463
GABA, 463
non-reward induced inhibition, 463
novelty-induced inhibition, 463
punishment-induced inhibition, 463
Pimozide
cocaine, 273
discriminative stimulus, 273
Pineal gland
n-acetylserotonin, 449
chromatophores, 183
dark avoidance, 183, 449
hydroxyindole-O-methyltransferase, 457
melatonin, 457
scotophobin, 183, 449, 457
shock threshold, 183
Pituitary-adrenal axis
adrenalectomy, 11
interaction of brain noradrenaline in learning and extinction, 11
Pituitary peptides
amnesia, 787
cyclo(leu-gly) 787
desglycinamide^{9}-lysine^{8}-vasopressin, 229
ethanol consumption, 229
memory, 787
prolyl-leucyl-glycinamide, 229
puromycin amnesia, 787
time course, 787
lysine^{8}-vasopressin, 229

Plasma corticosterone
antidepressants, 355
bulbectomy, 355
central stimulants, 355
effect of psychoactive drugs, 355
tranquilizers, 355
Polydipsia
alcohol withdrawl, 277
blood ethanol, 277
ethanol intake, 277
glucose, 277
saccharin, 277
Potential reinforcement efficacy
rapid substitution procedure for IV drug self-administration studies, 105
Prenatal effects
ethanol, 239
learning, 239
memory, 239
Prenatal ethanol exposure
discriminated escape, 255
fetal alcohol syndrome, 255
response perseveration, 255
spontaneous alternation, 255
Pressor responses
chlorpromazine, 903
diazepam, 903
effects of psychotropic drugs on pressor and behavioral responses to brain stimulation, 903
imipramine, 903
pentobarbital, 903
Progeny
impaired thermal regulation following perinatal methadone exposure, 551
L-Proline
amino acids, 643
3,4-dehydro-DL-proline, 643
memory, 643
retrograde amnesia, 643
Prolintane
brain DOPAC, 561
CNS stimulants, 561
spiperone, 561
Prolonged consumption
reversal of ethanol induced body dehydration, 31
Prolyl-leucyl-glycinamide
ethanol consumption, 229
pituitary peptide, 229
Propranolol
catecholaminergic agents, 723
cholinergic agents, 723
discriminative stimulus properties of cocaine, 535
intracranial self-stimulation, 723
stimulus generalization, 535
N-n-propylnorapomorphine
evaluation of stereotypic effects of antiparkinsonian agents, 161
videotyping, 161
Prostaglandin E_1
acute cell dehydration thirst, 895
compound 48/80, 895
drinking, 895
mast cells, 895
Prostaglandin synthetase
CNS depression, 865
ethanol, 865
inhibitors antagonize the depressant effects of ethanol, 865
sedative hypnotics, 865
Protein synthesis
cycloheximide, 245
lysine, 245
Protein synthesis inhibition
amnesia, 521
biochemical aspects, 929
cycloheximide, 929
inhibition of ^{14}C-leucine, 929
learning deficits, 521
memory, 521
puromycin, 521
temporal gradient, 521
visual discrimination, 521
Protriptyline
depression, 441
reward-reduction model, 441
self-stimulation, 441
Psychoactive drugs
antidepressants, 355
bulbectomy, 355
central stimulants, 355
effect on plasma corticosterone levels and behavior, 355
tranquilizers, 355
Psychopharmacogenetics
cyclic AMP, 335
cyclic GMP, 335
cyclic nucleotides, 335
ethanol, 335
ethanol hypothermia, 335
ethanol narcosis, 335
genotype, 335
Psychotropic drugs
chlorpromazine, 907
diazepam, 907
effects on pressor and behavioral responses to brain stimulation, 907
imipramine, 907
pentobarbital, 907
Pulse rate
alcohol intake, 303
blood acetaldehyde level, 303
carotid arterial blood flow, 303
facial flushing, 303
skin temperature, 303
urinary epinephrine and norepinephrine, 303
Punishment
induced inhibition
behavioral inhibition, 463
GABA, 463
picrotoxin, 463
Purines
CNS benzodiazepine receptors, 815
endogenous ligands, 815
physiological studies, 815
Puromycin
amnesia, 521
learning deficits, 521
memory, 521
protein synthesis inhibition, 521
temporal gradient, 521
visual discrimination, 521
Puromycin amnesia
cyclo(leu-gly), 787
memory, 787
pituitary peptides, 787
time course, 787
Push-pull perfusion
eating, 923
hypothalamus, 923
noradrenergic stimulation, 913
olfactory stimulation, 913

Rank-related responses
anosmic opponents, 663
LiCl, 663
locust-killing responses, 663
maternal aggression, 663
Raphe nucleus
p-chlorophenylalanine, 657
exploration, 687
habituation, 687
5-hydroxytryptamine, 687

mescaline increases startle responding, 293
orienting, 687
pain sensitivity, 657
serotonin, 293, 657
tryptophan, 657
tryptophan hydroxylase, 293
Receptor specificity
benzodiazepine receptors, 831
Regional brain blood flow
basal ganglia, 883
frontal cortex, 883
hippocampus, 883
occipital cortex, 883
ORG-2766 a potent analog of $ACTH_{4-9}$, 883
septal area, 883
Reinforcement
brain stimulation reward, 751
concurrent ethanol-water schedule, 777
decreased resistance to extinction after haloperidol, 751
dopamine, 751
ethanol self-administration, 777
Reinforcement thresholds
dopamine, 937
haloperidol, 937
self-stimulation, 937
REM sleep
abstinence, 585
l-α-acetylmethadol, 585
lever pressing, 585
morphine, 585
naloxone, 585
Reserpine
brain serotonin metabolism, 547
cardiac noradrenaline turnover, 361
cocaine, 273
discriminative stimulus, 273
diurnal rhythms, 361
head twitches, 547
6-hydroxydopamine, 361
5-hydroxyindoleacetic acid, 547
5-hydroxytryptamine, 547
lithium, 547
motility, 361
Response preservation
discriminated escape, 255
fetal alcohol syndrome, 255
prenatal ethanol exposure, 255
spontaneous alternations, 255
Response to novelty
auditory habituation, 679
cycloheximide, 679
forebrain, 679
hemispheric lateralisation, 679
visual learning, 679
Restraint
body temperature, 313
core temperature, 313
morphine, 313
Retrograde amnesia
amino acids, 643
3,4-dehydro-DL-proline, 643
memory, 643
L-proline, 643
Reversal learning deficits
cognitive development, 733
lead acetate, 733
visual discrimination, 733
Reward-reduction model
amphetamine, 441
depression, 441
imipramine, 441
protriptyline, 441
self-stimulation, 441
Rotarod performance
drug disposition, 49
THC-ethanol cross-tolerance, 49
Rotation
circling behavior, 433
monitoring for pharmacology research, 433
rotometer, 433
Rotational behavior
dopamine receptors, 855
an electrophysiological correlate of amphetamine revealed motor imbalance, 195
forebrain, 855
functional development, 855
Rotormeter
circling behavior, 433
rotation monitoring for pharmacology research, 433

Saccharin
alcohol withdrawl, 277
blood ethanol, 277
cell dehydration, 651
drinking, 651
ethanol intake, 277
glucose, 277
LiCl, 651
polydipsia, 277
selective depression, 651
taste aversion, 651
Schedule-controlled responding
acetylmethadol, 261
duration of action, 261
motor activity, 261
time course, 261
Schedule dependent behavior
adjunctive drinking, 299
eating, 299
methylphenidate, 299
Schedule induced behavior
adjuctive drinking, 299
body weight, 767
eating, 299
ethanol self-administration, 767
methylphenidate, 299
Schedule-induced drinking
d-amphetamine, 471
chlordiazepoxide, 471
thirst, 471
Schedule induced polydipsia
ethanol intake, 637
Schedule of reinforcement
rapid substitution procedure for IV drug self-administration studies, 105
Scheduled food presentations
ethanol intake, 637
Scopolamine
catecholaminergic agents, 723
cholinergic agents, 723
intracranial self-stimulation, 723
memory, 205
methamphetamine, 205
physostigmine, 205
Scotophobin
n-acetylserotonin, 449
chromatophores, 183
dark avoidance, 183, 449
hydroxyindole-O-methyltransferase, 457
melatonin, 457
pineal gland, 183, 449, 457
shock threshold, 183
Selective depression
cell dehydration, 651
drinking, 651
LiCl, 651
saccharin, 651
taste aversion, 651

Sedative hypnotics
CNS depression, 865
ethanol, 865
prostaglandin synthetase inhibitors antagonize the depressant effects of ethanol, 865
Self administration
ACTH, 325
body weight, 767
brain rewarding system, 325
concurrent ethanol-water schedule, 777
ethanol, 767
ethanol as a reinforcer, 777
neuropeptides, 325
schedule induced, 767
Self-mutilation
etonitazene, 155
food deprivation, 155
stereotypy, 155
Self-stimulation
amphetamine, 441
depression, 441
dopamine, 937
haloperidol, 937
imipramine, 441
protriptyline, 441
reinforcement thresholds, 937
reward-reduction model, 441
Sensorimotor deficits
chlorpromazine, 513
motor skills, 513
phenytoin, 513
suprasegmental reflex activity, 513
Septal area
footshock sensitivity, 381
hippocampus, 381
d, l-5-hydroxytryptophan, 381
ORG-2766 a potent analog of $ACTH_{4-9}$, 883
regional brain blood flow, 883
serotonin, 381
Serotonin
apomorpnine, 177
brain metabolism, 547
catalepsy, 177
p-chlorophenylalanine, 657
p-chlorophenylalanine-methyl ester, 951
5,6-dihydroxytryptamine, 79
5,7-dihydroxytryptamine, 79
dopamine, 177
extinction, 37
footshock sensitivity, 381
haloperidol, 177
head twitches, 547
hippocampus, 381
6-hydroxydopamine, 79
5-hydroxyindoleacetic acid, 547
5-hydroxytryptamine, 547
d, l-5-hydroxytryptophan, 381
hyperphagia, 951
intraventricular magnesium injections, 487
lithium, 547
locomotor activity, 177
magnesium deficiency, 487
medial forebrain bundle, 79
mescaline increases startle responding, 293
non specific effects of catecholamine and serotonin neurotoxins, 79
pain sensitivity, 657
parachlorophenylalanine, 37
raphe nucleus, 657
raphe nuclei lesion, 293
reserpine, 547
septal area, 381
tonic immobility, 177
tryptophan, 657
tryptophan hydroxylase, 293
tryptophan-methyl ester, 951
Serotonin-norepinephrine
interactions in tremorolytic actions of phenoxybenzamine and trazodone, 27
Serotonin synthesis
castration, 149
catecholamine synthesis, 149
hormone replacement, 149
testosterone, 149
Serotonergic-raphe system
catatonia, 499
p-chlorophenylalanine, 499
5,6-DHT, 499
morphine, 499
naloxone, 499
tonic immobility, 499
Sex
age, 349
blood and brain levels of nicotine, 349
nicotine-induced convulsive behavior, 349
Sexual performance
facilitation by opiate antagonsits, 615
naloxone, 615
naltrexone, 615
Shock threshold
chromatophores, 183
dark avoidance, 183
pineal gland, 183
scotophobin, 183
Shuttle-box learning
avoidance acquisition, 569
p-chloroamphetamine, 569
p-chlorophenylalanine, 569
open field activity, 569
Skin temperature
alcohol intake, 303
blood acetaldehyde level, 303
carotid arterial blood flow, 303
facial flushing, 303
pulse rate, 303
urinary epinephrine and norepinephrine, 303
Slow wave
abomasal function following injections of elfazepam and 9-aza-cannabinol, 63
Somatostatin
6-hydroxydopamine, 943
hypokinesia, 943
motor activity, 943
Spinal cordotomy
audiogenic seizures, 957
5-hydroxytryptamine, 957
norepinephrine, 957
Spiperone
brain DOPAC, 561
CNS stimulants, 561
prolintane, 561
Spontaneous activity
catecholamine-serotonin interaction, 223
p-chlorophenylalanine, 223
hyperactivity, 223
α-methyltryptamine, 223
Spontaneous alternation
alcohol deprivation effect, 597
genetic selection for ethanol preference, 597
response perseveration in rats exposed to alcohol prenatally, 255
strain differences, 597
Startle responding
mescaline, 293
raphe nuclei lesion, 293
serotonin, 293
tryptophan hydroxylase, 293
Stereotypy
antiparkinsonian agents, 161
apomorphine, 161, 189
catalepsy, 189

cocaine, 189, 267
etonitazene intake, 155
food deprivation, 155
haloperidol, 189
metabolism, 267
N-n-propylnorapomorphine, 161
self-mutilation, 155
tolerance, 189
videotyping, 161
Stimulus generalization
amphetamines, 535
discriminative stimulus properties of cocaine, 535
dopamine, 535
hallucination, 535
propranolol, 535
Strain differences
alcohol deprivation effect, 597
genetic selection for ethanol preference, 597
spontaneous alternation, 597
Stress-induced analgesia
cold-water swims, 761
cross tolerance between stressors, 761
2-deoxy-D-glucose, 761
morphine, 761
pain inhibitory mechanisms, 761
Subjective arousal
memory, 205
methamphetamine, 205
Substance P
differential effects on learning by VMH vs LH posttrial injection, 783
6-hydroxydopamine, 943
hypokinesia, 943
memory, 783
motor activity, 943
Substantia nigra
dopamine, 899
α endorphin, 899
[des-tyr^1]-γ-endorphin, 899
haloperidol, 899
intracranial self-stimulation, 899
Substitution procedure
IV drug self-administration, 105
potential reinforcement efficacy, 105
schedule of reinforcement, 105
Sulfin pyrazone
morphological changes in the coronary vasculature induced by prolonged unpredictable stress, 285
Suprasegmental reflex activity
chlorpromazine, 513
motor skills, 513
phenytoin, 513
sensorimotor deficits, 513
Swimming
quantitative relationships among measures of morphine tolerance and physical dependence, 397
Synergistic effect
conditioned suppression of key-pecking, 217
diazepam and ethanol drug interaction, 217
Systemic L-DOPA
depression, 711
intracranial dopamine, 711
locomotor activity, 711
mesolimbic forebrain, 711

Taste aversion
cell dehydration, 651
drinking, 651
LiCl, 651
saccharin, 651
selective depression, 651
Temperature
quantitative relationships among measures of morphine tolerance and physical dependence, 397
Temporal gradient
amnesia, 521
learning deficits, 521
memory, 521
protein synthesis inhibition, 521
puromycin, 521
visual discrimination, 521
Testosterone
castration, 149
catecholamine synthesis, 149
hormone replacement, 149
serotonin synthesis, 149
Tetrabenazine
alphamethyltyrosine, 577
d-amphetamine, 577
catecholamines, 577
DRL performance, 577
drug behavior interactions, 577
methylphenidate, 577
Δ^9-THC
absolute visual threshold, 851
aversive classical conditioning, 851
ethanol cross tolerance, 49
drug disposition, 49
rotarod performance, 49
Thermal regulation
body temperature, 551
eating, 551
maternal narcotics, 551
methadone, 551
progeny, 551
Thermoregulatory mechanisms
endogenous opioid peptides, 609
hyperthermia, 609
morphine, 609
pentazocine, 609
pharmacological responses, 609
Thermostabilities
benzodiazepine receptors, 825
multiple receptors, 825
Thirst
d-amphetamine, 471
chlordiazepoxide, 471
schedule-induced drinking, 471
Thyrotropin-releasing hormone
6-hydroxydopamine, 943
hypokinesia, 943
locomotor activity, 201
metal complex, 201
motor activity, 943
Time course
amnesia, 787
cyclo(leu-gly), 787
effects of acetylmethadol on motor activity and schedule-controlled responding, 261
memory, 787
pituitary peptides, 787
puromycin amnesia, 787
Tolerance
apomorphine, 189
benzodiazepines, 795
catalepsy, 189
chlordiazepines, 795
cocaine, 189
diazepam, 795
drug discrimination, 795
ethanol, 871
haloperidol, 189
metabolic tolerance, 871
pentylenetetrazol, 795
pharmacodynamic tolerance, 871
quantitative relationships among measures of morphine tolerance and physical dependence, 397
stereotypy, 189

Tonic immobility
apomorphine, 177
catalepsy, 177
catatonia, 499
p-chlorophenylalanine, 499
5,6-DHT, 499
dopamine, 177
haloperidol, 177
locomotor activity, 177
morphine, 499
naloxone, 499
serotonin, 177
serotonergic-raphe system, 499
Tranquilizers
bulbectomy, 355
effect of psychoactive drugs on plasma corticosterone levels and behavior, 355
Trazodone
phenoxybenzamine, 27
serotonin-norepinephrine interactions, 27
tremorolytic actions, 27
Tremor
harmaline induced, 421
locus coeruleus, 421
norepinephrine, 421
Tremorolytic actions
serotonin-norepinephrine interactions with phenoxybenzamine and trazodone, 27
Tryptophan
p-chlorophenylalanine, 657
pain sensitivity, 657
raphe nucleus, 657
serotonin, 657
Tryptophan hydroxylase
mescaline increases startle responding, 293
raphe nuclei lesions, 293
serotonin, 293
Tryptophan-methyl ester
hyperphagia, 951
serotonin, 951

Unpredictable stress
coronary vasculature, 285
morphological changes, 285
sulfinpyrazone, 285
Urinary epinephrine
alcohol intake, 303
blood acetaldehyde level, 303
carotid arterial blood flow, 303
facial flushing, 303
pulse rate, 303
skin temperature, 303
urinary norepinephrine, 303
Urinary norepinephrine
alcohol intake, 303
blood acetaldehyde, 303
carotid arterial blood flow, 303
facial flushing, 303
pulse rate, 303
skin temperature, 303
urinary epinephrine, 303
Urine
angiotensin II, 121
blood pressure, 121
drinking, 121
eating, 121

Ventral tegmental area
effects of clozapine on the activity of central dopaminergic and noradrenergic neurons, 5

Ventromedial hypothalamus
differential effects of learning by posttrial injections of substance P, 783
memory, 783
Videotape
apomorphine, 161
evaluation of stereotypic effects of antiparkinsonian agents, 161
N-n-propylnorapomorphine, 161
Visual discrimination
amnesia, 521
cognitive development, 733
lead acetate, 733
learning deficits, 521
memory, 521
protein synthesis inhibition, 521
puromycin, 521
reversal learning deficits, 733
temporal gradient, 521
visual discrimination, 733
Visual evoked potential
an electrophysiological correlate of amphetamine revealed motor imbalance, 195
Visual learning
auditory habituation, 679
cycloheximide, 679
forebrain, 679
hemispheric lateralisation, 679
response to novelty, 679
Visual temporal activity
aluminum, 505
behavior, 505
Voluntary ethanol intake
role of ascending dopamine systems, 603

Water-ethanol choice
ethanol concentration, 211
ethanol consumption, 211
food satiation, 211
water satiation, 211
Water maze
active avoidance, 437
avoidance facilitation, 437
methylphenidate, 437
Water satiation
ethanol consumption, 211
water-ethanol choice, 211
Weight
change, 397
quantitative relationships among measures of morphine tolerance and physical dependence, 397
Wheel running activity
caffeine, 339
ethanol, 339

Zona compacta
effects of clozapine on the activity of central dopaminergic and noradrenergic neurons, 5

AUTHOR INDEX

ABEL, E. L., 239
ADACHI, J., 303
AHLENIUS, S., 149
AIGNER, T. G., 105
ALEXANDER, G. J., 933
ALFERINK, L. A., 635
AL-MALIKI, S., 663
ALMGREN, O., 149
ALTIER, H., 5
ALTSHULER, H. L., 189
AMIT, Z., 17
ANDERSON, R. J., 513
ANDERSSON, K., 603
ANDRESEN, J., 577
ANSON, J. M., 679

BAILE, C. A., 63, 87
BALDWIN, J., 255
BALSTER, R. L., 105
BARALDI, M., 803
BARBEAU, A., 943
BARDO, M. T., 481
BARKER, G. F., 95
BARNES, C. D., 947
BARONE, F. C., 591
BARRACO, R. A., 521
BARTNESS, T. J., 637
BASSETT, J. R., 285
BAUM, M. J., 615
BEASLEY, D. S., 505
BEER, B., 825, 831
BEGLEITER, H., 393
BELANGER, F., 943
BELLINGHAM, W. P., 251
BENINGER, R. J., 37
BENSON, D. I., 825
BINKS, S. M., 441
BLOZOVSKI, D., 369
BODNAR, R. J., 761
BOGGAN, W., 875
BOLAS, K. C., 251
BOLTON, J. R., 63
BORNSCHEIN, R. L. 95
BOWDLER, N. C., 505
BOWMAN, R. E., 733
BRACY, O. L., 21
BRAESTRUP, C., 825
BRAIN, P. F., 663
BROWN, Z. W., 17
BRUST-CARMONA, H., 771
BUCK, D. R., 487
BUSHNELL, P. J., 733
BUTCHER, L. L., 695

CAIRNCROSS, K. D., 285, 355
CALLAHAN, M., 79, 165
CARLSSON, A., 149
CARNRIKE, JR., C. L., 177
CARP, J. S., 513
CARROLL, M. E., 155
CARTER, C. J., 475
CASE, J., 343
CHERKIN, A., 643
CHURCH, A. C., 335
CLARK, W. G., 609
COLE, S. O., 235
COLLINS, A. C., 865
COLPAERT, F. C., 535
CORFIELD-SUMNER, P. K., 471
CORNWELL-JONES, C., 319
CORNISH, K. G., 389
COSTA, E., 803
COUPET, J., 825, 831
COX, B., 355
CRANE, L. A., 799
CRITCHETT, D., 831

DAVIS, J. L., 643
DAWSON, JR., R., 79, 165
DEAKIN, J. F. W., 687
DEHAVEN, D. L., 591
DELAY, E. R., 861
DELLA FERA, M. A., 63
DENOBLE, V. J., 393
DEWEY, G. I., 177
DE WIED, D., 899
DILL, R. E., 711
DONLON, K., 31
DORSA, D. M., 899
DOWNS, D. A., 407
DOYLE, O. L., 49
DOYLE, R. S., 21
DUCRET, R. P., 951
DWYER, W. O., 851

ECKERMAN, D. A., 217
EDWARDS, J. D., 217
EDWARDS, M., 723
ENGEL, J., 149, 647
ENGLERT, L. F., 267, 273
EPSTEIN, P. N., 189
ESPOSITO, R. U., 937
ESTEVEZ, V. S., 267
EVERITT, B. J., 671

FAULKNER, W., 937
FELLER, D., 335
FELT, B. T., 883
FIBIGER, H. C., 11, 137, 373, 751
FILE, S. E., 687
FLEXNER, J. B., 787
FLEXNER, L. B., 787
FORSTER, C., 355
FRITZE, E. C., 505
FUJIWARA, S., 303
FUKUDA, T., 57
FULLER, R. W., 561
FURUKAWA, T., 547
FUXE, K., 603, 671

GALLAGER, D. W., 809
GALLUP, G. G. JR., 499
GEORGE, F. R., 865
GEYER, M. A., 293
GHONEIM, M. M., 205
GIBBS, M. E., 929
GILLIN, J. C., 711
GLICK, S. D., 799
GLUSMAN, M., 761
GOAS, J. A., 557
GOH, E., 343
GOLD, R. M., 1
GOLDMAN, H., 883
GOLDSTEIN, D. J., 895
GOODWIN, F. K., 815
GOULETTE, A. M., 505
GREENBLATT, E. N., 831
GREENWOOD, D. T., 441
GRONAN, R. J., 121
GUIDOTTI, A., 803
GUILLEMOT, J.-P., 657
GUNST, J.-P., 895

HALL, R. E., 389
HALPERIN, J. A., 895
HAMBLEY, J. W., 245
HAMBURGER, J. N., 651
HARRIS, R. A., 343, 527
HATTON, J. D., 505
HEDNER, T., 647
HENDRICKS, D. G., 487
HENNINGFIELD, J. E., 777
HERMANSEN, J. E., 429
HESSION, J., 505
HISHIDA, S., 303
HO, B. T., 267, 273
HODGE, G. K., 695
HOEBEL, B. G., 951
HOFFMAN, P. L., 787
HÖKFELT, T., 671

HOLTZMAN, S. G., 127, 565
HUSTON, J. P., 783
HUXTABLE, R. J., 429
HUGHES, K. A., 923
HUGHES, R. A., 481
HWANG, E. C., 27
HYDE, J. R. G., 687

IJIRI, I., 303
ISAAC, W., 861

JANICKI, P., 623
JANSSEN, P. A. J., 535
JÄRBE, T. U. C., 493
JENSEN, R. A., 145
JOHNSON, G., 619
JOLICOEUR, F. B., 299, 943
JONES, D. L., 711
JOSEPH, J., 875
JOUHANEAU-BOWERS, M., 325

KADZIELAWA, K., 917
KALANT, H., 229, 397
KAN, M., 201
KANAREK, R. B., 717
KATO, N., 201
KATZ, R., 1
KAWASAKI, H., 907
KEIM, D. A., 63
KELLY, D. D., 761
KENNEDY, M., 21
KHAZAN, N., 585
KIIANMAA, K., 603
KIJIMA, T., 303
KING, B., 631
KINNEY, L., 437
KLAUENBERG, B. J., 521
KLEIN, M. G., 1
KLEPNER, C. A., 825, 831
KOHNO, Y., 547
KORNETSKY, C., 937
KRAUSE, W., 343
KULKOSKY, P. J., 277
KUTSCHER, C. L., 651

LAIRD II, H. E., 429
LAL, H., 795
LARSSON, K., 149
LAVERTY, R., 113, 871
LEANDER, J. D., 941
LEE, H. K., 591
LE MAGNEN, J., 325, 329
LEMMER, B., 361
LEPORE, F., 657
LIBICH, J., 623
LIEBERMAN, K. W., 933
LINSEMAN, M. A., 397
LINTS, C. E., 957
LIPPA, A. S., 557, 831
LOCH, R. K., 95
LOCHRY, E. A., 255
LOMAN, P., 493
LONG, J. P., 223
LORDEN, J. F., 79, 165
LOWELL, B. B., 1
LUNDBORG, P., 647

McCALEB, M. L., 923
McGAUGH, J. L., 145
McGIVNEY, W. T., 261
McKENNA, M. L., 273
McLAUGHLIN, C. L., 87
McLAUGHLIN, P. J., 551, 743, 889
McMILLAN, D. E., 261
McNALLY, S. M., 21

MACDONALL, J. S., 211
MACKENZIE, R. G., 951
MACLEOD, N. K., 687
MACPHAIL, R. D., 577
MACRI, J., 43
MAHONEY, A. W., 487
MARANGOS, P. J., 815
MARANTE PEREZ, D. J., 895
MARASCO, E., 319
MARCUCELLA, H., 211
MARSDEN, C. A., 631
MARTIN, C., 285
MARTIN, G. E., 313
MARTIN, G. M., 251
MARTINEZ, JR., J. L., 145
MASON, S. T., 11, 373
MAYER, J., 717
MEADE, R. G., 717
MEISCH, R. A., 155, 777
MELLO, N. K., 415
MENDELSON, J. H., 415
MESSIHA, F. S., 947
MEWALDT, S. P., 205
MEYERS, J., 717
MICELI, D., 329
MICHAELSON, I. A., 95
MIKSIC, S., 795
MINAGAWA, S., 201
MINTZ, R. B., 299
MIZOI, Y., 303
MONTI, J. M., 5
MORGAN, I. G., 245
MORTON, B. E., 183, 449, 457
MUCHA, R. F., 229, 397
MURCHIE, J. K., 441
MURPHY, G., 711
MURPHY, S., 883
MYERS, B. M., 615
MYERS, R. D., 923
MYERS, V., 825
MYSLOBODSKY, M., 195

NAGASAKI, N., 547
NENJA, L. H., 957
NG, K. T., 929
NICHOLS, D. E., 223
NIEMEGEERS, C. J. E., 535
NONOYAMA, K., 201
NORMILE, H., 521

OEI, T. P. S., 767
OHKI, K., 201
OISHI, R., 57
OLTMANS, G. A., 79
ORMOND, D. L., 855
OSTMAN, D. L., 505

PAPP, N. L., 313
PAUL, S. M., 815
PELHAM, R. W., 557
PETERSEN, L. R., 293
PETTIJOHN, T. F., 339
PHILLIPS, A. G., 37, 751
PISA, M., 137
POWELL, D. A., 875
PYCOCK, C. J., 475

RAFALES, L. S., 95
RAINBOW, T. C., 787
REYES-VAZQUEZ, C., 771
RICHDALE, A. L., 929
RIFFEE, W. H., 161
RILEY, E. P., 255
RINGUETTE, B. A., 1
ROBERTS, D. C. S., 11

ROCKMAN, G., 17
ROGERS, L. J., 679
RONDEAU, D. B., 299, 943
ROSE, G. J., 293
ROSE, S. E., 851
RUGG, D. J., 505
RUSSELL, R. W., 43
RUSTERHOLZ, D. B., 223

SANBERG, P. R., 137
SANGER, D. J., 471
SANO, M. C., 831
SATAKE, N., 183, 449, 457
SCHAEFER, G. J., 127
SCHLESINGER, K., 349
SCHMITTDIEL, C. J., 505
SCHNEIDER, D. R., 883
SCHNIEDEN, H., 355
SCHOENFELD, R. I., 801
SCHWARTZ, J. P., 803
SEIDEN, L. S., 577
SHAPIRO, N. R., 255
SHAVIT, Y., 195
SHEARMAN, G. T., 795
SIEMENS, A. J., 49
SILBERGELD, E. K., 433
SIMON, P., 463
SINCLAIR, J. D., 597
SINGER, G., 767
SINNAMON, H. M., 723
SKOLNICK, P., 815
SMITH, B., 17
SMITH, R. F., 381
SMITH, R. V., 161
SNODDY, H. D., 561
SOBRIAN, S. K., 319
SÖDERSTEN, P., 149
SOUBRIE, P., 463
SOUMIREU-MOURAT, B., 145
SOUTO, M., 5
SPIAGGIA, A., 761
SQUIRES, R. F., 825
STAUBLI, U., 783
STEINER, N. O., 861
STEINFELS, G. F., 585
STETTNER, L. J., 521
STOKES, P., 933
STRAHLENDORF, H. K., 619
STRAHLENDORF, J. C., 619
SUENAGA, N., 57
SWEDBERG, M. D. B., 493
SYAPIN, P., 815

TAKAORI, S., 421
TALLMAN, J. F., 809
TANAKA, C., 421
TATSUNO, Y., 303
TELNER, J., 657
TEPPER. J. M., 349
TERAO, T., 201
THIEBOT, M., 463
THOMPSON, C. I., 551, 743, 889
THORNE, B. M., 21
TONOUE, T., 201
TRULSON, M. E., 951
TSAI, W. H., 591

UEKI, S., 907

VAN HARTESVELDT, C., 855
VAN REE, J. M., 899
VAN WOERT, M. H., 27
VASQUEZ, B. J., 145
VORHEES, C. V., 437, 569

WALLNAU, L. B., 177, 499
WALSH, M. J., 436
WALTER, R., 787
WANGSNESS, P. J., 63
WATANABE, S., 907
WAYNER, M. J., 299, 591
WEED, J. D., 21
WEIBEL, S. L., 71
WENDA, K., 361
WILCOX, R. E., 161
WILLOTT, J. F., 957
WILSON, J. R., 349
WISHIK, J., 723
WOLF, H. H., 71
WOOD, J. M., 113, 871
WOODSON, W. JR., 591
WOOLSTON, M. E., 245
WREN, A., 355
WRIGHT, J. W., 31
YAMADA, K., 547
YAMAZAKI, M., 421
YEHLE, A. L., 851
YORK, D. H., 121
YOUNG, G. A., 585
ZAGON, I. S., 551, 743, 889
ZARCO-CORONADO, I., 771

VOLUME 11 1979

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Editor-in-Chief

MATTHEW J. WAYNER

Published by

ANKHO International Inc

Fayetteville, New York

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Editor-in-Chief

MATTHEW J. WAYNER

Brain Research Laboratory, Syracuse University, 601 University Avenue, Syracuse, N. Y. 13210 U.S.A.

Regional Editors

A. BARBEAU, Department of Neurobiology, Clinical Research Institute of Montreal, 110 West Pine Avenue, Montreal (130), Quebec, Canada

J. R. BOISSIER, Faculté de Médecine de Paris, Unité de Neuropsychopharmacologie, 2 rue d'Alésia, 75014 Paris, France

G. R. BREESE, Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514

E. A. CARLINI, Department of Psychobiology, Escola Paulista de Medicina, Rua Botucatu, 862, 04023 – São Paulo, Brasil

J. COCHIN, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, 80 East Concord Street, Boston, Massachusetts 02118

D. V. COSCINA, Section of Neurochemistry, Clarke Institute of Psychiatry, 250 College Street, Toronto, Ontario M5T 1R8, Canada

G. ELLMAN, Langley Porter Institute, San Francisco, California 94122

K. ERIKSSON, Research Laboratories of State Alcohol Monopoly, Box 350, 00101 Helsinki 10, Finland

J. L. FALK, Department of Psychology, Rutgers University, New Brunswick, New Jersey 08903

E. GELLER, Neurobiochemistry Laboratory, T-85 Veterans Administration, Brentwood Hospital, Los Angeles, California 90073

S. P. GROSSMAN, Department of Psychology, University of Chicago, Chicago, Illinois 60637

Y. GUTMAN, Department of Pharmacology, The Hebrew University, Hadassah Medical School, P.O. Box 1172, Jerusalem, Israel

G. H. HALL, Department of Pharmacology, School of Pharmacy, Sunderland Polytechnic, Sunderland, SR1 3SD, Co. Durham, England

J. HANO, Polish Academy of Sciences, Institute of Pharmacology, 52, Ojcowska Street, 31 344 Krakow, Poland

J. A. HARVEY, Department of Psychology, University of Iowa, Iowa City, Iowa 52242

P. JANSSEN, Research Laboratoria, Janssen Pharmaceutica, 2340-Beerse, Belgium

D. A. KHARKEVICH, Department of Pharmacology, First Medical Institute, 2/6, Bolshaja Pirogovhkaja Street, Moscow, G-435, USSR

J. KNOLL, Director, Department of Pharmacology, Semmelweis University of Medicine,1445 Budapest, VIII, Nagyvárad tér 4

I. P. LAPIN, Laboratory of Psychopharmacology, Bekhterev Institute, Bekhtereva ul., 3, 193019 Leningrad, USSR

A. E. LEBLANC, Biological Studies Research Division, Alcoholism and Drug Addiction Research Foundation, 33 Russell Street, Toronto, Ontario M5S 2S1, Canada

V. G. LONGO, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Roma, Italy

H. MATTHIES, Institut für Pharmakologie und Toxikologie, Medizinische Akademie Magdeburg, 301 Magdeburg, Leipziger Strasse 44, German Democratic Republic

N. K. MELLO, Alcohol and Drug Abuse Research Center, Harvard Medical School, McLean Hospital, Belmont, Massachusetts 02178

R. D. MYERS, Departments of Psychiatry and Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC 27514

R. H. RECH, Department of Pharmacology, Michigan State University, B440 Life Sciences, East Lansing, Michigan 48824

J. A. ROSECRANS, Department of Pharmacology, Virginia Commonwealth University, Medical College of Virginia, Health Sciences Center, Richmond, Virginia 23219

C. R. SCHUSTER, Department of Psychiatry, University of Chicago, 950 East 59th Street, Chicago, Illinois 60637

D. S. SEGAL, Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, California 92037

L. S. SEIDEN, Department of Pharmacology, University of Chicago, Chicago, Illinois 60637

E. B. SIGG, Department of Neuropharmacology, Research Division, Hoffman-La Roche Inc., Nutley, New Jersey 07110

G. SINGER, Department of Psychology, La Trobe University, Bundoora, Victoria 3083, Australia

T. L. SOURKES, Allan Memorial Institute of Psychiatry, 1025 Pine Avenue West, Montreal 112, P.Q., Canada

P. STERN, Department of Pharmacology, Medical Faculty, Moše Pijade 6, Sarajeva 71001, Yugoslavia

W. C. STERN, Medical Division, Burroughs Wellcome Co., 3030 Cornwallis Road, Research Triangle Park, NC 27709

S. TADOKORO, Behavior Research Institute, School of Medicine, Gunma University, 3-39-22, Showamachi Maebashi 371, Japan

T. THOMPSON, Department of Psychiatry, University of Minnesota, Research Unit, Medical School, Box 392, Mayo Memorial Building, Minneapolis, Minnesota 55455

U. UNGERSTEDT, Department of Pharmacology, Karolinska Institutet, S-104 01 Stockholm 60, Sweden

W. L. VEALE, Division of Medical Physiology, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada

J. E. VILLARREAL, Department of Behavioral Pharmacology, Instituto Miles de Terepeutica Experimental, Division de Laboratorios Miles de Mexico, S.A. de C.V., Apartado Postal 22026, Mexico 22, D.F.

Z. VOTAVA, Department of Pharmacology, Research Institute of Pharmacy and Biochemistry, Praha 3, Kouřimská 17, Czechoslovakia

W. WUTTKE, Institut für Pharmakologie, Farbenfabriken Bayer AG, 56 Wuppertal-Elberfeld, Friederich-Ebert-Strasse 217, Germany

T. YANAGITA, Central Institute for Experimental Animals, 1433 Nogawa, Kawasaki 211, Japan

Editorial Advisory Board

B. AGRANOFF (*Ann Arbor*)
B. BEER (*Pearl River*)
M. H. APRISON (*Indianapolis*)
E. F. DOMINO (*Ann Arbor*)
D. X. FREEDMAN (*Chicago*)
E. GLASSMAN (*Chapel Hill*)
H. KALANT (*Toronto*)
A. J. MANDELL (*San Diego*)
J. MENDELSON (*Boston*)
P. A. SHORE (*Dallas*)
S. H. SNYDER (*Baltimore*)
E. USDIN (*Rockville*)
R. J. WURTMAN (*Cambridge*)

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR
ISSN 0091-3057

Subscription, postpaid: $200 per year for Libraries, Research Establishments and all other multiple-reader Institutions. Private individuals whose departmental libraries subscribe may obtain this Journal for their personal use at a reduced rate of $30 per year.

Publishing and Advertising Offices:
ANKHO Iinternational Inc.
7374 Highbridge Terrace, P.O. Box 426, Fayetteville, New York 13066 U.S.A.

Back issues are available. Write for Back Issues Price List.

Published monthly. Copyright © 1979 ANKHO International Inc.

Second class postage paid at Fayetteville, N.Y. 13066.

Printed at SALINA PRESS, Syracuse, New York U.S.A.

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 11 NUMBER 1 JULY 1979

CONTENTS

Evaluation of adrenergic, cholinergic and dopaminergic involvement in the inhibition of hyperreactivity and interanimal aggression by the medial hypothalamus in the rat. ALBERT, D. J., R. C. K. WONG, K. N. BRAYLEY and H. C. FIBIGER 1

Morphine withdrawal induced aggression in the Syrian hamster *(Mesocricetus auratus)*. AVIS, H. H. and H. V. S. PEEKE 11

Pargyline and tryptophan enhancement of tonic immobility: Paradoxical attenuation with combined administration. BOREN, J. L., G. G. GALLUP, JR., S. D. SUAREZ, L. B. WALLNAU and G. J. GAGLIARDI 17

Abnormal pattern of amphetamine locomotion after 6-OHDA lesion of anteromedial caudate. FINK, J. S. and G. P. SMITH 23

Developmental changes in amphetamine-induced taste aversion. INFURNA, R. N. and L. P. SPEAR 31

Effects of phencyclidine, atropine and physostigmine, alone and in combination, on variable-interval performance in the squirrel monkey. CHAIT, L. D. and R. L. BALSTER 37

Effects of response-contingent clock stimuli on behavior maintained by intravenous codeine in the rhesus monkey. YOUNG, A. M., T. THOMPSON, M. A. JENSEN and L. R. MUCHOW . 43

Feeding and depression of abomasal secretion in sheep elicited by elfazepam and 9-aza-cannabinol. VAN DEN BROEK, G. W., J. ROBERTSON, D. A. KEIM and C. A. BAILE 51

Effects of morphine upon the pituitary-adrenal system and adrenal catecholamines: A comparative study in cats and rats. GUAZA, C., A. TORRELLAS, J. BORRELL and S. BORRELL ... 57

A test of anxiety that distinguishes between the actions of benzodiazepines and those of other minor tranquilisers and of stimulants. FILE, S. E. and J. R. G. HYDE 65

Pimozide-induced extinction in rats: Stimulus control of responding rules out motor deficit. FRANKLIN, K. B. J. and S. N. McCOY 71

Catecholamine levels in discrete brain nuclei of seven month old genetically obese rats. LEVIN, B. E. and A. C. SULLIVAN 77

Ethanol consumption and hepatic enzyme activity. ANDERSON, S. M., G. E. McCLEARN and V. G. ERWIN 83

HPLC determination of biogenic amines in discrete brain areas in food deprived rats. LOULLIS, C. C., D. L. FELTEN and P. A. SHEA 89

Prenatal and postnatal chronic lead intoxication and running wheel activity in the rat. VERLANGIERI, A. J. 95

A synthetic non-benzodiazepine ligand for benzodiazepine receptors: A probe for investigating neuronal substrates of anxiety. LIPPA, A. S., J. COUPET, E. N. GREENBLATT, C. A. KLEPNER and B. BEER 99

BRIEF COMMUNICATIONS

Alteration of cyclic nucleotide levels in brain following intracranial self-stimulation in the rat. MILIARESSIS, E. and Z. MERALI 107

Toxic interactions of ethanol with other central depressants: antagonism by naloxone to narcosis and lethality. HO, A. K. S. and C. C. HO 111

Techniques for the chronic cannulation of the jugular vein in mice. BARR, J. E., D. B. HOLMES, L. J. RYAN and S. K. SHARPLESS 115

ANNOUNCEMENTS 119

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 11 NUMBER 2 AUGUST 1979

CONTENTS

Initiation of maternal behavior in the rat: Possible involvement of limbic norepinephrine. STEELE, M. K., D. ROWLAND and H. MOLTZ 123

Morphine reduces social cohesion in rats. PANKSEPP, J., N. NAJAM and F. SOARES 131

Dopaminergic pathways in the rat central nervous system and rotational behaviour. FUNK, K. F. and K. H. WESTERMANN 135

Effect of beta-adrenergic stimulation of the septal area on renal excretion of electrolytes and water in the rat. CAMARGO, L. A. A., W. A. SADD, C. R. SILVA NETO, J. ANTUNES-RODRIGUES and M. R. COVIAN 141

The effect of phenobarbital dose upon a variety of drinking related response measures. SCHMIDT, H., Jr. 145

The effects of fenfluramine on schedule-induced drinking in rats. SANGER, D. J. 151

Stimulus-response relationships in a quickly learned escape from shock: Effects of morphine. BABBINI, M., M. GAIARDI and M. BARTOLETTI 155

Effects of sodium pentobarbital on matching behavior in the pigeon. LANSON, R. N., D. A. ECKERMAN and R. BERRYMAN 159

Differential experience following developmental lead exposure: Effects on brain and behavior. PETIT, T. L. and D. P. ALFANO 165

Effects of MIF-I and melatonin on novelty-induced defecation and associated plasma 11-OHCS and brain catecholamines. DATTA, P. C. and M. G. KING 173

Simultaneous assay for L-tryptophan, serotonin, 5-hydroxyindoleacetic acid, norepinephrine and dopamine in brain. MARINI, J. L., S. P. WILLIAMS and M. H. SHEARD 183

Physostigmine: Effects on fear or defense responses in the rat. MOLLENAUER, S., M. WHITE, R. PLOTNIK and P. B. TIFFANY 189

Increased weight gain as a morphine withdrawal response in rats. MUCHA, R. F. and H. KALANT 197

Effects of psychotropic drugs on avoidance response in rats: role of baseline performances. KURIBARA, H. and S. TADOKORO 203

Androgens, estrogens and their anti-hormones: Effects on body weight and food consumption. EARLEY, C. J. and B. E. LEONARD 211

Consequences of reward and nonreward conditions: Runway behavior, neurotransmitters and physiological indicators of stress. EARLEY, C. J. an B. E. LEONARD 215

Effects of some anti-epileptic, neuroleptic and gabaminergic drugs on convulsions induced by D, L-allylglycine. ASHTON, D. and A. WAUQUIER 221

Naloxone antagonism of electrical stimulation induced tail erection in mice. LEE, H. K., C. Y. CHAI, M. J. WAYNER and L. C. KAO 227

BRIEF COMMUNICATIONS

A rapid and inexpensive technique for assessing the reinforcing effects of opiate drugs. KATZ, R. J. and G. GORMEZANO 231

Perinatal naloxone: When does naloxone produce hyperalgesia? MONDER, H., N. YASUKAWA and J. J. CHRISTIAN 235

Effects of clozapine and chlorpromazine upon operant response measures in rats. FORD, K. E., S. C. FOWLER and G. L. NAIL 239

The influence of cholinergic transmitter substances on the incorporation of (^{14}C)-leucine and (^{3}H)-fucose into the total proteins of hippocampus in vivo and in vitro. JORK, R., B. LÖSSNER and H. MATTHIES 243

Dopamine and macromolecule synthesis in rat hippocampus. JORK, R., B. LÖSSNER and H. MATTHIES 247

ANNOUNCEMENTS 251

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 11 NUMBER 3 SEPTEMBER 1979

CONTENTS

Effects of a novel experience on rat brain chromatin. TEDESCHI, B. and L. UPHOUSE 253

Clonidine reverses the amnesia induced by dopamine beta hydroxylase inhibition. FREEDMAN, L. S., M. Z. BACKMAN and D. QUARTERMAIN 259

Effects of γ-acetylenic GABA and γ-vinyl GABA on metrazol-activated, and kindled seizures. MYSLOBODSKY, M. S., R. F. ACKERMANN and J. ENGEL, JR. 265

The effects of methamphetamine on fine motor control in rhesus monkeys. JOHANSON, C. E., T. G. AIGNER, L. S. SEIDEN and C. R. SCHUSTER 273

Dependence in rats after one injection of heroin-, LAAM- or hydromorphone-zinc tannate. BRANDS, B., J. C. BASKERVILLE, M. HIRST and C. W. GOWDEY 279

Time course of dopaminergic hypersensitivity following chronic narcotic treatment. CARLSON, K. R. and J. ALMASI 283

Facilitation of self-stimulation behavior following intracerebral microinjections of opioids into the ventral tegmental area. BROEKKAMP, C. L., A. G. PHILLIPS and A. R. COOLS 289

2-Deoxy-D-glucose analgesia: Influences of opiate and non-opiate factors. BODNAR, R. J., D. D. KELLY and M. GLUSMAN 297

Differential effects of hypophysectomy upon analgesia induced by two glucoprivic stressors and morphine. BODNAR, R. J., D. D. KELLY, A. MANSOUR and M. GLUSMAN 303

Effects of 6-hydroxydopamine and 6-hydroxydopa on development of behavior. MORGAN, D. N., J. H. McLEAN and R. M. KOSTRZEWA 309

Partial anxiolytic action of morphine sulphate following microinjection into the central nucleus of the amygdala in rats. FILE, S. E. and R. J. RODGERS 313

Hypnotic effect of tryptophan analog in rats. FORNAL, C., W. J. WOJCIK, M. RADULOVACKI and H. G. SCHLOSSBERGER 319

Amphetamine: Effects on defensive flight or avoidance in the rat. MOLLENAUER, S., M. WHITE, R. PLOTNIK and P. B. TIFFANY 325

Coeliactomy: Differential toxiphobia conditioning with apomorphine and copper sulfate. MARTIN, J. R. 331

Similar effects of a monoamine oxidase inhibitor and a sympathomimetic amine on memory formation. GIBBS, M. E. and K. T. NG 335

Effects of an enkephalin analog on complex learning in the rhesus monkey. OLSON, G. A., R. D. OLSON, A. J. KASTIN, M. T. GREEN, R. ROIG-SMITH, C. W. HILL and D. H. COY 341

Effects of caffeine on FT-1 min schedule induced drinking at different body weights. BARONE, F. C., M. J. WAYNER and S. KLEINROCK 347

BRIEF COMMUNICATIONS

Actions and interactions of amphetamine on self-stimulation in rats. AULAKH, C. S. and S. N. PRADHAN 351

Micro-sample gas-chromatographic technique for the analysis of barbiturates. LAU, C. E., M. TANG and J. L. FALK 355

Serum phenobarbital and barbital concentrations in rats on a limited food regimen. TANG, M., C. E. LAU and J. L. FALK 359

An easily mass produced cannula system for chemical stimulation of the brain. STATON, D. M. and P. R. SOLOMON 363

Attenuation of saccharin neophobia by melatonin. GOLUS, P., R. MCGEE and M. G. KING 367

Serotonergic modulation of yawning. URBA-HOLMGREN, R., B. HOLMGREN, R. RODRIGUEZ and R. M. GONZALEZ 371

ANNOUNCEMENTS 373

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 11 NUMBER 4 OCTOBER 1979

CONTENTS

The effect of external stimulus change on ethanol-produced dissociation. DUNCAN, P. M. 377

Changes induced by hashish constituents on human erythrocyte phospholipids. KALOFOUTIS, A. and A. KOUTSELINIS 383

Suppressant effects of naltrexone on water intake in rats. FRENK, H. and J. B. ROSEN 387

Non-specific enhancement of ethanol-induced taste aversion by naloxone. MICELI, D., P. MARFAING-JALLAT and J. LE MAGNEN 391

Effects of acetone and toluene vapors on multiple schedule performance of rats. GELLER, I., R. J. HARTMANN, S. R. RANDLE and E. M. GAUSE 395

Effects of acetone, methyl ethyl ketone and methyl isobutyl ketone on a match-to-sample task in the baboon. GELLER, I., E. GAUSE, H. KAPLAN and R. J. HARTMANN 401

Systemic administration of Met-enkephalin, (D-Ala^2)-Met enkephalin, β-endorphin, and (D-Ala^2)-β-endorphin: Effects on eating, drinking and activity measures in rats. KING, M. G., A. J. KASTIN, R. D. OLSON and D. H. COY 407

Interaction of self-stimulation and ethanol-intake behaviors in rats. GALLARDO-CARPENTIER, A. and S. N. PRADHAN 413

A comparison of the effects of acute and subacute administration of β-phenylethylamine and *d*-amphetamine on mouse killing behavior of rats. BARR, G. A., J. L. GIBBONS and W. H. BRIDGER 419

d-Amphetamine effects on behavior produced by periodic food deliveries in the rat. NIETO, J., C. MAKHLOUF and R. RODRIGUEZ 423

Serotonergic influences on food intake: Effect of 5-hydroxytryptophan on parameters of feeding behaviour in deprived and free-feeding rats. BLUNDELL, J. E. and C. J. LATHAM 431

Free-choice ethanol intake and ethanol metabolism in the hamster and rat. KULKOSKY, P. J. and N. W. CORNELL 439

The involvement of interoceptive factors in the maintenance of heroin-seeking behavior. MADDEN, C., G. SINGER and T. P. S. OEI 445

Peripheral catecholamines and memory: Characteristics of syrosingopine-induced amnesia. WALSH, T. J. and T. PALFAI 449

Memory storage impairment of retrieval failure: Pharmacologically distinguishable processes. WALSH, T. J. and T. PALFAI 453

Resolution of two biochemically and pharmacologically distinct benzodiazepine receptors. KLEPNER, C. A., A. S. LIPPA, D. I. BENSON, M. C. SANO and B. BEER 457

BRIEF COMMUNICATION

An easily constructed durable chronic intracerebral cannula system. GRAY, D. S. and B. B. GORZALKA 463

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 11 NUMBER 5 NOVEMBER 1979

CONTENTS

Neurotensin: Distribution of hypothermic response in mammalian and submammalian vertebrates. PRANGE, A. J., JR., C. B. NEMEROFF, G. BISSETTE, P. J. MANBERG, A. J. OSBAHR, III, G. B. BURNETT, P. T. LOOSEN and G. W. KRAEMER 473

Psychotomimetics potentiate locomotor hyperactivity induced by dopaminergic drugs. FINK, H., R. MORGENSTERN and W. OELSSNER 479

Ketamine-induced rotation: Interaction with GABA-transaminase inhibitors and picrotoxin. MYSLOBODSKY, M. S., R. F. ACKERMAN, V. GOLOVCHINSKY and J. ENGEL, JR. 483

Oral and hypothalamic injections of barbiturates, benzodiazepines and cannabinoids and food intake in rats. ANDERSON-BAKER, W. C., C. L. McLAUGHLIN and C. A. BAILE 487

Postnatal α-methylphenylalanine treatment effects on adult mouse locomotor activity and avoidance learning. LUTTGES, M. W. and R. A. GERREN 493

Modification of motor activity, passive avoidance conditioning and evoked potentials by microinjections of picrotoxin in both caudate nuclei in cats. VÁZQUEZ, F., C. TÉLLEZ, P. DE LA MORA and H. BRUST-CARMONA 499

Exploratory behaviour & aversive thresholds following intra-amygdaloid application of opiates in rats. RODGERS, R. J. and S. E. FILE 505

Nose-poking and head-dipping behaviors in rats prenatally exposed to alcohol. RILEY, E. P., N. R. SHAPIRO and E. A. LOCHRY 513

Methadone depression of visual signal detection performance. ROTHENBERG, S., E. A. PECK, S. SCHOTTENFELD, C. E. BETLEY and J. L. ALTMAN 521

"Classical" and "atypical" antipsychotic drugs: Differential antagonism of amphetamine- and apomorphine-induced alterations of spontaneous neuronal activity in the neostriatum and nucleus accumbens. REBEC, G. V., T. R. BASHORE, K. S. ZIMMERMAN and K. D. ALLOWAY 529

Maternal responsiveness in the squirrel monkey following chronic administration of Δ^9-THC. KAPLAN, J. N. 539

Reniforcement with intragastric infusions of ethanol: Blocking effect of FLA 57. DAVIS, W. M., T. E. WERNER and S. G. SMITH 545

Effects of olfactory bulbectomy and estrogen on tyrosine hydroxylase and glutamic acid decarboxylase in the nigrostriatal and mesolimbic dopamine systems of adult female rats. TYLER, J. L., J. H. GORDON and R. A. GORSKI 549

Destruction of dopaminergic nerve terminals in nucleus accumbens: Effect on d-amphetamine self-administration. LYNESS, W. H., N. M. FRIEDLE and K. E. MOORE 553

Performance effects with repeated-response measures during pimozide-produced dopamine receptor blockade. ETTENBERG, A., S. A. CINSAVICH and N. WHITE 557

BRIEF COMMUNICATIONS

Actions and interactions of amphetamine on self-stimulation in rats. AULAKH, C. S. and S. N. PRADHAN 351

Micro-sample gas-chromatographic technique for the analysis of barbiturates. LAU, C. E., M. TANG and J. L. FALK 355

Serum phenobarbital and barbital concentrations in rats on a limited food regimen. TANG, M., C. E. LAU and J. L. FALK 359

An easily mass produced cannula system for chemical stimulation of the brain. STATON, D. M. and P. R. SOLOMON 363

Attenuation of saccharin neophobia by melatonin. GOLUS, P., R. MCGEE and M. G. KING 367

Serotonergic modulation of yawning. URBA-HOLMGREN, R., B. HOLMGREN, R. RODRIGUEZ and R. M. GONZALEZ 371

ANNOUNCEMENTS 373

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 11 NUMBER 6 DECEMBER 1979

CONTENTS

Effect of cued and uncued inescapable shock on voluntary alcohol consumption in rats. KINNEY, L. and H. SCHMIDT 601

Prenatal amphetamine exposure: Ovulation, sexual behavior and hypothalamic monoamine content in rats. RAMIREZ, O. A., H. F. CARRER and A. G. NASELLO 605

A frequency analysis of behavior components of the serotonin syndrome produced by p-chloroamphetamine. KUTSCHER, C. L. and B. K. YAMAMOTO 611

Effects of phencyclidine, *d*-amphetamine and pentobarbital on spaced responding in mice. BALSTER, R. L. and J. B. BAIRD 617

Central cholinergic mechanisms in electrical self-stimulation and in drug-induced tremor in rats. WISHART, T. B. and L. J. HERBERG 625

Long-term consequences of early iron deficiency in the rat. WEINBERG, J., S. LEVINE and P. R. DALLMAN 631

Lack of cross-tolerance between morphine and autoanalgesia. CHANCE, W. T. and J. A. ROSECRANS 639

Lack of effect of naloxone on autoanalgesia. CHANCE, W. T. and J. A. ROSECRANS 643

GABA and hypothalamic feeding systems. II. A comparison of GABA, glycine and acetylcholine agonists and their antagonists. KELLY, J. and S. P. GROSSMAN 647

Pharmacological basis for N-*n*-propylnorapomorphine induced stereotypic cage climbing and behavioral arousal in mice. WILCOX, R. E., W. H. RIFFEE and R. V. SMITH 653

Effects of clozapine, chlorpromazine and haloperidol on schedule-controlled behavior. WENGER, G. R. 661

Reinforcing properties of some local anesthetics in rhesus monkeys. WOOLVERTON, W. L. and R. L. BALSTER 669

Morphine and naloxone's effects on sexual behavior of the female golden hamster. OSTROWSKI, N. L., J. M. STAPLETON, R. G. NOBLE and L. D. REID 673

Behavioral antecedents of cocaine-induced stereotypy. COLLINS, J. P., H. LESSE and L. A. DAGAN 683

Effects of cocaine on propagation of limbic seizure activity. LESSE, H. and J. P. COLLINS ... 689

Stress responses of rats with septal lesions. BRICK, J., R. G. BURRIGHT and P. J. DONOVICK 695

PCPA potentiates the effects of specific copulatory experience on the sexual behavior of the pudendectomized male rat. DAHLÖF, L.-G. and K. LARSSON 701

Possible non-narcotic component to action of opiate peptides on tonic immobility. OLSON, R. D., A. J. KASTIN, G. J. LAHOSTE, G. A. OLSON and D. H. COY 705

Effects of phenobarbital on taste aversion induced by X-radiation. JOLICOEUR, F. B., M. J. WAYNER, D. B. RONDEAU, A. D. MERKEL and D. A. BASSANO 709

Analgesia after peripheral administration of enkephalin and endorphin analogues. KASTIN, A. J., M. T. JEMISON and D. H. COY 713

Additional evidence that small amounts of a peptide can cross the blood-brain barrier. KASTIN, A. J., C. NISSEN, A. V. SCHALLY and D. H. COY 717

BRIEF COMMUNICATIONS

MIF-I's differential actions as an opiate antagonist. KASTIN, A. J., R. D. OLSON, R. H. EHRENSING, M. C. BERZAS, A. V. SCHALLY and D. H. COY 721

Effects of imipramine on schedule dependent and schedule induced behavior. LOULLIS, C. C. and M. J. WAYNER 725

Naloxone-induced suppression of food intake in normal and hypothalamic obese rats. KING, B. M., F. X. CASTELLANOS, A. J. KASTIN, M. C. BERZAS, M. D. MAUK, G. A. OLSON and R. D. OLSON 729

Experiments with a reported anorexigenic tripeptide: Pyro-Glu-His-Gly-Oh. NANCE, D. M., D. H. COY and A. J. KASTIN 733

Self-administration of Δ^9-tetrahydrocannabinol by rats. TAKAHASHI, R. N. and G. SINGER 737

Effect of autoanalgesia on CNS enkephalin receptors. DEVRIES, G. H., W. T. CHANCE, W. R. PAYNE and J. A. ROSECRANS 741

BOOKS RECEIVED 745

ANNOUNCEMENTS 746

AIMS AND SCOPE

Pharmacology Biochemistry & Behavior will publish original reports of systematic studies in the areas of pharmacology, biochemistry, toxicology and behavior in which the primary emphasis and theoretical context are behavioral; and brief communications which describe a new method, technique or apparatus and results of experiments which can be reported briefly with limited figures and tables. Behavioral studies as such will not be published unless they are obviously pertinent and make a significant contribution to pharmacology, biochemistry or toxicology. A limited number of relevant reviews and theoretical articles, results of symposia, and more comprehensive studies as monograph supplements will also be published. Articles will be published in English.

The accepted abbreviation for *Pharmacology Biochemistry & Behavior* for bibliographic citation is *Pharmac. Biochem. Behav.*

INSTRUCTIONS TO AUTHORS

Manuscripts should be sent directly to the Editor-in-Chief or to the most proximal Regional Editor for review and will be published within three months or less after formal acceptance.

STYLE OF MANUSCRIPT

General Form. (1) Manuscripts should be submitted in duplicate and should be typewritten, double spaced with wide margins on good quality paper. (2) The title page should contain: title of paper; author(s); laboratory or institution of origin with city, state, zip code, and country; complete address for mailing proofs; a running head not to exceed 50 characters including spaces between words. (3) References, footnotes, and legends for illustrations should be typed on separate sheets, double spaced. (4) Illustrations (unmounted photographs) should be identified on the reverse with figure number and author(s) name; when necessary the top should be clearly marked. (5) Each table should be typed on a separate sheet and double spaced. (6) All dimensions and measurements must be specified in the metric system. Standard nomenclature, abbreviations and symbols, as specified by Royal Society Conference of Editors. Metrication in Scientific Journals, *Am. Scient.* **56**: 159–164, 1968, should be used throughout. (7) Italics should not be used for the purpose of emphasis.

Title. The title should not be longer than 85 characters, including spaces between words.

Papers in a series such as: "Studies on . . . I." will not be accepted.

Length of Paper. The Editors insist upon clear, concise statement of facts and conclusions. Fragmentation of material into numerous short reports is discouraged.

Abstract. Each paper submitted must be accompanied by an abstract, which does not exceed 170 words and must be suitable for use by abstracting journals. Abstracts should be prepared as follows:

> EVANS, B. K., S. ARMSTRONG, G. SINGER, R. D. COOK AND G. BURNSTOCK. *Intracranial injection of drugs: comparison of diffusion of* . . . PHARMAC. BIOCHEM. BEHAV. Marked differences in extent of diffusion have been . . .

A list of from 3–12 (or more) words or short phrases suitable for indexing terms should be typed at the bottom of the abstract page accompanying the manuscript. These terms will be printed with the paper at the end of the abstract.

Drugs. Proprietary (trademarked) names should be capitalized. The chemical name should precede the trade, popular name, or abbreviation of a drug the first time it occurs.

Footnotes. Title page footnotes should be numbered consecutively. Text footnotes should not be used, the material should be incorporated into the text. Table footnotes: see *Tables* (b).

References. Literature cited should be numbered in brackets in text (only one reference to a number) and listed in alphabetical order on a separate sheet at the end of the manuscript. *Do not recite names of authors within the text.* Journal citations in the reference list should contain the following: (a) surnames and initials of all authors (surname of first author precedes initials; initials precede surnames of all co-authors); (b) title of article; (c) journal title abbreviated as listed in the 4th edition of the *World List of Scientific Periodicals;* (d) volume, inclusive pages, and year. Example:

1. Abrams, R. and H. T. Hammel. Hypothalamic temperature in unanesthetized albino rats during feeding and sleeping. *Am. J. Physiol.* **206**: 641–646, 1964.

Book references should be in the following order: author, title, city of publication, publisher, year, and pages. Example:

1. Thompson, T. and C. R. Schuster. *Behavioral Pharmacology.* Englewood, New Jersey: Prentice-Hall, Inc., 1968, p. 297.

Citations such as "Unpublished observations," "Personal communication," "Manuscript in preparation," "To be published," should not be entered in the list of References, but may be noted in the text without serial numbers, in parentheses.

Illustrations. (a) Prepare for use in a single column width whenever possible. (b) All drawings for reduction to a given size should be drawn and lettered to the same scale. (c) All illustrations should be referred to as figures and numbered in Arabic numerals. (d) Lettering should be done in India ink or other suitable material and must be proportionate to the size of the illustrations if it is to be legible after reduction. Lettering should be sized so that its smallest elements (subscripts or superscripts) will be readable when reduced. (e) When possible all lettering should be within the framework of the illustration; likewise the key to symbols should be on the face of the chart. The following standard symbols should be used as they are easily available to the printer. ○ ● △ ▲ □ ■ + (f) Actual magnification of all photomicrographs should be given. Dimension scale should be indicated. (g) Sharply contrasting unmounted photographs of figures on glossy paper are required.

Tables. (a) Each table should have a brief heading; explanatory matter should be in footnotes, not as part of the title. (b) Table footnotes should be indicated in the body of the table in order of their appearance with the following symbols: * † ‡ § ¶ # **, etc. (c) Tables must not duplicate material in text or illustrations. (d) Vertical rules should be omitted. (e) Short or abbreviated column heads should be used. (f) Statistical measures of variation, SD, SE, etc., should be identified. (g) Analysis of Variance Tables should not be submitted but significant F's should be incorporated where appropriate within the text. The appropriate form for reporting F values is: $F(11,20) = 3.05$, $p < 0.01$.

Formulas and Equations. Structural chemical formulas, process flow-diagrams, and complicated mathematical expressions should be kept to a minimum. Usually chemical formulas and flow-diagrams should be drawn in India ink for reproduction as line cuts.

All subscripts, superscripts, Greek letters, and unusual characters must be clearly identified.

Anesthesia. In describing surgical procedures on animals, the type and dosage of the anesthetic agent should be specified. Curarizing agents are not anesthetics; if these were used, evidence must be provided that anesthesia of suitable grade and duration was employed.

Proofs. Corrections to the proofs must be restricted to printer's errors only. Other than these, any other alterations will be charged to the author.

Reprints. Each author will receive with his galley proofs a reprint order form which must be completed and returned with the proofs. Late orders cannot be filled since reprints are run at the time the Journal is printed. Senior author receives 25 reprints free.

Pharmacology Biochemistry & Behavior, Vol. 11, © ANKHO International Inc., 1979. Printed in the U.S.A.

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 11 1979

SUBJECT INDEX

Abomasal acid secretion
  9-aza-cannabinol, 51
  chemical feed intake stimulants, 51
  elfazepam, 51
  sheep, 51
Abuse
  early drug exposure, s1
  methadone, s1
  PCP, s1
  pharmacokinetics, s1
  protracted effects, s1
  psychomotor deficits, s1
  psychotrophic drugs, s1
Acetone
  delayed match-to-sample task, 401
  methyl ethyl ketone, 401
  methyl isobutyl ketone, 401
  multiple schedule performance, 395
  toluene, 395
Acetylcholine
  apomorphine, 625
  central cholinergic mechanisms, 625
  hyoscine, 625
  methylscopolamine, 625
  oxotremorine, 625
  propranolol, 625
  scopolamine, 625
  self-stimulation, 625
  tremor, 625
α-Acetylenic GABA
  GABA-T inhibitors, 265
  kindled seizures, 265
  metrazol, 265
  α-vinyl GABA, 265
l-α-acetylmethadol
  body weight, 279
  core temperature, 279
  heroin, 279
  hydromorphone, 279
  naloxone, 279
  narcotic zinc tannate salts, 279
  physical dependence, 279
Active avoidance
  long-term consequences of early iron deficiency, 631
Activity
  d-amphetamine, 23
  caudate nucleus, 23
  corticosterone, 695
  dopamine, 23
  drinking, 407
  eating, 407
  endorphin, 407
  enkephalin, 407
  6-hydroxydopamine, 23
  locomotion, 23
  norepinephrine, 695
  nucleus accumbens, 23
  septal lesions, 695
  stress, 695
  temperature, 695
  ulcers, 695
Adjunctive behavior
  cued and uncued inescapable shock, 601
  ethanol, 601
  imipramine, 725
  schedule dependent behavior, 725
  schedule induced behavior, 725
  voluntary alcohol consumption, 601
Adjunctive drinking
  body weight, 347
  caffeine, 347
  FT-1 min schedule, 347
  schedule induced polydipsia, 347
Adrenal ascorbic acid
  corticosterone, 215
  neurotransmitters, 215
  nonreward, 215
  physiological indicators of stress, 215
  reward, 215
  runway behavior, 215
Adrenal catecholamines
  corticosteroids, 57
  morphine, 57
  nalorphine, 57
  pituitary-adrenal system, 57
Adrenergic system
  involvement in the inhibition of hyperreactivity and interanimal aggression, 1
Afferent nerves
  apomorphine, 331
  coeliac ganglionectomy, 331
  conditioned toxiphobia, 331
  copper sulfate, 331
  gastric irritation, 331
  taste aversion learning, 331
Aggression
  amphetamine, 419
  morphine withdrawal induced behavior, 11
  muricide, 419
  β-phenylethylamine, 419
Akinesia
  dopamine, 71
  extinction, 71
  neuroleptics, 71
  pimozide, 71
D-Ala²-leu-enkephalinamide, 231
  classical conditioning, 231
  morphine, 231
  technique for assessing the reinforcing effects of opiate drugs, 231

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl, Vol. 11, 1979.

Alcohol dehydrogenase
aldehyde dehydrogenase, 83
ethanol consumption, 83
hepatic enzyme activity, 83
Alcohol dehydrogenase activity
ethanol intake and metabolism, 439
preference, 439
Aldehyde dehydrogenase
alcohol dehydrogenase, 83
ethanol consumption, 83
hepatic enzyme activity, 83
D,L-Allylglycine
anti-epileptic drugs, 221
convulsions, 221
gabaminergic drugs, 221
Alpha-noradrenergic receptors
amnesia, 259
clonidine, 259
diethyldithiocarbamate, 259
dopamine beta hydroxylase, 259
Amnesia
alpha-noradrenergic receptors, 259
catecholamines, 449
clonidine, 259
consolidation, 453
diethyldithiocarbamate, 259
dopamine beta hydroxylase, 259
epinephrine, 449, 453
memory, 449
norepinephrine, 449
passive avoidance, 449
rauwolfia alkaloids, 453
reserpine, 453
retrieval failure, 453
storage impairment, 453
syrosingopine, 449, 453
Amniotic fluid
breast milk, s7
disposition, s7
methadone, s7
narcotics, s7
perinatal, s7
pregnancy, s7
d-Amphetamine
activity, 23
aggression, 419
antipsychotic drugs, 529
anxiety, 65
apomorphine, 479, 529
avoidance, 325
avoidance baseline, 203
azaperone, 351
baseline levels and drug effects, 203
behavioral teratogenesis, 605
behavioral toxicology, 31
benzodiazepines, 65
brain opioids, 131
caudate nucleus, 23
chlorpromazine, 203
clozapine, 529
cyproheptadine, 479
defensive flight, 325
defensive responses, 325
developmental psychopharmacology, 31
diazepam, 203
differential reinforcement of low rates, 617
discriminated avoidance response, 203
dopamine, 23
dopaminergic drugs, 479
dopaminergic nerve terminals, 553
drinking, 423
drug responsiveness, 31
fenfluramine, 151
fixed-time schedule, 423
grooming, 423
haloperidol, 351, 529
6-hydroxydopamine, 23
hypothalamic monoamine content, 605
locomotion, 23
locomotor activity, 65, 479
muricide, 419
neostriatum, 529
nucleus accumbens, 23, 529, 553
ovulation, 605
pentobarbital, 617
phencyclidine, 617
β-phenylethylamine, 419
posterior hypothalamus, 351
psychotomimetics, 479
schedule controlled behavior, 617
schedule-induced behavior, 423
schedule-induced drinking, 151
self administration, 553
self-stimulation, 351
sexual behavior, 605
spaced responding, 617
spontaneous neuronal activity, 529
social cohesion, 131
social interaction, 65
stereotypy, 325
taste aversion learning, 31
ventral tegmental area, 351
Amygdala
anxiolytic action of morphine, 313
aversive thresholds, 505
cocaine, 689
exploratory behavior, 505
hippocampus, 689
limbic seizure discharges, 689
morphine, 505
motor activity, 505
naloxone, 505
open field, 313
opiates, 505
social interaction, 313
temporal lobe epilepsy, 689
Analgesia
2-deoxy-D-glucose, 297, 303
drinking, 387
eating, 721
β-endorphin, 713
hypophysectomy, 303
insulin, 303
met-enkephalin, 713
MIF-I's differential actions as an opiate antagonist, 721
morphine, 297, 303, 387
naloxone, 297
naltrexone, 387
opiate, 387
peripheral administration, 713
stress, 303
suppression effects, 387
synergy, 297
vas deferens, 721
Androgen
body weight, 211
cyproterone acetate, 211
dihydroxytestosterone, 211
eating, 211
estrogen, 211
testosterone, 211
Anorexia
anorexigenic tripeptide, 733
body weight, 733
eating, 733
pyro-glu-his-gly-OH, 733
Anticholinesterase
aversive stimulus, 189
cholinergic, 189
defense responses, 189

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl, Vol. 11, 1979.

fear, 189
physostigmine, 189
Anti-epileptic drugs
D,L-allylglycine, 221
convulsions, 221
gabaminergic drugs, 221
Antinoception
autoanalgesia, 639
conditioned fear, 639
naloxone, 639
pain, 639
stress, 639
Antipsychotic drugs
amphetamine, 529
apomorphine, 529
clozapine, 529
haloperidol, 529
neostriatum, 529
nucleus accumbens, 529
spontaneous neuronal activity, 529
Anxiety
amphetamine, 65
benzodiazepines, 65, 99
caffeine, 65
^{3}H-diazepam, 99
flurazepam, 65
GABA, 99
glycine, 99
meprobamate, 65
phenobarbitone, 65
serotonin, 99
social interaction, 65
synthetic non-benzodiazepine ligand, 99
triazolopyridazine, 99
Anxiolytic action
amygdala, 313
morphine, 313
open field, 313
social interaction, 313
Apomorphine
acetylcholine, 625
afferent nerves, 331
amphetamine, 479, 529
antipsychotic drugs, 529
central cholinergic mechanisms, 625
clozapine, 529
coeliac ganglionectomy, 331
conditioned toxiphobia, 331
copper sulfate, 331
cyproheptadine, 479
dopamine, 283
dopaminergic drugs, 479
gastric irritation, 331
haloperidol, 529
hyoscine, 625
hypersensitivity, 283
locomotor activity, 479
methadone, 283
methylscopolamine, 625
morphine, 283
narcotics, 283
neostriatum, 529
nucleus accumbens, 529
oxotremorine, 625
propranolol, 625
psychotomimetics, 479
scopolamine, 625
self-stimulation, 625
spontaneous neuronal activity, 529
taste aversion learning, 331
tremor, 625
Aporphines
behavioral arousal, 653
cage climbing, 653
pharmacological basis for N-n-propylnorapomorphine induced stereotypy, 653
receptor blockers, 653
Apparatus
an easily constructed durable chronic intracerebral cannula system, 463
an easily produced cannula system for chemical stimulation of the brain, 363
Atropine
drug interactions, 37
phencyclidine, 37
physostigmine, 37
variable-interval, 37
Autoanalgesia
antinoception, 639
conditioned fear, 639, 643, 741
cross-tolerance, 643
endorphin, 643
leu-enkephalin, 741
morphine, 643
naloxone, 639, 741
opiate receptors, 741
pain, 639
stress, 639
Autoradiography
comparison of neuronal and glial protein metabolism, 593
food-motivated conditioning, 593
footshock-motivated conditioning, 593
hippocampus, 593
Aversive stimulus
anticholinesterase, 189
cholinergic, 189
defense responses, 189
fear, 189
physostigmine, 189
Aversive thresholds
amygdala, 505
exploratory behavior, 505
morphine, 505
motor activity, 505
naloxone, 505
opiates, 505
Avoidance
amphetamine, 325
defensive flight, 325
defensive responses, 325
stereotypy, 325
Avoidance baseline
d-amphetamine, 203
baseline levels and drug effects, 203
chlorpromazine, 203
diazepam, 203
discriminated avoidance response, 203
Avoidance learning
learning and memory deficits, 493
locomotor activity, 493
α-methylphenylalanine, 493
phenylalanine development, 493
phenylketonuria, 493
9-Aza-cannabinol
abomasal acid secretion, 51
chemical feed intake stimulants, 51
elfazepam, 51
sheep, 51
Azaperone
amphetamine, 351
haloperidol, 351
posterior hypothalamus, 351
self-stimulation, 351
ventral tegmental area, 351

Barbital
barbiturate serum level, 359
effect of food deprivation, 359
phenobarbital, 359
Barbiturates
benzodiazepines, 487

cannabinoids, 487
conditional discrimination, 159
diazepam, 487
eating, 487
hypothalamic injection, 487
matching-behavior, 159
sodium pentobarbital, 159, 487
stimulus control, 159
Δ^9-THC, 487
Barbiturate analysis
micro-method, 355
nitrogen-phosphorus detector, 355
Barbiturate serum level
barbital, 359
effect of food deprivation, 359
phenobarbital, 359
Baseline levels and drug effects
amphetamine, 203
avoidance baseline, 203
chlorpromazine, 203
diazepam, 203
discriminated avoidance response, 203
Behavior and physiological responsiveness
long-term consequences of early iron deficiency, 631
Behavioral alterations
morphology, s39
neonatal, s39
phencyclidine, s39
postnatal, s39
prenatal, s39
teratology, s39
Behavioral antecedents
cocaine, 683
discrimination, 683
rats and cats, 683
stereotyped behavior, 683
Behavioral arousal
aporphines, 653
cage climbing, 653
pharmacological basis for N-n-propylnorapomorphine induced stereotypy, 653
receptor blockers, 653
Behavioral development
children, s3
mental development, s3
methadone-treated women, s3
narcotic drugs, s3
psychomotor development, s3
transplacental exposure, s3
Behavioral effects
conditioned emotional response, s19
long-term, s23
maze learning, s29
morphine, s23, s29
morphine antinociception, s19
morphine-pellet implantation, s29
naltrexone, s19
neonatal addiction, s29
neuroendocrine, s29
offspring of male mice injected with opioids prior to mating, s23
perinatal drug exposure, s19
pregestation, s23
preliminary investigation, s19
prenatal, s23
protracted tolerance, s29
Behavioral impairment
chronic parental drug exposure, s47
development, s47
infant, s47
primate model for detection, s47
psychoactive drug, s47
social behavior, s47
Δ^9-THC, s47
Behavioral specificity
limbic involvement, 123
maternal behavior, 123
norepinephrine, 123
Behavioral teratogenesis
amphetamine, 605
hypothalamic monoamine content, 605
ovulation, 605
sexual behavior, 605
Behavioral toxicology
amphetamine, 31
developmental psychopharmacology, 31
drug responsiveness, 31
taste aversion learning, 31
Benzodiazepine
amphetamine, 65
anxiety, 65
barbiturates, 487
caffeine, 65
cannabinoids, 487
chloride ionophores, 457
diazepam, 487
eating, 487
flurazepam, 65
GABA, 457
hypothalamic injection, 487
locomotor activity, 65
meprobamate, 65
neuronal substrates of anxiety, 99
pentobarbital sodium, 487
phenobarbitone, 65
receptors, 457
social interaction, 65
Δ^9-THC, 487
triazolopyridazines, 457
type I and type II BDZ receptors, 457
Beta-adrenergic stimulation
isoproterenol, 141
renal excretion of electrolytes and water, 141
septal area, 141
Bicuculline methiodide
comparison of GABA, glycine and acetylcholine agonists and their antagonists, 647
GABA and hypothalamic feeding systems, 647
Blocking effect
FLA 57, 545
reinforcement with intragastric infusions of ethanol, 545
Blood acetaldehyde
drinking, 575
ethanol elimination rate, 575
ethanol intake and metabolism, 575
glutathione reductase, 575
N^1-methylnicotinamide, 575
niacin, 575
Blood brain barrier
delta-sleep inducing peptide (DSIP), 717
peptide antigenic-determinants, 717
radioimmunoassay, 717
Body weight
1-α-acetylmethadol, 279
adjunctive drinking, 347
androgen, 211
anorexigenic tripeptide, 733
caffeine, 347
core temperature, 279
cyproterone acetate, 211
dihydroxytestosterone, 211
eating, 211, 733
estrogen, 211
FT-1 min schedule, 347
heroin, 279
hydromorphone, 279
licking, 347
naloxone, 279
narcotic zinc tannate salts, 279
physical dependence, 279
pyro-glu-his-gly-OH, 733

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl, Vol. 11, 1979.

schedule induced polydipsia, 347
testosterone, 211
Body weight reduction
food delivery schedule, 737
self-administration, 737
Δ^9-THC, 737
Brain
amygdala
313, 505, 689
caudate nucleus, 23, 499
hippocampus, 107, 165, 243, 247, 593, 689
hypothalamus, 77, 487
lateral hypothalamus, 89
lead, 95
limbic, 123
medial hypothalamus, 1
mesencephalic central gray, 227
neostriatum, 529
nucleus accumbens, 23, 529, 553
pituitary, 303
posterior hypothalamus, 351
raphe nucleus, 17, 89
septum, 141, 695
striatum, 107
ventral tegmental area, 289, 351
ventromedial hypothalamus, 89, 729
Brain and behavior
lead, 165
Brain catecholamines
melatonin, 173
MIF-I, 173
novelty-induced defecation, 173
plasma 11-hydroxycorticosterone, 173
Brain chromatin
footshock, 253
macromolecular changes in CNS, 253
RNA synthesis in vitro, 253
Brain non-heme iron
behavior and physiological responsiveness, 631
long-term consequences of early iron deficiency, 631
Brain opioids
amphetamine, 131
morphine, 131
social cohesion, 131
Brain-stimulation reward
extinction, 557
performance deficits, 557
pimozide-produced dopamine receptor blockade, 557
repeated-response measures, 557
Breast milk
amniotic fluid, s7
methadone, s7
narcotic disposition, s7
perinatal, s7
pregnancy, s7

Caffeine
adjunctive drinking, 347
anxiety, 65
benzodiazepines, 65
body weight, 347
FT-1 min schedule, 347
licking, 347
locomotor activity, 65
schedule induced polydipsia, 347
social interaction, 65
Cage climbing
aporphines, 653
behavioral arousal, 653
pharmacological basis for N-n-propylnorapomorphine induced stereotypy, 653
receptor blockers, 653
Cannabinoids
barbiturates, 487
benzodiazepines, 487
diazepam, 487
eating, 487
hypothalamic injection, 487
pentobarbital sodium, 487
Δ^9-THC, 487
Carbachol
comparison of GABA, glycine and acetylcholine agonists and their antagonists, 647
GABA and hypothalamic feeding systems, 647
Catecholamine activity
attenuation by tryptophan, 319
hypnotic effect, 319
induced slow wave sleep, 319
reduced sleep latency, 319
Catecholamine concentration
epinephrine, 557
norepinephrine-N-methyltransferase, 557
pigeon brain, 557
Catecholamines
amnesia, 449
development, 309
dopamine, 77
epinephrine, 77, 449
food deprivation, 89
HPLC, 89
6-hydroxydopa, 309
6-hydroxydopamine, 309
hyperactivity, 309
hypothalamus, 77
indoles, 89
lateral hypothalamus, 89
memory, 449
neonatal activity, 309
norepinephrine, 77, 309, 449
obesity, 77
passive avoidance, 449
raphe nucleus, 89
syrosingopine, 449
ventromedial hypothalamus, 89
Caudate nucleus
activity, 23
d-amphetamine, 23
dopamine, 23
evoked potentials, 499
GABA, 499
6-hydroxydopamine, 23
locomotion, 23
modification of motor activity, 499
nucleus accumbens, 23
passive avoidance conditioning, 499
picrotoxin, 499
Central cholinergic mechanisms
acetylcholine, 625
apomorphine, 625
hyoscine, 625
methylscopolamine, 625
oxotremorine, 625
propranolol, 625
scopolamine, 625
self-stimulation, 625
tremor, 625
Central depressant combinations
diazepam, 111
ethanol, 111
interaction toxicity, 111
lithium, 111
methaqualone, 111
phenobarbital, 111
Cerebral cannula
chemical stimulation, 363
Chemical feed intake stimulants
abomasal acid secretion, 51
chemical feed intake stimulants, 51
elfazepam, 51

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl, Vol. 11, 1979.

sheep, 51
Chemical stimulation
cerebral cannula, 363
intracerebral cannula system, 463
intracranial, 463
intraventricular, 463
Children
behavioral development, s3
children, s3
methadone-treated women, s3
narcotic drugs, s3
psychomotor development, s3
transplacental exposure, s3
Chloride ionophores
benzodiazepine receptors, 457
GABA, 457
triazolopyridazines, 457
type I and type II BDZ receptors, 457
p-Chloroamphetamine
frequency analysis of behavior components of the serotonin syndrome, 611
halogenated amphetamine, 611
stereotypy, 611
p-Chlorophenylalanine
copulatory experience, 701
paradoxical attention, 17
pargyline, 17
pudendal nerve section, 701
serotonergic model, 17
sexual behavior, 701
tonic immobility, 17
tryptophan, 17
Chlorpromazine
amphetamine, 203
avoidance baseline, 203
baseline levels and drug effects, 203
clozapine, 239, 661
diazepam, 203
discriminated avoidance response, 203
haloperidol, 661
response force, 239
response rate, 239
schedule-controlled behavior, 661
Cholinergic
anticholinesterase, 189
aversive stimulus, 189
defense responses, 189
fear, 189
physostigmine, 189
Cholinergic system
involvement in the inhibition of hyperreactivity and interanimal aggression, 1
Cholinergic transmitter substance
(^{3}H)-fucose, 243
hippocampus, 243
(^{14}C)-leucine, 243
Chronic drug administration
intravenous cannula, 115
jugular vein, 115
maternal responsiveness, 539
squirrel monkey, 539
Δ^{9}-THC, 539
Chronic intake level
discriminative motor control, 581
ethanol, 581
schedule-induced polydipsia, 581
withdrawal, 581
Chronic parental drug exposure
development, s47
infants, s47
mother-infant interaction, s47
primate model for detecting behavioral impairment, s47
psychoactive drug, s47
social behavior, s47
Δ^{9}-THC, s47
Classical conditioning
D-ala^{2}-leu-enkephalinamide, 231
morphine, 231
technique for assessing the reinforcing effects of opiate drugs, 231
Clock stimuli
codeine self-administration, 43
FI clock schedule, 43
multiple schedule, 43
Clonidine
alpha-noradrenergic receptors, 259
amnesia, 259
diethyldithiocarbamate, 259
dopamine beta hydroxylase, 259
Clozapine
amphetamine, 529
antipsychotic drugs, 529
apomorphine, 529
chlorpromazine, 239, 661
haloperidol, 529, 661
neostriatum, 529
nucleus accumbens, 529
response force, 239
response rate, 239
schedule-controlled behavior, 661
spontaneous neuronal activity, 529
Cocaine
amygdala, 689
behavioral antecedents, 683
discrimination, 683
hippocampus, 689
limbic seizure discharges, 689
rats and cats, 683
stereotyped behavior, 683
temporal lobe epilepsy, 689
Codeine
clock stimuli, 43
FI clock schedule, 43
multiple schedule, 43
self-administration, 43
Coelic ganglionectomy
afferent nerves, 331
apomorphine, 331
conditioned toxiphobia, 331
copper sulfate, 331
gastric irritation, 331
taste aversion learning, 331
Cognitive flexibility
discrimination reversal learning, 341
enkephalin analog, 341
Conditional discrimination
barbiturate, 159
matching-behavior, 159
sodium pentobarbital, 159
stimulus control, 159
Conditioned drinking suppression
effect of external stimulus change on ethanol-produced dissociation, 377
generalization, 377
state-dependent learning, 377
Conditioned emotional response
behavioral effects, s19
morphine antinociception, s19
naltrexone, s19
perinatal drug exposure, s19
preliminary investigation, s19
Conditioned fear
antinoception, 639
autoanalgesia, 639, 643, 741
cross-tolerance, 643
endorphin, 643
leu-enkephalin, 741
morphine, 643
naloxone, 639, 741
pain, 639

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl, Vol. 11, 1979.

stress, 639
Conditioned taste aversion
ethanol, 391
naloxone, 391
non-specific enhancement, 391
Conditioned toxiphobia
afferent nerves, 331
apomorphine, 331
coeliac ganglionectomy, 331
copper sulfate, 331
gastric irritation, 331
taste aversion learning, 331
Conditioning
heroin, 445
interoceptive factors, 445
self-injection, 445
Consolidation
amnesia, 453
memory, 453
rauwolfia alkaloids, 453
reserpine, 453
retrieval failure, 453
storage impairment, 453
syrosingopine, 453
Convulsions
D,L-allylglycine, 221
anti-epileptic drugs, 221
gabaminergic drugs, 221
Copper sulfate
afferent nerves, 331
apomorphine, 331
coeliac ganglionectomy, 331
conditioned toxiphobia, 331
gastric irritation, 331
taste aversion learning, 331
Copulatory experience
p-chlorophenylalanine, 701
pudendal nerve section, 701
sexual behavior, 701
Core temperature
1-α-acetylmethadol, 279
body weight, 279
heroin, 279
hydromorphone, 279
naloxone, 279
narcotic zinc tannate salts, 279
physical dependence, 279
Corticosteroids
adrenal catecholamines, 57
morphine, 57
nalorphine, 57
pituitary-adrenal system, 57
Corticosterone
activity, 695
adrenal ascorbic acid, 215
neurotransmitters, 215
nonreward, 215
norepinephrine, 695
physiological indicators of stress, 215
reward, 215
runway behavior, 215
septal lesions, 695
stress, 695
temperature, 695
ulcers, 695
Cross-foster
hot-plate, 235
hyperalgesia, 235
naloxone, 235
perinatal, 235
Cross-tolerance
autoanalgesia, 643
conditioned fear, 643
endorphin, 643
morphine, 643
Cued shock
adjunctive behavior, 601
ethanol, 601
uncued inescapable shock, 601
voluntary alcohol consumption, 601
Cumulative drug effects
rauwolfia alkaloids, 585
reserpine, 585
spontaneous activity, 585
syrosingopine, 585
Cyclic nucleotides
hippocampus, 107
intracranial self-stimulation, 107
motor activity, 107
striatum, 107
Cycloheximide
metaraminol, 335
monoamine oxidase inhibitor, 335
ouabain, 335
pargyline, 335
single trial passive avoidance learning, 335
sympathomimetic amine, 335
Cyproheptadine
amphetamine, 479
apomorphine, 479
dopaminergic drugs, 479
locomotor activity, 479
psychotomimetics, 479
Cyproterone acetate
androgen, 211
body weight, 211
dihydroxytestosterone, 211
eating, 211
estrogen, 211
testosterone, 211

Defense responses
amphetamine, 325
anticholinesterase, 189
aversive stimulus, 189
avoidance, 325
cholinergic, 189
defensive flight, 325
fear, 189
physostigmine, 189
stereotypy, 325
Defensive flight
amphetamine, 325
avoidance, 25
defensive responses, 325
stereotypy, 325
Delayed match-to-sample task
acetone, 401
methyl ethyl ketone, 401
methyl isobutyl ketone, 401
Delta-sleep inducing peptide (DSIP)
blood brain barrier, 717
peptide antigenic-determinants, 717
radioimmunoassay, 717
2-Deoxy-d-glucose
analgesia, 297, 303
hypophysectomy, 303
insulin, 303
morphine, 297, 303
naloxone, 297
stress, 303
synergy, 297
Development
catecholamine, 309
chronic parental drug exposure, s47
6-hydroxydopa, 309
6-hydroxydopamine, 309
hyperactivity, 309
in utero, s15

infants, s15, s47
methadone exposure, s15
mental developmental index, s15
mother-infant interaction, s47
neonatal activity, 309
norepinephrine, 309
primate model for detecting behavioral impairment, s47
psychoactive drug, s47
social behavior, s47
Δ^9-THC, s47
Developmental psychopharmacology
amphetamine, 31
behavioral toxicology, 31
drug responsiveness, 31
taste aversion learning, 31
Diazepam
d-amphetamine, 203
avoidance baseline, 203
barbiturates, 487
baseline levels and drug effects, 203
benzodiazepines, 487
cannabinoids, 487
chlorpromazine, 203
discriminated avoidance response, 203
eating, 487
ethanol and central depressant combinations, 111
hypothalamic injection, 487
interaction toxicity, 111
neuronal substrates of anxiety, 99
pentobarbital sodium, 487
Δ^9-THC, 487
Diethylaminoethanol
drug self-administration, 669
lidocaine, 669
local anesthetics, 669
procainamide, 669
procaine, 669
reinforcing properties, 669
Diethyldithiocarbamate
alpha-noradrenergic receptors, 259
amnesia, 259
clonidine, 259
dopamine beta hydroxylase, 259
Differential reinforcement
amphetamine, 617
pentobarbital, 617
phencyclidine, 617
schedule controlled behavior, 617
spaced responding, 617
Dihydroxytestosterone
androgen, 211
body weight, 211
cyproterone acetate, 211
eating, 211
estrogen, 211
testosterone, 211
Discriminated avoidance response
d-amphetamine, 203
avoidance baseline, 203
baseline levels and drug effects, 203
chlorpromazine, 203
diazepam, 203
Discrimination
behavioral antecedents, 683
cocaine, 683
rats and cats, 683
stereotyped behavior, 683
Discrimination reversal learning
enhanced cognitive flexibility, 341
enkephalin analog, 341
Discriminative motor control
chronic intake level, 581
ethanol, 581
schedule-induced polydipsia, 581
withdrawal, 581
Dopamine
activity, 23
akinesia, 71
d-amphetamine, 23
apomorphine, 283
catecholamines, 77
caudate nucleus, 23
dopaminergic pathways, 135
drinking, 413
epinephrine, 77
estrogen, 549
extinction, 71
fluorometric assay, 183
(^{3}H)-fucose, 247
GABA, 549
GAD activity, 549
hippocampus, 247
6-hydroxydopamine, 23
hypersensitivity, 283
hypothalamus, 77
ion-exchange resin, 183
lesion, 135
(^{14}C)-leucine, 247
locomotion, 23
mesolimbic dopamine system, 549
methadone, 283
morphine, 283
narcotics, 283
neuroleptics, 71
nigrostriatal dopamine system, 549
norepinephrine, 77, 413
nucleus accumbens, 23
obesity, 77
olfactory bulbectomy, 549
pimozide, 71
rotational behavior, 135
self-stimulation, 413
serotonin, 413
TH activity, 549
Dopamine beta hydroxylase
alpha-noradrenergic receptors, 259
amnesia, 259
clonidine, 259
diethyldithiocarbamate, 259
Dopamine receptor blockade
brain-stimulation reward, 557
extinction, 557
performance deficits, 557
pimozide-produced, 557
repeated-response measures, 557
Dopaminergic drugs
amphetamine, 479
apomorphine, 479
cyproheptadine, 479
locomotor activity, 479
psychotomimetics, 479
Dopaminergic nerve terminals
d-amphetamine self administration, 553
nucleus accumbens, 553
Dopaminergic pathways
dopamine, 135
lesion, 135
rotational behavior, 135
Dopaminergic system
involvement in the inhibition of hyperreactivity and interanimal aggression, 1
Dosage
exploratory patterns, s35
maternal lead exposure, s35
nutrition, 35
offspring open field performance, s35
postnatal lead exposure, s35
prenatal lead exposure, s35
Drinking
activity, 407

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl, Vol. 11, 1979.

amphetamine, 423
analgesia, 387
blood acetaldehyde, 575
comparison of GABA, glycine and acetylcholine agonists and their antagonists, 647
dopamine, 413
eating, 407, 567
endorphin, 407, 567
enkephalin, 407
ethanol elimination rate, 575
ethanol intake and metabolism, 575
fixed-time schedule, 423
food deprivation, 567
GABA and hypothalamic feeding systems, 647
glutathione reductase, 575
grooming, 423
N-methylnicotinamide, 575
morphine, 387
naloxone, 567
naltrexone, 387
narcotic antagonist, 567
niacin, 575
norepinephrine, 413
opiate, 387
phenobarbital, 145, 709
response measures, 145
riboflavin, 575
schedule-induced behavior, 423
self-stimulation, 413
serotonin, 413
suppression effects, 387
taste aversion, 709
x-radiation, 709

Drug
acetazolamide, 221
acetone, 395, 401
acetylcholine, 625
α-acetylenic GABA, 265
1-α-acetylmethadol, 279
adrenal ascorbic acid, 215
D-L-allyglycine, 221
aminoxyacetic acid, 221
amphetamine, 23, 31, 65, 131, 151, 203, 325, 351, 419, 423, 479, 529, 553, 605, 617
apomorphine, 283, 331, 479, 529, 625
aporphines, 653
atropine, 1, 37
azaperone, 351
baclofen, 221
barbital, 359
barbiturates, 487
benzodiazepines, 65, 99, 457, 487
bicuculline methiodide, 647
caffeine, 65, 347
9-aza-cannabinol, 51
carbachol, 647
p-chloroamphetamine, 611
p-chlorophenylalanine, 17, 701
chlorpromazine, 203, 239, 661
clonazepam, 221
clonidine, 259
clozapine, 239, 529, 661
cocaine, 683, 689
codeine, 43
copper sulfate, 331
corticosterone, 215
cycloheximide, 335
cyproheptadine, 479
cyproterone acetate, 211
delta-sleep inducing peptide (DSIP), 717
2-deoxy-D-glucose, 297, 303
diazepam, 99, 111, 203, 487
diethylaminoethanol, 669
diethyldithiocarbamate, 259
diphenylhydantoin, 221
dopamine, 23, 71, 77, 135, 173, 183, 247, 283, 413, 549, 557
dopamine-beta-hydroxylase, 259
elfazepam, 51
β-endorphin, 407, 713
(D-ala^2)-β-endorphin, 407
(D-ala^2)-met-enkephalin, 407
(D-ala^2)-F_5,Phe^4-enkephalin-NH_2, 341
D-ala^2-leu-enkephalinamide, 231
ethanol, 83, 111, 377, 391, 413, 439, 513, 545, 575, 581, 589, 601
ethosuximide, 221
etomidate, 221
fenfluramine, 151
flunarizine, 221
flurazepam, 65, 647
^{3}H-fucose, 243, 247
GABA, 549, 647
glutamic acid decarboxylase, 549
glutathione reductase, 575
glycine, 99, 647
haloperidol, 1, 351, 529, 661
heroin, 279, 445
hydralazine, 1
hydromorphone, 267
6-hydroxydopa, 309
6-hydroxydopamine, 1, 23, 309
5-hydroxyindoleacetic acid, 183
5-hydroxytryptophan, 431
hyoscine, 625
imipramine, 725
insulin, 303
isoproterenol, 141
ketamine, 483
lead, 165, s35
(^{14}C)-leucine, 243, 247
leu-enkepahlin, 741
lidocaine, 669
lithium, 111
Lu 10,171 371
meprobamate, 65
metaraminol, 335
met-enkephalin, 407, 713
metergoline, 371
methadone, 283, 521, s1, s3, s5, s7
methaqualone, 111
methyl ethyl ketone, 401
methyl isobutyl ketone, 401
N^1-methylnicotinamide, 575
α-methylphenylalanine, 493
methylscopolamine, 625
metrazol, 265
MIF-1, 721
morphine, 11, 57, 131, 155, 197, 231, 283, 289, 297, 303, 313, 387, 505, 643, 673, s19, s23, s29
muscimol, 647
naloxone, 227, 235, 279, 289, 297, 391, 505, 567, 639, 673, 705, 729, 741
naltrexone, 387, s19
narcotic zinc tannate salts, 279
neurotensin, 473
niacin, 575
ouabain, 335
oxotremorine, 625
pargyline, 335
pentobarbital, 617
pentobarbital sodium, 487
phencyclidine, 37, 617, s39
phenobarbital, 111, 145, 221, 359, 709
phenobarbitone, 65
phentolamine, 1
β-phenylethylamine, 419
physostigmine, 37, 189, 371
picrotoxin, 483, 499, 647
pimozide, 71, 557
pipamperone, 221
primidone, 221

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl, Vol. 11, 1979.

procainamide, 669
procaine, 669
propranolol, 1, 625
N-n-propylnorapomorphine, 653
pyro-glu-his-gly-OH, 733
rauwolfia alkaloids, 449, 453, 585
reserpine, 453, 585
riboflavin, 575
saccharin, 367
scopolamine, 625
serotonin, 17, 99, 183, 371, 413, 431, 611
sodium pentobarbital, 159
strychnine, 647
syrosingopine, 449, 453, 585
tetracaine, 669
Δ^9-tetrahydrocannabinol, 383, 487, 539, 737, s47
tolazoline, 1
toluene, 395
trizaolopyridazine, 99, 457
trimethadione, 221
tryptophan, 17, 183, 319
tyrosine hydroxylase, 549
valproate sodium, 221
γ-vinyl GABA, 265
Drug interactions
atropine, 37
phencyclidine, 37
physostigmine, 37
variable-interval, 37
Drug responsiveness
amphetamine, 31
behavioral toxicology, 31
developmental psychopharmacology, 11
taste aversion learning, 11
Drug self-administration
diethylaminoethanol, 669
lidocaine, 669
local anesthetics, 669
procainamide, 669
procaine, 669
reinforcing properties, 669
Drug-produced dissociation
conditioned drinking suppression, 377
effect of external stimulus change on ethanol-produced dissociation, 377
generalization, 377
state-dependent learning, 377

Early drug exposure
abuse, s1
mehtadone, s1
PCP, s1
pharmacokinetics, s1
protracted effects, s1
psychomotor deficits, s1
psychotrophic drugs, s1
Eating
activity, 407
analgesia, 721
androgen, 211
anorexigenic tripeptide, 733
barbiturates, 487
benzodiazepines, 487
body weight, 211, 733
cannabinoids, 487
comparison of GABA, glycine and acetylcholine agonists and their antagonists, 647
cyproterone acetate, 211
diazepam, 487
dihydroxytestosterone, 211
drinking, 407, 567
endorphin, 407, 567
enkephalin, 407
estrogen, 211
feeding patterns, 431
food deprivation, 567
GABA and hypothalamic feeding systems, 647
5-hydroxytryptophan, 431
hypothalamic injection, 487
MIF-I's differential actions as an opiate antagonist, 721
naloxone, 567
narcotic antagonist, 567
pentobarbital sodium, 487
pyro-glu-his-gly-OH, 733
serotonin, 431
testosterone, 211
Δ^9-THC, 487
vas deferens, 721
Electrolytes
β-adrenergic stimulation, 141
isoproterenol, 141
septal area, 141
Elfazepam
abomasal acid secretion, 51
9-aza-cannabinol, 51
chemical feed intake stimulants, 51
sheep, 51
Emotionality
melatonin, 367
saccharin neophobia, 367
Endogenous opioid peptide
focal electrical stimulation, 227
mesencephalic central gray, 227
naloxone, 227
tail erection, 227
Endorphin
activity, 407
autoanalgesia, 643
conditioned fear, 643
cross-tolerance, 643
drinking, 407, 567
eating, 407, 567
enkephalin, 407
food deprivation, 567
morphine, 643
naloxone, 567
narcotic antagonist, 567
β-Endorphin
analgesia, 713
met-enkephalin, 713
peripheral administration, 713
Enkephalin
activity, 407
drinking, 407
eating, 407
endorphin, 407
morphine, 289
naloxone, 289, 705
non-narcotic component, 705
opiate peptides, 705
self-stimulation, 289
tonic immobility, 705
ventral tegmental area, 289
Enkephalin analog
discrimination reversal learning, 341
enhanced cognitive flexibility, 341
Environmental stress
prenatal and postnatal chronic lead intoxication, 95
running wheel activity, 95
Epinephrine
amnesia, 449
catecholamine concentration, 563
catecholamines, 77, 449
dopamine, 77
hypothalamus, 77
memory, 449
norepinephrine, 77, 449
norepinephrine N-methyltransferase, 563
passive avoidance, 449

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl, Vol. 11, 1979.

pigeon brain, 563
obesity, 77
syrosingopine, 449
Erythrocytes
changes induced by hashish constituents, 383
phospholipids, 383
Δ^9-THC, 383
Escape
morphine, 155
shock, 155
stimulus-response relationships, 155
Estrogen
androgen, 211
body weight, 211
cyproterone activity, 211
dihydroxytestosterone, 211
dopamine, 549
eating, 211
GABA, 549
GAD activity, 549
mesolimbic dopamine system, 549
nigrostriatal dopamine system, 549
olfactory bulbectomy, 549
testosterone, 211
TH activity, 549
Ethanol
adjunctive behavior, 601
alcohol dehydrogenase activity, 439
blood acetaldehyde, 575
central depressant combinations, 111
chronic intake level, 581
conditioned drinking suppression, 377
conditioned taste aversion, 391
cued and uncued inescapable shock, 601
diazepam, 111
discriminative motor control, 581
drug-produced dissociation, 377
effect of external stimulus change on ethanol-produced dissociation, 377
elimination rate, 575
fetal alcohol syndrome, 513
FLA 57 blocking effect, 545
generalization, 377
glutathione reductase, 575
hole poke, 513
inhibition, 513
intake, 429
intake and metabolism, 575
interaction toxicity, 111
learning ability, 589
liquid diets, 589
lithium, 111
metabolism, 439
methaqualone, 111
N-methylnicotinamide, 575
naloxone, 391
niacin, 575
non-specific enhancement, 391
nose poke, 513
phenobarbital, 111
preference, 439
prenatal, 513
reinforcement with intragastric infusions, 545
riboflavin, 575
schedule-induced polydipsia, 581
shuttlebox avoidance learning, 589
state-dependent learning, 377
voluntary alcohol consumption, 601
withdrawal, 581, 589
Ethanol consumption
alcohol dehydrogenase, 83
aldehyde dehydrogenase, 83
hepatic enzyme activity, 83
Evoked potentials
caudate nucleus, 499
GABA, 499
modification of motor activity, 499
passive avoidance conditioning, 499
picrotoxin, 499
Exploratory behavior
amygdala, 505
aversive thresholds, 505
morphine, 505
motor activity, 505
naloxone, 505
opiates, 505
Exploratory patterns
dosage, s35
maternal lead exposure, s35
nutrition, s35
offspring open field performance, s35
postnatal lead exposure, s35
prenatal lead exposure, s35
Extinction
akinesia, 71
brain-stimulation reward, 557
dopamine, 71
neuroleptics, 71
performance deficits, 557
pimozide, 71
pimozide-produced dopamine receptor blockade, 557
repeated-response measures, 557

Fear
anticholinesterase, 189
aversive stimulus, 189
cholinergic, 189
defense responses, 189
physostigmine, 189
Feeding patterns
eating, 431
5-hydroxytryptophan, 431
serotonin, 431
Fenfluramine
d-amphetamine, 151
schedule-induced drinking, 151
Fetal alcohol syndrome
ethanol, 513
hole poke, 513
inhibition, 513
nose poke, 513
prenatal, 513
FI clock schedule
clock stimuli, 43
codeine, 43
multiple schedule, 43
Fine motor control
methamphetamine, 273
rhesus monkey, 273
Fixed-time schedule
d-amphetamine, 423
drinking, 423
grooming, 423
schedule-induced behavior, 423
FLA 57
blocking effect, 545
reinforcement with intragastric infusions of ethanol, 545
Flurazepam
anxiety, 65
benzodiazepines, 65
locomotor activity, 65
social interaction, 65
Flurazepam diHCl
comparison of GABA, glycine and acetylcholine agonists and their antagonists, 647
GABA and hypothalamic feeding systems, 647
Fluorometric assay
dopamine, 183
5-hydroxyindoleacetic acid, 183

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl, Vol. 11, 1979.

ion-exchange resin, 183
norepinephrine, 183
serotonin, 183
l-tryptophan, 183
Focal electrical stimulation
endogenous opioid peptide, 227
mesencephalic central gray, 227
naloxone, 227
tail erection, 227
Food delivery schedule
body weight reduction, 737
self-administration, 737
Δ^9-THC, 737
Food deprivation
barbital, 359
barbiturate serum level, 359
catecholamines, 89
drinking, 567
eating, 567
endorphin, 567
HPLC, 89
indoles, 89
lateral hypothalamus, 89
naloxone, 567
narcotic antagonist, 567
phenobarbital, 359
raphe nucleus, 89
ventromedial hypothalamus, 89
Food-motivated conditioning
autoradiographic comparison of neuronal and glial protein metabolism, 593
footshock-motivated conditioning, 593
hippocampus, 593
Footshock
brain chromatin, 253
macromolecular changes in CNS, 253
RNA synthesis in vitro, 233
Footshock-motivated conditioning
Autoradiographic comparison of neuronal and glial protein metabolism, 593
food-motivated conditioning, 593
hippocampus, 593
Frequency analysis
behavior components of the serotonin syndrome, 611
p-chloroamphetamine, 611
halogenated amphetamine, 611
stereotypy, 611
FT-1 min schedule
adjunctive drinking, 347
body weight, 347
caffeine, 347
licking, 347
schedule induced polydipsia, 347
(^{3}H)-Fucose
cholinergic transmitter substance, 243
dopamine, 247
hippocampus, 243, 247
(^{14}C)-leucine, 243, 247

GABA
benzodiazepine receptors, 457
caudate nucleus, 499
chloride ionophores, 457
comparison of GABA, glycine and acetylcholine agonists and their antagonists, 647
dopamine, 549
estrogen, 549
evoked potentials, 499
GABA and hypothalamic feeding systems, 647
GAD activity, 549
mesolimbic dopamine system, 549
modification of motor activity, 499
neuronal substrates of anxiety, 99
nigrostriatal dopamine system, 549
olfactory bulbectomy, 549
passive avoidance, 499
picrotoxin, 499
TH activity, 549
triazolopyridazines, 457
type I and type II BDZ receptors, 457
GABA-T inhibitors
γ-acetylenic GABA, 265
ketamine, 483
kindled seizures, 265
metrazol, 265
picrotoxin, 483
rotation, 483
γ-vinyl GABA, 265
Gabaminergic drugs
D,L-allylglycine, 221
anti-epileptic drugs, 221
convulsions, 221
GAD activity
dopamine, 549
estrogen, 549
GABA, 549
mesolimbic dopamine system, 549
nigrostriatal dopamine system, 549
olfactory bulbectomy, 549
TH activity, 549
Gastric irritation
afferent nerves, 331
apomorphine, 331
coeliac ganglionectomy, 331
conditioned toxiphobia, 331
copper sulfate, 331
taste aversion learning, 331
Generalization
conditioned drinking suppression, 377
drug-produced dissociation, 377
effect of external stimulus change on ethanol-produced dissociation, 377
state-dependent learning, 377
Glial protein metabolism
autoradiographic comparison with neuronal protein metabolism, 593
food-motivated conditioning, 593
footshock-motivated conditioning, 593
hippocampus, 593
Glutathione reductase
blood acetaldehyde, 575
drinking, 575
ethanol elimination rate, 575
ethanol intake and metabolism, 575
N-methylnicotinamide, 575
niacin, 575
riboflavin, 575
Glycine
comparison of GABA, glycine and acetylcholine agonists and their antagonists, 647
GABA and hypothalamic feeding systems, 647
neuronal substrates of anxiety, 99
Grooming
d-amphetamine, 423
drinking, 423
fixed-time schedule, 423
schedule-induced behavior, 423

Halogenated amphetamine
p-chloroamphetamine, 611
frequency analysis of behavior components of the serotonin syndrome, 611
stereotypy, 611
Haloperidol
amphetamine, 351, 529
antipsychotic drugs, 529
apomorphine, 529
azaperone, 351

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl, Vol. 11, 1979.

chlorpromazine, 661
clozapine, 529, 661
neostriatum, 529
nucleus accumbens, 529
posterior hypothalamus, 351
schedule-controlled behavior, 661
self-stimulation, 351
spontaneous neuronal activity, 529
ventral tegmental area, 351
Hamster
morphine, 673
naloxone, 673
opioids, 673
sexual behavior, 673
Hashish
changes induced by hashish constituents on human erythrocyte phospholipids, 383
Δ^9-THC, 383
Hepatic enzyme activity
alcohol dehydrogenase, 83
aldehyde dehydrogenase, 83
ethanol consumption, 83
Heroin
1-α-acetylmethadol, 279
body weight, 279
conditioning, 445
core temperature, 279
hydromorphone, 279
interoceptive factors, 445
naloxone, 279
narcotic zinc tannate salts, 279
physical dependence, 279
self-injection, 445
Hibernators
hypothermia, 473
neuropeptides, 473
neurotensin, 473
thermoregulation, 473
High performance liquid chromatography
catecholamines, 89
food deprivation, 89
indoles, 89
lateral hypothalamus, 89
raphe nucleus, 89
ventromedial hypothalamus, 89
Hippocampus
amygdala, 689
autoradiographic comparison of neuronal and glial protein metabolism, 593
cholinergic transmitter substance, 243
cocaine, 689
cyclic nucleotides, 107
dopamine, 247
food-motivated conditioning, 593
footshock-motivated conditioning, 593
(^{3}H)-fucose, 243, 247
hyperactivity, 165
intracranial self-stimulation, 107
lead, 165
(^{14}C)-leucine, 243, 247
limbic seizure discharges, 689
mental retardation, 165
motor activity, 107
striatum, 107
temporal lobe epilepsy, 689
Hole poke
ethanol, 513
fetal alcohol syndrome, 513
inhibition, 513
nose poke, 513
prenatal, 513
Hormone
androgen, 211
corticosterone, 695
dihydroxytestosterone, 211
epinephrine, 77, 449, 563
estrogen, 211, 549
melatonin, 367
MSH-inhibiting factor-I, 173
norepinephrine, 77, 123, 173, 183, 309, 413, 449, 563, 695
norepinephrine N-methyltransferase, 563
testosterone, 211
Hot plate
cross-foster, 235
hyperalgesia, 235
naloxone, 235
perinatal, 235
Hydromorphone
1-α-acetylmethadol, 279
body weight, 279
core temperature, 279
heroin, 279
naloxone, 279
narcotic zinc tannate salts, 279
physical dependence, 279
6-Hydroxydopa
catecholamine, 309
development, 309
6-hydroxydopamine, 309
hyperactivity, 309
neonatal activity, 309
norepinephrine, 309
6-Hydroxydopamine
activity, 23
d-amphetamine, 23
catecholamine, 309
caudate nucleus, 23
development, 309
dopamine, 23
6-hydroxydopa, 309
hyperactivity, 309
locomotion, 23
neonatal activity, 309
norepinephrine, 309
nucleus accumbens, 23
5-Hydroxyindole acetic acid
fluorometric assay, 183
ion-exchange resin, 183
5-Hydroxytryptophan
eating, 431
feeding patterns, 431
serotonin, 431
Hyoscine
acetylcholine, 625
apomorphine, 625
central cholinergic mechanisms, 625
methylscopolamine, 625
oxotremorine
propranolol, 625
scopolamine, 625
self-stimulation, 625
tremor, 625
Hyperactivity
catecholamine, 309
development, 309
hippocampus, 165
6-hydroxydopa, 309
6-hydroxydopamine, 309
lead, 165
mental retardation, 165
neonatal activity, 309
norepinephrine, 309
Hyperalgesia
cross-foster, 235
hot-plate, 325
naloxone, 235
perinatal, 235
Hyperreactivity
adrenergic involvement, 1
cholinergic involvement, 1

dopaminergic involvement, 1
inhibition, 1
interanimal aggression, 1
medial hypothalamus, 1
Hypersensitivity
apomorphine, 283
dopamine, 283
methadone, 283
morphine, 283
narcotics, 283
Hypnotic effect
attenuation of catecholamine activity, 319
induced slow wave sleep, 319
reduced sleep latency, 319
Hypophysectomy
analgesia, 303
2-deoxy-D-glucose, 303
insulin, 303
morphine, 303
stress, 303
Hypothalamic injection
barbiturates, 487
benzodiazepines, 487
cannabinoids, 487
diazepam, 487
eating, 487
pentobarbital sodium, 487
Δ^9-THC, 487
Hypothalamic monoamine content
amphetamine, 605
behavioral teratogenesis, 605
ovulation, 605
sexual behavior, 605
Hypothalamic obese rats
naloxone, 729
suppression of eating, 729
VMH, 729
Hypothalamus
catecholamines, 77
dopamine, 77
epinephrine, 77
norepinephrine, 77
obesity, 77
Hypothermia
hibernators, 473
neuropeptides, 473
neurotensin, 473
thermoregulation, 473

Imipramine
adjunctive behavior, 725
schedule dependent behavior, 725
schedule induced behavior, 725
Indoles
catecholamines, 89
food deprivation, 89
HPLC, 89
lateral hypothalamus, 89
raphe nucleus, 89
ventromedial hypothalamus, 89
Infants
chronic parental drug exposure, s47
development, s15, s47
in utero methadone exposure, s15
mental developmental index, s15
mother-infant interaction, s47
primate model for detecting behavioral impairment, s47
psychoactive drug, s47
social behavior, s47
Δ^9-THC, s47
Inhibition
ethanol, 513
fetal alcohol syndrome, 513
hole poke, 513
nose poke, 513
prenatal, 513
Insulin
analgesia, 303
2-deoxy-D-glucose, 303
hypophysectomy, 303
morphine, 303
stress, 303
Interaction toxicity
central depressant combinations, 111
diazepam, 111
ethanol, 111
lithium, 111
methaqualone, 111
phenobarbital, 111
Interanimal aggression
adrenergic involvement, 1
cholinergic involvement, 1
dopaminergic involvement, 1
hyperreactivity, 1
inhibition, 1
medial hypothalamus, 1
Interoceptive factors
conditioning, 445
heroin, 445
self-injection, 445
Intracerebral cannula system
chemical stimulation, 463
intracranial, 463
intraventricular, 463
Intracranial
chemical stimulation, 463
intracerebral cannula system, 463
intraventricular, 463
Intracranial self-stimulation
cyclic nucleotides, 107
hippocampus, 107
motor activity, 107
striatum, 107
Intragastric infusions
FLA 57 blocking effect, 545
reinforcement with ethanol, 545
Intravenous cannula
chronic drug administration, 115
jugular vein, 115
Intraventricular
chemical stimulation, 463
intracerebral cannula system, 463
intracranial, 463
In utero
development, s15
infant, s15
mental developmental index, s15
methadone exposure, s15
Ion-exchange resin
dopamine, 183
fluorometric assay, 183
5-hydroxyindoleacetic acid, 183
fluorometric assay, 183
norepinephrine, 183
serotonin, 183
l-tryptophan, 183
Iron deficiency
active avoidance, 631
behavior and physiological responsiveness, 631
brain non-heme iron, 631
long-term consequences, 631
pituitary-adrenal system, 631
Isoproterenol
beta-adrenergic stimulation, 141
renal excretion of electrolytes and water, 141
septal area, 141

Jugular vein
chronic drug administration, 115
intravenous cannula, 115

Ketamine
GABA-T inhibitors, 483
picrotoxins, 483
rotation, 483
Kindled seizures
γ-acetylenic GABA, 265
GABA-T inhibitors, 265
metrazol, 265
γ-vinyl GABA, 265

Lateral hypothalamus
catecholamines, 89
food deprivation, 89
HPLC, 89
indoles, 89
raphe nucleus, 89
ventromedial hypothalamus, 89
Lead
brain and behavior, 165
chronic intoxication, 95
environmental stress, 95
hippocampus, 165
hyperactivity, 165
mental retardation, 165
postnatal, 95
prenatal, 95
running wheel activity, 95
Learning ability
ethanol, 589
liquid diets, 589
shuttlebox avoidance learning, 589
withdrawal, 589
Learning and memory deficits
avoidance learning, 493
locomotor activity, 493
α-methylphenylalanine, 493
phenylalanine development, 493
phenylketonuria, 493
(^{14}C)-Leucine
cholinergic transmitter substance, 243
dopamine, 247
(^{3}H)-fucose, 243, 247
hippocampus, 243, 247
Leu-enkephalin
autoanalgesia, 741
conditioned fear, 741
naloxone, 741
opiate receptors, 741
Lesion
dopamine, 135
dopaminergic pathway, 135
rotational behavior, 135
Licking
body weight, 347
caffeine, 347
FT-1 min schedule, 347
schedule induced polydipsia, 347
Lidocaine
diethylaminoethanol, 669
drug self-administration, 669
local anesthetics, 669
procainamide, 669
procaine, 669
reinforcing properties, 669
Limbic involvement
behavioral specificity, 123
maternal behavior, 123
norepinephrine, 123
Limbic seizure discharges
amygdala, 689
cocaine, 689
hippocampus, 689
temporal lobe epilepsy, 689
Liquid diets
ethanol, 589
learning ability, 589
shuttlebox avoidance learning, 589
withdrawal, 589
Lithium
ethanol and central depressant combinations, 111
interaction toxicity, 111
Local anesthetics
diethylaminoethanol, 669
drug self-administration, 669
lidocaine, 669
procainamide, 669
procaine, 669
reinforcing properties, 669
Locomotor activity
activity, 23
amphetamine, 65, 479
d-amphetamine, 23
apomorphine, 479
avoidance learning, 493
benzodiazepines, 65
caffeine, 65
caudate nucleus, 23
cyproheptadine, 479
dopamine, 23
dopaminergic drugs, 479
flurazepam, 65
6-hydroxydopamine, 23
learning and memory deficits, 493
meprobamate, 65
α-methylphenylalanine, 493
nucleus accumbens, 23
phenobarbitone, 65
phenylalanine development, 493
phenylketonuria, 493
psychotomimetics, 479
Long-term
behavioral effects, s23
morphine, s23
offspring of male mice injected with opioids prior to mating, s23
pregestation, s23
prenatal, s23
Lu 10-171
metergoline, 371
physostigmine, 371
serotonin, 371
yawning, 371

Macromolecular changes in CNS
brain chromatin, 253
footshock, 253
RNA synthesis in vitro, 253
Male mice
behavioral effects in offspring injected with opioids prior to mating, s23
long-term, s23
morphine, s23
pregestation, s23
prenatal, s23
Matching-behavior
barbiturate, 159
conditional discrimination, 159
sodium pentobarbital, 159
stimulus control, 159
Maternal behavior
behavioral specificity, 123
limbic involvement, 123
norepinephrine, 123
Maternal lead exposure
dosage, s35
exploratory patterns, s35
nutrition, s35
offspring open field performance, s35
postnatal lead exposure, s35
prenatal lead exposure, s35

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl., Vol. 11, 1979.

Maternal responsiveness
chronic administration, 539
squirrel monkey, 539
Δ^9-THC, 539
Maze learning
behavioral effects, s29
morphine, s29
morphine-pellet implantation, s29
neonatal addiction, s29
neuroendocrine, s29
protracted tolerance, s29
Medial hypothalamus
adrenergic involvement, 1
cholinergic involvement, 1
dopaminergic involvement, 1
hyperreactivity, 1
interanimal aggression, 1
Melatonin
brain catecholamines, 173
emotionality, 367
MIF-I, 173
novelty-induced defecation, 173
plasma 11-hydroxycorticosterone, 173
saccharin neophobia, 367
Memory
amnesia, 449, 453
catecholamines, 449
consolidation, 453
epinephrine, 449
norepinephrine, 449
passive avoidance, 449
rauwolfia alkaloids, 453
reserpine, 453
retrieval failure, 453
storage impairment, 453
syrosingopine, 449, 453
Mental development
behavioral development, s3
children, s3
methadone-treated women, s3
narcotic drugs, s3
psychomotor development, s3
transplacental exposure, s3
Mental developmental index
development, s15
infants, s15
in utero methadone exposure, s15
Mental retardation
hippocampus, 165
hyperactivity, 165
lead, 165
Meprobamate
anxiety, 65
benzodiazepines, 65
locomotor activity, 65
social interaction, 65
Mesencephalic central gray
endogenous opioid peptide, 227
focal electrical peptide, 227
naloxone, 227
tail erection, 227
Mesolimbic dopamine system
dopamine, 549
estrogen, 549
GABA, 549
GAD activity, 549
nigrostriatal dopamine system, 549
olfactory bulbectomy, 549
TH activity, 549
Metabolism
alcohol dehydrogenase activity, 439
ethanol intake and preference, 439
Metaraminol
cycloheximide, 335
ouabain, 335
pargyline, 335
single trial passive avoidance learning, 335
sympathomimetic amine, 335
Met-enkephalin
analgesia, 713
β-endorphin, 713
peripheral administration, 713
Metergoline
Lu 10-171, 371
physostigmine, 371
serotonin, 371
yawning, 371
Methadone
amniotic fluid, s7
apomorphine, 283
breast milk, s7
development, s15
dopamine, 283
early exposure to drugs of abuse, 1
hypersensitivity, 283
infants, s15
in utero, s15
mental developmental index, s15
morphine, 283
narcotic disposition, s7
narcotics, 283
opioids, 521
PCP, 1
perinatal, s7
pharmacokinetics, 1
pregnancy, s7
protracted effects, 1
psychomotor deficits, 1
psychotrophic drugs, 1
signal detectability, 521
visual evoked potentials, 521
visual sensitivity, 521
Methadone-treated women
behavioral development, s3
children, s3
mental development, s3
narcotic drugs, s3
psychomotor development, s3
Methamphetamine
fine motor control, 273
rhesus monkey, 273
Methaqualone
ethanol and central depressant combinations, 111
interaction toxicity, 111
Method
micro-sample gas-chromatographic technique for the analysis of barbiturates, 355
a rapid and inexpensive technique for assessing the reinforcing effects of opiate drugs, 231
techniques for the chronic cannulation of the jugular vein in mice, 115
Methyl ethyl ketone
acetone, 401
delayed match-to-sample task, 401
methyl isobutyl ketone, 401
Methyl isobutyl ketone
acetone, 401
delayed match-to-sample task, 401
methyl ethyl ketone, 401
N-Methylnicotinamide
blood acetaldehyde, 575
drinking, 575
ethanol elimination rate, 575
ethanol intake and metabolism, 575
glutathione reductase, 575
niacin, 575
riboflavin, 575
α-Methylphenylalanine
avoidance learning, 493
learning and memory deficits, 493

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl., Vol. 11, 1979.

locomotor activity, 493
phenylalanine development, 493
phenylketonuria, 493
Methylscopolamine
acetylcholine, 625
apomorphine, 625
central cholinergic mechanisms, 625
hyoscine, 625
oxotremorine, 625
propranolol, 625
scopolamine, 625
self-stimulation, 625
tremor, 625
Metrazol
γ-acetylenic GABA, 265
GABA-T inhibitors, 265
kindled seizures, 265
γ-vinyl GABA, 265
Micro-method
barbiturate analysis, 355
nitrogen-phosphorus detector, 355
MIF-I
analgesia, 721
brain catecholamines, 173
differential actions as an opiate antagonist, 721
eating, 721
melatonin, 173
novelty-induced defecation, 173
plasma 11-hydroxycorticosterone, 173
vas deferens, 721
Monoamine oxidase inhibitor, 335
cycloheximide, 335
pargyline, 335
Morphine
adrenal catecholamines, 57
aggression, 11
amphetamine, 131
amygdala, 313, 505
analgesia, 297, 303, 387
anxiolytic action, 313
apomorphine, 283
autoanalgesia, 643
aversive thresholds, 505
behavioral effects, s23, s29
brain opioids, 131
classical conditioning, 231
conditioned fear, 643
corticosteroids, 57
cross-tolerance, 643
2-deoxy-D-glucose, 297, 303
dopamine, 283
drinking, 387
endorphin, 643
D-ala^2-leu-enkephalinamide, 231
escape from shocks of different intensity, 155
exploratory behavior, 505
hamster, 673
hypersensitivity, 283
hypophysectomy, 303
insulin, 303
long-term, s23
maze learning, s29
methadone, 283
morphine-pellet implantation, s29
motor activity, 505
nalorphine, 57
naloxone, 289, 297, 505, 673
naltrexone, 387
narcotics, 283
neonatal addiction, s29
neuroendocrine, s29
offspring of male mice injected with opioids prior to mating, s23
opiate, 387, 505
opioids, 673
physical dependence, 197
pituitary-adrenal system, 57
pregestation, s23
prenatal, s23
protracted tolerance, s29
self-stimulation, 289
sexual behavior, 673
social cohesion, 131
social interaction, 313
stimulus-response relationships, 155
strain differences, 197
stress, 303
suppression effects, 387
synergy, 297
technique for assessing the reinforcing effects of opiate drugs, 231
ventral tegmental area, 289
weight changes, 197
withdrawal induced behavior, 11
Morphine antinociception
behavioral effects, s19
conditioned emotional response, s19
naltrexone, s19
perinatal drug exposure, s19
preliminary investigation, s19
Morphine-pellet implantation
behavioral effects, s29
maze learning, s29
morphine, s29
neonatal addiction, s29
neuroendocrine, s29
protracted tolerance, s29
Morphology
behavioral alterations, s39
neonatal, s39
phencyclidine, s39
postnatal, s39
prenatal, s39
teratology, s39
Mother-infant interaction
chronic parental drug exposure, s47
development, s47
infant, s47
primate model for detecting behavioral impairment, s47
psychoactive drug, s47
social behavior, s47
Δ^9-THC, s47
Motor activity
amygdala, 505
aversive thresholds, 505
caudate nucleus, 499
evoked potentials, 499
exploratory behavior, 505
GABA, 499
morphine, 505
naloxone, 505
opiates, 505
passive avoidance, 499
picrotoxin, 499
Multiple schedule
clock stimuli, 43
codeine self-administration, 43
FI clock schedule, 43
Multiple schedule performance
acetone, 395
toluene, 395
Muricide
aggression, 419
amphetamine, 419
β-phenylethylamine, 419
Muscimol
comparison of GABA, glycine and acetylcholine agonists and their antagonists, 647
GABA and hypothalamic feeding systems, 647

Nalorphine
adrenal catecholamines, 57

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl., Vol. 11, 1979.

corticosteroids, 57
morphine, 57
pituitary-adrenal system, 57
Naloxone
1-α-acetylmethadol, 279
amygdala, 505
analgesia, 297
antinoception, 639
autoanalgesia, 639, 741
aversive thresholds, 505
body weight, 279
conditioned fear, 639, 741
conditioned taste aversion, 391
core temperature, 279
cross-foster, 235
2-deoxy-D-glucose, 297
drinking, 567
eating, 567
endogenous opioid peptide, 227
endorphin, 567
enkephalin, 289, 705
ethanol, 391
exploratory behavior, 505
focal electrical stimulation, 227
food deprivation, 567
hamster, 673
heroin, 279
hot-plate, 235
hydromorphone, 279
hyperalgesia, 235
hypothalamic obese rats, 729
leu-enkephalin, 741
mesencephalic central gray, 227
morphine, 289, 297, 505, 673
motor activity, 505
narcotic antagonist, 567
narcotic zinc tannate salts, 279
non-narcotic component, 705
non-specific enhancements, 391
opiate peptides, 705
opiate receptors, 741
opiates, 505
opioids, 673
pain, 639
perinatal, 235
physical dependence, 279
self-stimulation, 289
sexual behavior, 673
stress, 639
suppression of eating, 729
synergy, 297
tail erection, 227
tonic immobility, 705
ventral tegmental area, 289
VMH, 729
Naltrexone
analgesia, 387
behavioral effects, s19
conditioned emotional response, s19
drinking, 387
morphine, 387
morphine antinociception, s19
opiate, 387
perinatal drug exposure, s19
preliminary investigation, s19
suppression effects, 387
Narcotic antagonist
drinking, 567
eating, 567
endorphin, 567
food deprivation, 567
naloxone, 567
Narcotic disposition
amniotic fluid, s7
breast milk, s7
methadone, s7
perinatal, s7
pregnancy, s7
Narcotic drugs
behavioral development, s3
children, s3
mental development, s3
methadone-treated women, s3
psychomotor development, s3
transplacental exposure, s3
Narcotic zinc tannate salts
1-α-acetylmethadol, 279
body weight, 279
core temperature, 279
heroin, 279
hydromorphone, 279
naloxone, 279
physical dependence, 279
Narcotics
apomorphine, 283
dopamine, 283
hypersensitivity, 283
methadone, 283
morphine, 283
Neonatal
behavioral alterations, s39
morphology, s39
phencyclidine, s39
postnatal, s39
prenatal, s39
teratology, s39
Neonatal activity
catecholamine, 309
development, 309
6-hydroxydopa, 309
6-hydroxydopamine, 309
hyperactivity, 309
norepinephrine, 309
Neonatal addiction
behavioral effects, s29
maze learning, s29
morphine, s29
morphine-pellet implantation, s29
neuroendocrine, s29
protracted tolerance, s29
Neostriatum
amphetamine, 529
antipsychotic drugs, 529
apomorphine, 529
clozapine, 529
haloperidol, 529
nucleus accumbens, 529
spontaneous neuronal activity, 529
Neuroendocrine
behavioral effects, s29
maze learning, s29
morphine, s29
morphine-pellet implantation, s29
neonatal addiction, s29
protracted tolerance, s29
Neuroleptics
akinesia, 71
dopamine, 71
extinction, 71
pimozide, 71
Neuronal protein metabolism
autoradiographic comparison with glial protein metabolism, 593
food-motivated conditioning, 593
footshock-motivated conditioning, 593
hippocampus, 593
Neuropeptides
hibernators, 473
hypothermia, 473
neurotensin, 473
thermoregulation, 473

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl., Vol. 11, 1979.

Neurotensin
hibernators, 473
hypothermia, 473
neuropeptides, 473
thermoregulation, 473
Neurotransmitters
adrenal ascorbic acid, 215
corticosterone, 215
neurotransmitters, 215
nonreward, 215
physiological indicators of stress, 215
reward, 215
runway behavior, 215
Niacin
blood acetaldehyde, 575
drinking, 575
ethanol elimination rate, 575
ethanol intake and metabolism, 575
glutathione reductase, 575
N-methylnicotinamide, 575
riboflavin, 575
Nigrostriatal dopamine system
dopamine, 549
estrogen, 549
GABA, 549
GAD activity, 549
mesolimbic dopamine system, 549
olfactory bulbectomy, 549
TH activity, 549
Nitrogen-phosphorus detector
barbiturate analysis, 355
micro-method, 355
Non-narcotic component
enkephalin, 705
naloxone, 705
opiate peptides, 705
tonic immobility, 705
Nonreward
adrenal ascorbic acid, 215
corticosterone, 215
neurotransmitters, 215
physiological indicators of stress, 215
reward, 215
runway behavior, 215
Non-specific enhancement
conditioned taste aversion, 391
ethanol, 391
naloxone, 391
Norepinephrine
activity, 695
amnesia, 449
behavioral specificity, 123
catecholamines, 77, 309, 449
corticosterone, 695
development, 309
dopamine, 77
epinephrine, 77, 449, 563
fluorometric assay, 183
6-hydroxydopa, 309
6-hydroxydopamine, 309
hyperactivity, 309
hypothalamus, 77
ion-exchange resin, 183
limbic involvement, 123
maternal behavior, 123
memory, 449
neonatal activity, 309
obesity, 77
passive avoidance, 449
septal lesions, 695
stress, 695
syrosingopine, 449
temperature, 695
ulcers, 695
Norepinephrine N-methyltransferase
catecholamine concentration, 563
epinephrine, 563
pigeon brain, 563
Nose poke
ethanol, 513
fetal alcohol syndrome, 513
hole poke, 513
inhibition, 513
prenatal, 513
Novelty-induced defecation
brain catecholamines, 173
melatonin, 173
MIF-I, 173
plasma 11-hydroxycorticosterone, 173
Nucleus accumbens
activity, 23
d-amphetamine, 23, 529
d-amphetamine self administration, 553
antipsychotic drugs, 529
apomorphine, 529
caudate nucleus, 23
clozapine, 529
dopamine, 23
dopaminergic nerve terminals, 553
haloperidol, 529
6-hydroxydopamine, 23
locomotor activity, 23
neostriatum, 529
spontaneous neuronal activity, 529
Nutrition
dosage, s35
exploratory patterns, s35
maternal lead exposure, s35
offspring open field performance, s35
postnatal lead exposure, s35
prenatal lead exposure, s35

Obesity
catecholamines, 77
dopamine, 77
epinephrine, 77
hypothalamus, 77
norepinephrine, 77
Offspring
dosage, s35
exploratory patterns, s35
maternal lead exposure, s35
nutrition, s35
open field performance, s35
postnatal lead exposure, s35
prenatal lead exposure, s35
Olfactory bulbectomy
dopamine, 549
estrogen, 549
GABA, 549
GAD activity, 549
mesolimbic dopamine system, 549
nigrostriatal dopamine system, 549
TH activity, 549
Open field
amygdala, 313
anxiolytic action, 313
morphine, 313
social interaction, 313
Open field performance
dosage, s35
exploratory patterns, s35
maternal lead exposure, s35
nutrition, s35
offspring, s35
postnatal lead exposure, s35
prenatal lead exposure, s35

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl., Vol. 11, 1979.

Opiate antagonist
analgesia, 721
eating, 721
MIF-I, 721
vas deferens, 721
Opiate peptides
enkephalin, 705
naloxone, 705
non-narcotic component, 705
tonic immobility, 705
Opiate receptors
autoanalgesia, 741
conditioned fear, 741
leu-enkephalin, 741
naloxone, 741
Opiate
amygdala, 505
analgesia, 387
aversive thresholds, 505
drinking, 387
exploratory behavior, 505
morphine, 387, 505
motor behavior, 505
naloxone, 505
naltrexone, 387
suppression effects, 387
Opioids
behavioral effects in offspring of male mice, s23
hamster, 673
long-term, s23
methadone, 521
morphine, 673, s23
naloxone, 673
pregestation, s23
prenatal, s23
sexual behavior, 673
signal detectability, 521
visual evoked potentials, 521
visual sensitivity, 521
Ouabain
cycloheximide, 335
metaraminol, 335
pargyline, 335
passive avoidance learning, 335
Ovulation
amphetamine, 605
behavioral teratogenesis, 605
hypothalamic monoamine content, 605
sexual behavior, 605
Oxotremorine
acetylcholine, 625
apomorphine, 625
central cholinergic mechanisms, 625
hyoscine, 625
methylscopolamine, 625
propranolol, 625
scopolamine, 625
self-stimulation, 625
tremor, 625

Pain
antinoception, 639
autoanalgesia, 639
conditioned fear, 639
naloxone, 639
stress, 639
Paradoxical immobility
p-chlorophenylalanine, 17
pargyline, 17
serotonergic model, 17
tonic immobility, 17
tryptophan, 17
Paraventricular hypothalamic nucleus
comparison of GABA, glycine and acetylcholine agonists and their antagonists, 647
GABA and hypothalamic feeding systems, 647
Pargyline
p-chlorophenylalanine, 17
cycloheximide, 335
metaraminol, 335
monoamine oxidase inhibitor, 335
ouabain, 335
paradoxical attenuation, 17
serotonergic model, 7
single trial passive avoidance learning, 335
tonic immobility, 7
tryptophan, 7
Passive avoidance
amnesia, 449
catecholamines, 449
caudate nucleus, 499
epinephrine, 449
evoked potentials, 499
GABA, 499
memory, 449
modification of motor activity, 499
norepinephrine, 449
picrotoxin, 499
syrosingopine, 449
Passive avoidance learning
cycloheximide, 335
metaraminol, 335
ouabain, 335
pargyline, 335
PCP
early exposure to drugs of abuse, s1
methadone, s1
pharmacokinetics, s1
protracted effects, s1
psychomotor deficits, s1
psychotrophic drugs, s1
Pentobarbital
amphetamine, 617
differential reinforcement of low rates, 617
phencyclidine, 617
schedule controlled behavior, 617
spaced responding, 617
Pentobarbital sodium
barbiturates, 487
benzodiazepines, 487
cannabinoids, 487
diazepam, 487
eating, 487
hypothalamic injection, 487
Δ^9-THC, 487
Peptide antigenic-determinants
blood brain barrier, 717
delta-sleep inducing peptide (DSIP), 717
radioimmunoassay, 717
Performance deficits
brain-stimulation reward, 557
extinction, 557
pimozide-produced dopamine receptor blockade, 557
repeated-response measures, 557
Perinatal
amniotic fluid, s7
breast milk, s7
cross-foster, 235
hot-plate, 235
hyperalgesia, 235
methadone, s7
naloxone, 235
narcotic disposition, s7
pregnancy, s7
Perinatal drug exposure
behavioral effects, s19

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl., Vol. 11, 1979.

conditioned emotional response, s19
naltrexone, s19
morphine antinociception, s19
preliminary investigation, s19
Peripheral administration
analgesia, 713
β-endorphin, 713
met-enkephalin, 713
Pharmacokinetics
early exposure to drugs of abuse, s1
methadone, s1
PCP, s1
protracted effects, s1
psychomotor deficits, s1
psychotrophic drugs, s1
Phencyclidine
amphetamine, 617
atropine, 37
behavioral alterations, s39
differential reinforcement of low rates, 617
drug interactions, 37
morphology, s39
neonatal, s39
pentobarbital, 617
physostigmine, 37
postnatal, s39
prenatal, s39
schedule controlled behavior, 617
spaced responding, 617
teratology, s39
variable-interval, 37
Phenobarbital
barbital, 359
barbiturate serum level, 359
drinking, 145, 705
effect of food deprivation, 359
ethanol and central depressant combinations, 111
interaction toxicity, 111
response measures, 145
taste aversion, 709
x-radiation, 709
Phenobarbitone
anxiety, 65
benzodiazepines, 65
locomotor activity, 65
social interaction, 65
Phenylalanine development
avoidance learning, 493
learning and memory deficits, 493
locomotor activity, 493
α-methylphenylalanine, 493
phenylketonuria, 493
β-phenylethylamine
aggression, 419
amphetamine, 419
muricide, 419
Phenylketonuria
avoidance learning, 493
learning and memory deficits, 493
locomotor activity, 493
α-methylphenylalanine, 493
phenylalanine development, 493
Phospholipids
changes induced by hashish constituents, 383
erythrocytes, 383
Δ^9-THC, 383
Physical dependence
1-α-acetylmethadol, 279
body weight, 279
core temperature, 279
heroin, 279
hydromorphone, 279
morphine, 197
naloxone, 279
narcotic zinc tannate salts, 279
strain differences, 197
weight changes, 197
Physostigmine
anticholinesterase, 189
atropine, 37
aversive stimulus, 189
cholinergic, 189
defense responses, 189
drug interactions, 37
fear, 189
Lu 10-171, 371
metergoline, 371
phencyclidine, 37
serotonin, 371
variable-interval, 37
yawning, 371
Picrotoxin
caudate nucleus, 499
comparison of GABA, glycine and acetylcholine agonists and their antagonists, 647
evoked potentials, 499
GABA, 499
GABA and hypothalamic feeding systems, 647
GABA-T inhibitors, 483
ketamine, 483
modification of motor activity, 499
passive avoidance conditioning, 499
rotation, 483
Pigeon brain
catecholamine-concentration, 563
epinephrine, 563
norepinephrine N-methyltransferase, 563
Pimozide
akinesia, 71
brain-stimulation reward, 557
dopamine, 71
dopamine receptor blockade, 557
extinction, 71, 557
neuroleptics, 71
performance deficits, 557
repeated-response measures, 557
Pituitary-adrenal system
adrenal catecholamines, 57
behavior and physiological responsiveness, 631
corticoids, 57
long-term consequences of early iron deficiency, 631
morphine, 57
nalorphine, 57
Plasma 11-hydroxycorticosterone
brain catecholamines, 173
melatonin, 173
MIF-I, 173
novelty-induced defecation, 173
Posterior hypothalamus
amphetamine, 351
azaperone, 351
haloperidol, 351
self-stimulation, 351
ventral tegmental area, 351
Postnatal
behavioral alterations, s39
chronic lead intoxication, 95
environmental stress, 95
morphology, s39
neonatal, s39
phencyclidine, s39
prenatal, s39
running wheel activity, 95
teratology, s39
Postnatal lead exposure
dosage, s35
exploratory patterns, s35
maternal lead exposure, s35
nutrition, s35
offspring open field performance, s35

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl., Vol. 11, 1979.

prenatal lead exposure, s35
Preference
alcohol dehydrogenase activity, 439
ethanol intake and metabolism, 439
Pregestation
behavioral effects in offspring of male mice injected with opioids prior to mating, s23
long-term, s23
morphine, s23
prenatal, s23
Pregnancy
amniotic fluid, s7
breast milk, s7
methadone, s7
narcotic disposition, s7
perinatal, s7
Preliminary investigation
behavioral effects, s19
conditioned emotional response, s19
morphine anticiception, s19
naltrexone, s19
perinatal drug exposure, s19
Prenatal
behavioral alterations, s39
behavioral effects, s23
chronic lead intoxication, 95
environmental stress, 95
ethanol, 513
fetal alcohol syndrome, 513
hole poke, 513
inhibition, 513
long-term, s23
morphine, s23
morphology, s39
neonatal, s39
nose poke, 513
offspring of male mice injected with opioids prior to mating, s23
phencyclidine, s39
postnatal, s39
pregestation, s23
running wheel activity, 95
teratology, s39
Prenatal lead exposure
dosage, s35
exploratory patterns, s35
maternal lead exposure, s35
nutrition, s35
offspring open field performance, s35
postnatal lead exposure, s35
Primate model
behavioral impairment, s47
chronic parental drug exposure, s47
development, s47
infants, s47
mother-infant interaction, s47
psychoactive drug, s47
social behavior, s47
Δ^9-THC, s47
Procainamide
diethylaminoethanol, 669
drug self-administration, 669
lidocaine, 669
local anesthetics, 669
procaine, 669
reinforcing properties, 669
Procaine
diethylaminoethanol, 669
drug self-administration, 669
lidocaine, 669
local anesthetics, 669
procainamide, 669
reinforcing properties, 669
Propranolol
acetylcholine, 625
apomorphine, 625
central cholinergic mechanisms, 625
hyoscine, 625
methylscopolamine, 625
oxotremorine, 625
propranolol, 625
scopolamine, 625
self-stimulation, 625
tremor, 625
N-n-Propylnorapomorphine
aporphines, 653
behavioral arousal, 653
cage climbing, 653
pharmacological basis for stereotypy, 653
receptor blockers, 653
Protracted effects
early exposure to drugs of abuse, s1
methadone, s1
PCP, s1
pharmacokinetics, s1
psychomotor deficits, s1
psychotrophic drugs, s1
Protracted tolerance
behavioral effects, s29
maze learning, s29
morphine, s29
morphine-pellet implantation, s29
neonatal addiction, s29
neuroendocrine, s29
Psychoactive drug
chronic parental drug exposure, s47
development, s47
mother-infant interaction, s47
primate model for detecting behavioral impairment, s47
social behavior, s47
Δ^9-THC, s47
Psychomotor deficits
early exposure to drugs of abuse, s1
methadone, s1
PCP, s1
pharmacokinetics, s1
protracted effects, s1
psychotrophic drugs, s1
Psychomotor development
behavioral development, s3
children, s3
mental development, s3
methadone-treated women, s3
narcotic drugs, s3
Psychotomimetics
amphetamine, 479
apomorphine, 479
cyproheptadine, 479
dopaminergic drugs, 479
locomotor activity, 479
Psychotrophic drugs
early exposure to drugs of abuse, s1
methadone, s1
PCP, s1
pharmacokinetics, s1
protracted effects, s1
psychomotor deficits, s1
Pudendal nerve section
p-chlorophenylalanine, 701
copulatory experience, 701
sexual behavior, 701
Pyro-glu-his-gly-OH
anorexigenic tripeptide, 733
body weight, 733
eating, 733

Radioimmunoassay
blood brain barrier, 717
delta-sleep inducing peptide (DSIP), 717
peptide antigenic-determinants, 717

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl., Vol. 11, 1979.

Raphe nucleus
catecholamines, 89
food deprivation, 89
HPLC, 89
indoles, 89
lateral hypothalamus, 89
ventromedial hypothalamus, 89
Rats and cats
behavioral antecedents, 683
cocaine, 683
discrimination, 683
stereotyped behavior, 683
Rauwolfia alkaloids
amnesia, 453
consolidation, 453
cumulative drug effects, 585
memory, 453
reserpine, 453, 585
retrieval failure, 453
spontaneous activity, 585
storage impairment, 453
syrosingopine, 453, 585
Receptor blockers
aporphines, 653
behavioral arousal, 653
cage climbing, 653
pharmacological basis for N-n-propylnorapomorphine induced stereotypy, 653
Reinforcement
FLA 57 blocking effect, 545
intragastric infusions of ethanol, 545
Reinforcing properties
diethylaminoethanol, 669
drug self-administration, 669
lidocaine, 669
local anesthetics, 669
procainamide, 669
procaine, 669
Renal excretion
beta-adrenergic stimulation, 141
electrolytes and water, 141
isoproterenol, 141
septal area, 141
Repeated-response measures
brain-stimulation reward, 557
extinction, 557
performance deficits, 557
pimozide-produced dopamine receptor blockade, 557
Reserpine
amnesia, 453
consolidation, 453
cumulative drug effects, 585
memory, 453
rauwolfia alkaloids, 453, 585
retrieval failure, 453
spontaneous activity, 585
storage impairment, 453
syrosingopine, 453, 585
Response force
chlorpromazine, 239
clozapine, 239
response rate, 239
Response measures
drinking, 145
phenobarbital, 145
Response rate
chlorpromazine, 239
clozapine, 239
response force, 239
Retrieval failure
amnesia, 453
consolidation, 453
memory, 453
rauwolfia alkaloids, 453
reserpine, 453
storage impairment, 453
syrosingopine, 453
Reward
adrenal ascorbic acid, 215
corticosterone, 215
neurotransmitters, 215
nonreward, 215
physiological indicators of stress, 215
runway behavior, 215
Rhesus monkey
fine motor control, 273
methamphetamine, 273
Riboflavin
blood acetaldehyde, 575
drinking, 575
ethanol elimination rate, 575
ethanol intake and metabolism, 575
glutathione reductase, 575
N-methylnicotinamide, 575
niacin, 575
RNA synthesis
brain chromatin, 253
footshock, 253
macromolecular changes in CNS, 253
Rotation
GABA-T inhibitors, 483
ketamine, 483
picrotoxin, 483
Rotational behavior
dopamine, 135
dopaminergic pathways, 135
lesions, 135
Running wheel activity
environmental stress, 95
prenatal and postnatal chronic lead intoxication, 95
Runway behavior
adrenal ascorbic acid, 215
corticosterone, 215
neurotransmitters, 215
nonreward, 215
physiological indicators of stress, 215
reward, 215

Saccharin neophobia
emotionality, 367
melatonin, 367
Schedule controlled behavior
amphetamine, 617
chlorpromazine, 661
clozapine, 661
differential reinforcement of low rates, 617
haloperidol, 661
pentobarbital, 617
phencyclidine, 617
spaced responding, 617
Schedule dependent behavior
adjunctive behavior, 725
imipramine, 725
schedule induced behavior, 725
Schedule induced behavior
adjunctive behavior, 725
d-amphetamine, 423
drinking, 423
fixed-time schedule, 423
grooming, 423
imipramine, 725
schedule dependent behavior, 725
Schedule-induced drinking
d-amphetamine, 151
fenfluramine, 151
Schedule-induced polydipsia
adjunctive drinking, 347

body weight, 347
caffeine, 347
chronic intake level, 581
discriminative motor control, 581
ethanol, 581
FT-1 min schedule, 347
licking, 347
withdrawal, 581
Scopolamine
acetylcholine, 625
apomorphine, 625
central cholinergic mechanisms, 625
hyoscine, 625
methylscopolamine, 625
oxotremorine, 625
propranolol, 625
self-stimulation, 625
tremor, 625
Self-administration
body weight reduction, 737
food delivery schedule, 737
Δ^9-THC, 737
Self-injection
conditioning, 445
heroin, 445
interoceptive factors, 445
Self-stimulation
acetylcholine, 625
amphetamine, 351
apomorphine, 625
azaperone, 351
central cholinergic mechanisms, 625
dopamine, 413
drinking, 413
enkephalin, 289
haloperidol, 351
hyosine, 625
methylscopolamine, 625
morphine, 289
naloxone, 289
norepinephrine, 413
oxotremorine, 625
posterior hypothalamus, 351
propranolol, 625
scopolamine, 625
serotonin, 413
tremor, 625
ventral tegmental area, 289, 351
Septal area
beta-adrenergic stimulation, 141
isoproterenol, 141
renal excretion of electrolytes and water, 141
Septal lesions
activity, 695
corticosterone, 695
norepienphrine, 695
stress, 695
temperature, 695
ulcers, 695
Serotonergic model
p-chlorophenylalanine, 17
paradoxical attention, 17
pargyline, 17
tonic immobility, 17
tryptophan, 17
Serotonin
dopamine, 413
drinking, 413
eating, 431
feeding patterns, 431
fluorometric assay, 183
5-hydroxytryptophan, 431
ion-exchange resin, 183
Lu 10-171, 371
metergoline, 371
neuronal substrates of anxiety, 99
norepinephrine, 413
physostigmine, 371
self-stimulation, 413
yawning, 371
Serotonin syndrome
p-chloroamphetamine, 611
frequency analysis of behavior components of the serotonin syndrome, 611
stereotypy, 611
Sexual behavior
amphetamine, 605
behavioral teratogenesis, 605
p-chlorophenylalanine, 701
copulatory experience, 701
hamster, 673
hypothalamic monoamine content, 605
morphine, 673
naloxone, 673
opioids, 673
ovulation, 605
pudendal nerve section, 701
Sheep
abomasal acid secretion, 51
9-aza-cannabinol, 51
chemical feed intake, 51
elfazepam, 51
Shock
escape, 155
morphine, 155
stimulus-response relationships, 155
Shuttlebox avoidance learning
ethanol, 589
learning ability, 589
liquid diets, 589
withdrawal, 589
Signal detectability
methadone, 521
opioids, 521
visual evoked potentials, 521
visual sensitivity, 521
Sleep latency
attenuation of catecholamine activity, 319
hypnotic effect, 319
induced slow wave sleep, 319
tryptophan, 319
Slow wave sleep
attenuation of catecholamine activity, 319
hypnotic effect, 319
reduced sleep latency, 319
tryptophan, 319
Social behavior
chronic parental drug exposure, s47
development, s47
infants, s47
mother-infant interaction, s47
primate model for detecting behavioral impairment, s47
psychoactive drug, s47
Δ^9-THC, s47
Social cohesion
amphetamine, 131
brain opioids, 131
morphine, 131
Social interaction
amphetamine, 65
amygdala, 313
anxiety, 65
anxiolytic action, 313
benzodiazepines, 65
caffeine, 65
flurazepam, 65
meprobamate, 65
morphine, 313
open field, 313
phenobarbitone, 65

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl., Vol. 11, 1979.

Sodium pentobarbital
barbiturate, 159
conditional discrimination, 159
matching-behavior, 159
stimulus control, 159
Spaced responding
amphetamine, 617
differential reinforcement of low rates, 617
pentobarbital, 617
phencyclidine, 617
schedule controlled behavior, 617
Spontaneous activity
cumulative drug effects, 585
rauwolfia alkaloids, 585
reserpine, 585
syrosingopine, 585
Spontaneous neuronal activity
amphetamine, 529
antipsychotic drugs, 529
apomorphine, 529
clozapine, 529
haloperidol, 529
neostriatum, 529
nucleus accumbens, 529
Squirrel monkey
chronic administration, 539
maternal responsiveness, 539
Δ^9-THC, 539
State-dependent learning
conditioned drinking suppression, 377
drug-produced dissociation, 377
effect of external stimulus change on ethanol-produced dissociation, 377
generalization, 377
Stereotyped behavior
behavioral antecedents, 683
cocaine, 683
discrimination, 683
rats and cats, 683
Stereotypy
amphetamine, 325
aporphines, 653
avoidance, 325
behavioral arousal, 653
cage climbing, 653
p-chloroamphetamine, 611
defensive flight, 325
defensive responses, 325
frequency analysis of behavior components of the serotonin syndrome, 611
halogenated amphetamine, 611
pharmacological basis for N-n-propylnorapomorphine, 653
receptor blockers, 653
Stimulus control
barbiturate, 159
conditional discrimination, 159
matching behavior, 159
sodium pentobarbital, 159
Stimulus-response relationships
escape from shocks of different intensity, 155
morphine, 155
Storage impairment
amnesia, 453
consolidation, 453
memory, 453
rauwolfia alkaloids, 453
reserpine, 453
retrieval failure, 453
syrosingopine, 453
Strain differences
morphine, 197
physical dependence, 197
weight changes, 197
Stress
activity, 695
adrenal ascorbic acid, 215
analgesia, 303
antinoception, 639
autoanalgesia, 639
conditioned fear, 639
corticosterone, 215, 695
2-deoxy-D-glucose, 303
hypophysectomy, 303
insulin, 303
morphine, 303
naloxone, 639
neurotransmitters, 215
nonreward, 215
norepinephrine, 695
pain, 639
physiological indicators, 215
reward, 215
runway behavior, 215
septal lesions, 695
temperature, 695
ulcers, 695
Striatum
cyclic nucleotides, 107
hippocampus, 107
intracranial self-stimulation, 107
motor activity, 107
Strychnine
comparison of GABA, glycine and acetylcholine agonists and their antagonists, 647
GABA and hypothalamic feeding systems, 647
Suppression effects
analgesia, 387
drinking, 387
morphine, 387
naltrexone, 387
opiate, 387
Suppression of eating
hypothalamic obest rats, 729
naloxone, 729
VMH, 729
Sympathomimetic amine
cycloheximide, 335
metaraminol, 335
Synergy
analgesia, 297
2-deoxy-D-glucose, 297
morphine, 297
naloxone, 297
Synthetic non-benzodiazepine ligand
neuronal substrates of anxiety, 99
Syrosingopine
amnesia, 449, 453
catecholamines, 449
consolidation, 453
cumulative drug effects, 585
epinephrine, 449
memory, 449, 453
norepinephrine, 449
passive avoidance, 449
rauwolfia alkaloids, 453, 585
reserpine, 453, 585
retrieval failure, 453
spontaneous activity, 585
storage impairment, 453

Tail erection
endogenous opioid peptide, 227
focal electrical stimulation, 227
mesencephalic central gray, 227
naloxone, 227
Taste aversion
drinking, 709
phenobarbital, 709
x-radiation, 709

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl., Vol. 11, 1979.

Taste aversion learning
afferent nerves, 331
amphetamine, 31
apomorphine, 331
behavioral toxicology, 31
coeliac ganglionectomy, 331
conditioned toxiphobia, 331
copper sulfate, 331
developmental psychopharmacology, 11
drug responsiveness, 31
gastric irritation, 331
Technique
assessing the reinforcing effects of opiate drugs, 231
classical conditioning, 231
D-ala^2-leu-enkephalinamide, 231
morphine, 231
Temperature
activity, 695
corticosterone, 695
norepinephrine, 695
septal lesions, 695
stress, 695
ulcers, 695
Temporal lobe epilepsy
amygdala, 689
cocaine, 689
hippocampus, 689
limbic seizure discharges, 689
Teratology
behavioral alterations, s39
morphology, s39
neonatal, s39
phencyclidine-induced, s39
postnatal, s39
prenatal, s39
Testosterone
androgen, 211
body weight, 211
cyproterone acetate, 211
dihydroxytestosterone, 211
eating, 211
estorgen, 211
TH activity
dopamine, 549
estrogen, 549
GABA, 549
GAD activity, 549
mesolimbic dopamine system, 549
nigrostriatal dopamine system, 549
olfactory bulbectomy, 549
Δ^9-THC
barbiturates, 487
benzodiazepines, 487
body weight reduction, 737
cannabinoids, 487
changes induced by hashish constituents on human erythrocyte phospholipids, 383
chronic administration, 539
chronic parental drug exposure, s47
development, s47
diazepam, 487
eating
food delivery schedule, 737
hypothalamic injection, 487
infants, s47
maternal responsiveness, 539
mother-infant interaction, s47
pentobarbital sodium, 487
primate model for detecting behavioral impairment, s47
psychoactive drug, s47
self-administration, 737
social behavior, s47
squirrel monkey, 539
Thermoregulation
hibernators, 473
hypothermia, 473
neuropeptides, 473
neurotensin, 473
Toluene
acetone, 395
multiple schedule performance, 395
Tonic immobility
p-chlorophenylalanine, 17
enkephalin, 705
naloxone, 705
non-narcotic component, 705
opiate peptides, 705
paradoxical attenuation, 17
pargyline, 17
serotonergic model, 17
tryptophan, 17
Tremor
acetylcholine, 625
apomorphine, 625
central cholinergic mechanisms, 625
hyoscine, 625
methylscopolamine, 625
oxotremorine, 625
propranolol, 625
scopolamine, 625
self-stimulation, 625
Triazolopyridazine
benzodiazepine receptors, 457
chloride ionophores, 457
GABA, 457
neuronal substrates of anxiety, 99
type I and type II BDZ receptors, 457
Tryptophan
attenuation of catecholamine activity, 319
p-chlorophenylalanine, 17
hypnotic effect, 319
induced slow wave sleep, 319
paradoxical attenuation, 17
pargyline, 17
reduced sleep latency, 319
serotonin, 17
tonic immobility, 17
l-Tryptophan
fluorometric assay, 183
ion-exchange resin, 183
Type I and Type II BDZ receptors
benzodiazepine receptors, 457
chloride ionophores, 457
GABA, 457
triazolopyridazines, 457

Uncued inescapable shock
adjunctive behavior, 601
cued shock, 601
ethanol, 601
voluntary alcohol consumption, 601
Ulcers
activity, 695
corticosterone, 695
norepinephrine, 695
septal lesions, 695
stress, 695
temperature, 695

Vas deferens
analgesia, 721
eating, 721
MIF-I's differential actions as an opiate antagonist, 721
Variable-interval
atropine, 37
drug interaction, 37
phencyclidine, 37
physostigmine, 37

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl, Vol. 11, 1979.

Ventral tegmental area
amphetamine, 351
azaperone, 351
enkephalin, 289
haloperidol, 351
morphine, 289
naloxone, 289
posterior hypothalamus, 351
self-stimulation, 289, 351
Ventromedial hypothalamus
catecholamines, 89
food deprivation, 89
HPLC, 89
hypothalamic obese rats, 729
indoles, 89
lateral hypothalamus, 89
naloxone, 729
raphe nucleus, 89
suppression of eating, 729
γ-Vinyl GABA
γ-acetylenic GABA, 265
GABA-T inhibitors, 265
kindled swizures, 265
γ-vinyl GABA, 265
Visual evoked potentials
methadone, 521
opioids, 521
signal detectability, 521
visual sensitivity, 521
Visual sensitivity
methadone, 521
opioids, 521
signal detectability, 521
visual evoked potentials, 521

Voluntary alcohol consumption
adjunctive behavior, 601
cued and uncued inescapable shock, 601
ethanol, 601

Weight changes
morphine, 197
physical dependence, 197
strain differences, 197
Withdrawal
chronic intake level, 581
discriminative motor control, 581
ethanol, 581, 589
learning ability, 589
liquid diets, 589
schedule-induced polydipsia, 581
shuttlebox avoidance learning, 589
Withdrawal induced behavior
aggression, 11
morphine, 11

X-Radiation
drinking, 709
phenobarbital, 709
taste aversion, 709

Yawning
Lu 10-171, 371
metergoline, 371
physostigmine, 371
serotonin, 371

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl, Vol. 11, 1979.

AUTHOR INDEX

ACKERMANN, R. F., 265, 483
AIGNER, T. G., 273
ALBERT, D. J., 1
ALFANO, D. P., 165
ALLOWAY, K. D., 529
ALMASI, J., 283
ALTMAN, J. L., 521
ANDERSON, S. M., 83
ANDERSON-BAKER, W. C., 487
ANTUNES-RODRIGUES, J., 141
ARAGON, P., s35
ASHTON, D., 221
AULAKH, C. S., 351
AVIS, H. H., 11

BABBINI, M., 155
BACKMAN, M. Z., 259
BAILE, C. A., 51, 487
BAIRD, J. B., 617
BALSTER, R. L., 37, 617, 669
BARONE, F. C., 347
BARR, G. A., 419
BARR, J. E., 115
BARTOLETTI, M., 155
BASHORE, T. R., 529
BASKERVILLE, J. C., 279
BASSANO, D. A., 709
BEER, B., 99, 457
BENSON, D. I., 457
BERRYMAN, R., 159
BERZAS, M. C., 721, 729
BETLEY, C. E., 521
BISSETTE, G., 473
BLUNDELL, J. E., 431
BODNAR, R. J., 297, 303
BOND, N. W., 589
BOREN, J. L., 17
BORRELL, J., 57
BORRELL, S., 57
BRANDS, B., 279
BRAYLEY, K. N., 1
BRICK, J., 695
BRIDGER, W. H., 419
BROEKKAMP, C. L., 289
BROWN, D. R., 567
BRUST-CARMONA, H., 499
BURNETT, G. B., 473
BURRIGHT, R. G., 695

CAMARGO, L. A. A., 141
CARLSON, K. R., 283
CARRER, H. F., 605
CASTELLANOS, F. X., 729
CHAI, C. Y., 227
CHAIT, L. D., 37
CHANCE, W. T., 639, 643, 741
CHAVEZ, C. J., s3
CHRISTIAN, J. J., 235
CINSAVICH, S. A., 557
COLLINS, J. P., 683, 689
COOLS, A. R., 289
CORNELL, N. W., 439
COUPET, J., 99
COVIAN, M. R., 141
COY, D. H., 341, 407, 705, 713, 717, 721, 733

DAGAN, L. A., 683
DAHLOF, L. G., 701
DALLMAN, P. R., 631
DATTA, P. C., 173
DAVIS, W. M., 545
DE LA MORA, P., 499
DEVRIES, G. H., 741
DINWIDDIE, S. H., s39
DONOVICK, P. J., 695
DUNCAN, P. M., 377

EARLEY, C. J., 211, 215
ECKERMAN, D. A., 159
EHRENSING, R. H., 721
ENGEL, J., JR., 265, 483
ERWIN, V. G., 83
ETTENBERG, A., 557

FALK, J. L., 355, 359, 581
FELTEN, D. L., 89
FIBIGER, H. C., 1
FILE, S. E., 65, 313, 505
FINK, H., 479
FINK, J. S., 23
FINNEGAN, L. P., s15
FORD, K. E., 239
FORNAL, C., 319
FOWLER, S. C., 239
FRANKLIN, R. B. J., 71
FREEDMAN, L. S., 259
FRENK, H., 387
FRIEDLE, N. M., 553
FRIEDLER, G., s23
FULLER, R. W., 563
FUNK, K. F., 135

GAGLIARDI, G. J., 17
GAIARDI, M., 155
GALLARDO-CARPENTIER, A., 413
GALLUP, G. G., JR., 17
GAUSE, E. M., 395, 401
GELLER, I., 395, 401
GERREN, R. A., 493
GIBBONS, J. L., 419
GIBBS, M. E., 335
GLUSHCHENKO, T. S., 593
GLUSMAN, M., 297, 303
GOLOVCHINSKY, V., 483
GOLUB, M. S., s47
GOLUS, P., 367
GONZALEZ, R. M., 371
GORDON, J. H., 549
GORMEZANO, G., 231
GORSKI, R. A., 549
GORZALKA, B. B., 463
GOWDEY, C. W., 279
GRAY, D. S., 463
GRAZIANI, L. J., s15
GREEN, M. T., 341
GREENBLATT, E. N., 99
GROSSMAN, S. P., 647
GUAZA, C., 57

HARRY, G. J. s19, s39
HARTMANN, R. J., 395, 401
HEMRICK, S. K., 563
HERBERG, L. J., 625
HILL, C. W., 341
HIRST, M., 279
HO, A. K. S., 111
HO, C. C., 111
HOLMGREN, B., 371
HOLMES, D. B., 115
HOLTZMAN, S. G., 567
HYDE, J. R. G., 65

INFURNA, R. N., 31

JEMISON, M. T., 713
JENSEN, M. A., 43
JOHANSON, C. E., 273
JALICOEUR, F. B., 709
JORDAN, R. L., s39
JORK, R., 243, 247

KALANT, H., 197
KALOFOUTIS, A., 383
KALTENBACH, K., s15
KAO, L. C., 227
KAPLAN, H., 401
KAPLAN, J. N., 539
KASTIN, A. J., 341, 407, 705, 713, 717, 721, 729, 733
KATZ, R. J., 231
KEIM, D. A., 51
KELLY, D. D., 297, 303
KELLY, J., 647
KING, B. M., 729
KING, M. G., 173, 367, 407
KINNEY, L., 601
KLEINROCK, S., 347
KLENIKOVA, V. A., 593
KLEPNER, C. A., 99, 457

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl, Vol. 11, 1979.

KOSTRZEWA, R. M., 309
KOUTSELINIS, A., 383
KRAEMER, G. W., 473
KREEK, M. J., s7
KULKOSKY, P. J., 439
KURIBARA, H., 203
KUTSCHER, C. L., 611

LAHOSTE, G. J., 705
LANSON, R. N., 159
LARSSON, K., 701
LATHAM, C. J., 431
LAU, C. E., 355, 359
LEE, H. K., 227
LE MAGNEN, J., 391
LEONARD, B. E., 211, 215
LESSE, H., 683, 689
LESSEN-FIRESTONE, J. K., s3
LEVIN, B. E., 77
LEVINE, S., 631
LIPPA, A. S., 99, 457
LOCHRY, E. A., 513
LOOSEN, P. T., 473
LÖSSNER, B., 243, 247
LOULLIS, C. C., 89, 725
LUTTGES, M. W., 493
LYNESS, W. H., 553

McCLEARN, G. E., 83
McCOY, S. N., 71
McGEE, R., 367
McLAUGHLIN, C. L., 487
McLEAN, J. H., 309

MADDEN, C., 445
MAKHLOUF, C., 423
MANBERG, P. J., 473
MANSOUR, A., 303
MARFAING-JALLAT, P., 391
MARINI, J. L., 183
MARTIN, J. R., 331
MATTHIES, H., 243, 247
MAUK, M. D., 729
MERALI, Z., 107
MERKEL, A. D., 709
MICELI, D., 391
MILIARESSIS, E., 107
MOLLENAUER, S., 189, 325
MOLTZ, H., 123
MONDER, H., 235
MOORE, K. E., 553
MORGAN, D. N., 309
MORGENSTERN, R., 479
MUCHA, R. F., 197
MUCHOW, L. R., 43
MYSLOBODSKY, M. S., 265, 483

NAIL, G. L., 239
NAJAM, N., 131
NANCE, D. M., 733
NASELLO, A. G., 605
NEMEROFF, C. B., 473
NG, K. T., 335
NIETO, J., 423
NISSEN, C., 717
NOBLE, R. G., 673

OEI, T. P. S., 445
OELSSNER, W., 479
OLSON, G. A., 341, 705, 729
OLSON, R. D., 341, 407, 705, 721, 729
OSBAHR, A. J., III, 473
O'SHEA, S., s29
OSTROWSKI, N. L., 673

PALFAI, T., 449, 453, 585
PANKSEPP, J., 131
PAYNE, W. R., 741
PECK, E. A., 521
PEEKE, H. V. S., 11
PEKKANEN, L., 575
PETIT, T. L., 165
PEVZNER, L. Z., 593
PHILLIPS, A. G., 289
PLOTNIK, R., 189, 325
PRADHAN, S. N., 351, 413
PRANGE, A. J., JR., 473

QUARTERMAIN, D., 259

RADULOVACKI, M., 319
RAMIREZ, O. A., 605
RANDLE, S. R., 395
REBEC, G. V., 529
REID, L. D., 673
RIFFEE, W. H., 653
RILEY, E. P., 513
ROBERTSON, J., 51
RODGERS, R. J., 313, 505
RODRIGUEZ, R., 371, 423
RODRIGUEZ, W., s35
ROIG-SMITH, R., 341
RONDEAU, D. B., 709
ROSECRANS, J. A., s19, 639, 643, 741
ROSEN, J. B., 387
ROTHENBERG, S., 521
ROWLAND, D., 123
RUSI, M., 575
RYAN, L. J., 115

SAAD, W. A., 141
SANGER, D. J., 151
SANO, M. C., 457
SCHALLY, A. V., 717, 721
SCHLOSSBERGER, H. G., 319
SCHMIDT, H., JR., 145, 601
SCHOTTENFELD, S., 521
SCHUSTER, C. R., 273
SCRIVSETH, R., s35
SEIDEN, L. S., 273
SHAPIRO, N. R., 513
SHARPLESS, S. K., 115
SHEA, P. A., 89
SHEARD, M. H., 183
SILVA NETO, C. R., 141
SINGER, G., 445, 737
SMITH, G. P., 23
SMITH, R. V., 653
SMITH, S. G., 545
SOARES, F., 131
SOLOMON, P. R., 363
SONDEREGGER, T., s1, s29
SPEAR, L. P., 31
STAPLETON, J. M., 673
STATON, D. M., 363
STEELE, M. K., 123
STRAUSS, M. E., s3
STRYKER, J. C., s3
SUAREZ, S. D., 17
SULLIVAN, A. C., 77

TADOKORO, S., 203
TAKAHASHI, R. N., 737
TANG, M., 355, 359, 581
TEDESCHI, B., 253
TELLEZ, C., 499
THOMPSON, T., 43
TIFFANY, P. B., 189, 325
TORRELLAS, A., 57
TYLER, J. L., 549

UPHOUSE, L., 253
URBA-HOLMGREN, R., 371

VAN DEN BROEK, G. W., 51
VAZQUEZ, F., 499
VERLANGIERI, A. J., 95

WALLNAU, L. B., 17
WALSH, T. J., 449, 453, 585
WARD, J., s35
WAUQUIER, A., 221
WAYNER, M. J., 227, 347, 709, 725
WEINBERG, J., 631
WENGER, G. R., 661
WERNER, T. E., 545
WESTERMANN, H., 135
WHEELING, H. S., s23
WHITE, M., 189, 325
WHITE, N., 557
WILCOX, R. E., 653
WILLIAMS, S. P., 183
WISHART, T. B., 625
WOJCIK, W. J., 319
WONG, R. C. K., 1
WOOLVERTON, W. L., 669

YAMAMOTO, B. K., 611
YASUKAWA, N., 235
YOUNG, A. M., 43
YOUNG, T. R., s39

ZENICK, H., s35
ZIMMERMAN, K. S., 529
ZIMMERMANN, E., s1, s29

Numbers preceded by the letter s indicate articles appearing in *Protracted Effects of Perinatal Drug Dependence*, Suppl, Vol. 11, 1979.